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ABSTRACT 
 
Vaccines currently represent one of the most effective means to control and prevent infectious 
diseases affecting humans and animals and have dramatically improved public health, quality of 
life, and life expectancy. Over the last years several conceptual and technological advances in the 
field of bioengineering and immunology have allowed the development of new vaccines designs. 
Expanding novel domains such as structural biology, human monoclonal antibody isolation, high 
throughput sequencing, and design of new nanocarrier delivery platforms have changed the 
landscape of vaccinology. These new vaccine formulations allow the design of tailor-made 
antigens and particulate vehicles which allow better and fine-tuned protective immune responses 
against known and newly emerging pathogens. Over the past decades emerging human pathogens 
with the potential to cause severe epidemics have become a major public health problem. The last 
Ebola and Zika virus epidemics demonstrated in a dramatic manner that there is an urgent need 
to develop prophylactic and therapeutic approaches against pathogenic emerging viruses. 
Most successful vaccines rely on attenuated live microorganisms to induce protective immunity. 
However, changed demographics and associated safety concerns makes the development of a 
safer alternative a priority. Subunit vaccines composed of microbial components and proteins 
have emerged as a suitable alternative, however they are generally less immunogenic. To address 
this problematic our laboratory works on the development of immunization platforms which 
allow 1) the development of safe recombinant subunit vaccines and 2) the rapid generation of 
specific monoclonal antibodies using biosynthetic immunogens without the need for prior 
isolation and culture of the agent.  
The approach evaluated in the present studies is based on a novel polymersome (PS) platform 
serving as nanocarrier for efficient antigen delivery and the induction of humoral immunity. The 
potential of PS was assessed in the context of two important human emerging pathogens form the 
arenavirus family that cause severe hemorrhagic fevers and of which there are neither FDA-
approved vaccines not prophylactic treatments: Lassa virus (LASV), endemic in Western Africa, 
and Machupo virus (MACV), the causative agent of Bolivian hemorrhagic fever. In a first part, 
we evaluated the PS platform’s capacity to enhance humoral immunity against the envelope 
glycoprotein 1 of LASV, (LASV GP1) that is notorious for its weak immunogenicity and poor 
antibody response. Immunization of mice with adjuvanted PS (LASV GP1) enhanced the quality 
of the humoral response to LASV GP1, eliciting antibodies with higher binding affinity to virion 
GP1, increased levels of polyfunctional anti-viral CD4 T cells, and the frequency of IgG-secreting 
B cells. PS (LASV GP1) elicited a more diverse epitope repertoire of anti-viral IgG. In a second 
part, we employed the PS platform in combination with single cell B cell sorting and cloning of 
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recombinant IgG to generate a first set of species-specific mAbs against MACV. These new mAbs 
show exquisite specificity and negligible cross-reactivity to closely related arenaviruses in 
relevant techniques making them a unique and powerful tool for research and diagnostics 
purposes. 
 
Keywords:  
Polymersomes, monoclonal antibodies, Lassa, Machupo, vaccine, quality, CD4 T cell, B cell, 
dendritic cell, diagnostic. 
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RÉSUMÉ 
 
Les vaccins représentent aujourd’hui le plus effective moyen de contrôler et prévenir les maladies 
infectieuses et ayant un impact sur la santé publique ainsi que la qualité et l’espérance de vie. 
Pendant ces dernières années plusieurs innovations technologiques et conceptuels dans les 
domaines de la bioingénierie et l’immunologie ont permis le développement d’un nouveau genre 
de vaccin. L’expansion des domaines tels que la biologie structurelle, l’isolation des anticorps 
monoclonaux humain, le séquençage « high throughput » et le design des nouveaux transports 
des antigènes par « nanocarrier delivery platforms » ont complètement changé le concept actuel 
de la vaccination. La nouvelle formulation des vaccins a permis le design des antigènes dit « sur 
mesure » et des nano-véhicules lesquels ont donné la possibilité d’améliorer et maîtriser la 
réponse immunitaire contre des pathogènes connus et émergeants. Au cours des dernières années 
les pathogènes émergeants chez l’homme capables de causer des épidémies sérieuses sont devenu 
un problème de santé publique majeur. Les récentes épidémies provoquées par les virus Ebola et 
Zika ont démontré qu’il existe un besoin urgent de développer des mesures prophylactiques et 
thérapeutiques contre les virus pathogéniques humain. 
Les vaccins qui rencontrent le plus de succès jusqu’à présent dépendent principalement de 
l’immunisation à l’aide de vecteurs vivants atténués. Néanmoins, les problèmes de sécurité 
associés aux vecteurs vivants atténués font du développent d’alternatives plus sures une priorité. 
Par conséquent, les vaccins sous-unités, composés d’éléments microbiaux et protéiques, sont 
apparus comme une solution plus sûre, par contre moins immunogénique. Pour adresser cette 
problématique notre laboratoire travaille dans le développement des systèmes d’immunisation qui 
permet à la fois la conception des vaccins recombinants sous-unités et la production rapide des 
anticorps monoclonaux spécifiques en utilisant que des immunogènes biosynthétiques sans 
besoin de l’isolation et culture préalable de l’agent pathogène. 
La stratégie suivie dans cette thèse est basée sur une nouvelle plateforme de polymersome (PS) 
comme moyen de cargaison et de livraison de l’antigène pour l’induction d’une réponse 
immunitaire humorale améliorée. Les caractéristiques des PS ont été investigué à l’aide de deux 
pathogènes humain appartenant aux arénavirus, le Lassa virus (LASV), endémique dans l’Afrique 
de l’ouest, et le virus de Machupo (MACV) présent à Bolivie. Ces deux virus sont à l’origine de 
nombreux cas de fièvres hémorragiques sévères chez l’homme et pour lesquelles il n’existe ni de 
vaccin ou de traitement disponible approuvés ni d’outils de diagnostic spécifiques. 
Dans une première partie nous avons décidé d’étudier la faisabilité d’un vaccin PS pour la 
livraison de l’antigène du virus Lassa, dont la glycoprotéine 1 (LASV GP1). Cette protéine est 
connue pour faible antigenicité et une faible réponse humorale. L’immunisation des suries avec 
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LASV GP1 encapsulée dans des PS enrichie la qualité de la réponse humorale contre LASV GP1 
et élicite un répertoire des épitopes IgG plus diverse. Dans une deuxième partie nous avons utilisé 
la plateforme PS en combinaison avec l’isolation unicellulaire des cellules B et le clonage des 
IgGs recombinantes pour générer des premiers anticorps monoclonaux contre MACV. Ces 
nouveaux anticorps ont une haute spécificité pour les protéines de MACV et ont montré une 
réactivité négligeable contre des virus semblables de la même famille, faisant de ces anticorps des 
outils uniques pour le développement des techniques de recherche et diagnostique. 
En résumé, cette thèse décrit deux études exhaustives, qui ont permis la production rapide 
d’anticorps spécifiques grâce à l’amélioration des réponses immunitaires adaptatives générées 
après la l’administration des vaccins basés sur des nano-vecteurs. De plus, les avances 
scientifiques ici exposées sont immédiatement applicables pour établir de nouvelles lignes 
directrices pour le design de nouveaux vaccins. On espère que cette thèse peut bénéficier à la 
communauté afin qu’elle soit mieux préparée pour la prochaine menace pandémique. 
 
Mots-clefs 
Nanoparticule, polymersome, anticorps, Lassa, ganglion lymphatique, vaccin, qualité, cellule T 
CD4+, cellule T CD8+, cellule B, cellule dendritique 
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INTRODUCTION 
 
MOTIVATION 
 
Over the past decades emerging human pathogens with the potential to cause severe epidemics have 
become a major public health problem. In 2015, experts from the World Health Organization published 
a priority list of eight pathogens likely to cause serious outbreaks in the near future. The list includes 
highly pathogenic viruses like Ebola virus, Middle East respiratory syndrome (MERS), and Lassa virus. 
Most of these highly contagious viral pathogens are causative agents of severe diseases with high case 
fatality rates. These emerging pathogens frequently affect poor countries of the developing world, which 
is exacerbated by the current lack of effective therapies or preventive measures. For these reasons, the 
development of affordable and reliable diagnostics, efficacious anti-viral drugs, and protective vaccines 
represents an urgent need.  
Arenaviruses belong to a diverse viral family of emerging zoonotic pathogens that are important 
causative agents of severe hemorrhagic fevers in humans. They are predominately found in the Americas 
and Africa and are commonly classified as either New or Old World arenaviruses, respectively. The 
most relevant pathogen among all arenaviruses is Lassa virus (LASV) that currently threatens circa 200 
million people living in Western Africa. With several hundred thousand infections per year and over 
5,000 deaths annually, LASV represents a serious public health problem in the affected regions [1]. The 
South American hemorrhagic fever viruses Junin (JUNV), Machupo (MACV), and Guanarito (GTOV) 
have emerged as causative agents of severe human diseases with high fatality rates in the Americas. Due 
to their proven transmissibility via aerosol and high lethality, hemorrhagic arenaviruses are considered 
category A select agents by the Centers for Disease Control and Prevention. Currently, there are no 
FDA-approved vaccines available for the prevention of arenavirus infection. Treatment options are 
limited to supportive care and the off-label use of ribavirin, which is effective only when given early 
during the course of infection and has relevant side effects [2].  
The last Ebola virus outbreak in Western Africa 2013-2016 demonstrated in a dramatic manner 
that there is an urgent need to develop prophylactic and therapeutic approaches against hemorrhagic 
fever viruses as part of a global preparedness for future epidemics. Vaccines are a major success in 
modern medicine as a prophylactic measure to reduce the mortality of viral infections. Considering the 
amount of people affected and the limited public health infrastructure in the regions with high pathogen 
prevalence, the development of safe and efficacious vaccines and therapeutic approaches against 
hemorrhagic arenaviruses is of high priority. Antibodies targeting viral attachment proteins play a 
crucial role in vaccine-mediated protection against many viral infections [3-5] and hold promise for 
therapeutic approaches [6]. Specific antibodies to emerging viruses are further invaluable tools for 
diagnostics and biomedical research. Despite successful development of promising experimental life 
vaccine candidates against some pathogenic arenaviruses, biosafety concerns prevented so far FDA-
?
?
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approval for human use. Therefore, there is an urgent need to engineer immunization platforms which 
allow 1) the development of safe recombinant subunit vaccines and 2) the rapid generation of specific 
monoclonal antibodies using biosynthetic immunogens without the need for prior isolation of the agent. 
The development of such a platform must combine a state-of-the art bioengineering, protein 
biochemistry, and viral immunology. The approach evaluated in the present studies is based on a novel 
polymersome (PS) platform serving as nanocarrier for efficient antigen delivery and the induction of 
humoral immunity. In a first part, we evaluated the PS platform’s capacity to enhance humoral immunity 
against the envelope glycoprotein of LASV that is notorious for its weak immunogenicity and poor 
antibody response. In a second part, we employed the PS platform in combination with single cell B cell 
sorting and cloning of recombinant IgGs to try to generate a first set of species-specific mAbs against 
MACV.   
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BACKGROUND 
 
Discovery, classification, and ecology of Arenaviruses 
The discovery of arenaviruses dates back to 1933 when the prototypic lymphocytic choriomeningitis 
virus (LCMV) was isolated by Armstrong and Lillie from brain tissue of a victim of a St. Louis 
encephalitis epidemic [7, 8]. A few years later, Rivers and Scott isolated a similar virus from a case of 
aseptic meningitis and found serologic cross-reactivity with the filterable agent previously isolated by 
Armstrong and Lillie. In sections of electron microscopic images, the virions showed a characteristic 
“sandy” (Lat. arenosus) aspect, due to inclusion of ribosomes. Combined with serological and 
biochemical evidence, a new virus family, the Arenaviridae, was proposed in 1970. 
The Arenaviridae family has been recently separated by the International Committee on 
Taxonomy of Viruses into a main genus Mammarenavirus and a novel genus Reptarenavirus [9], the 
latter including several species of arenaviruses isolated from snakes. Based on phylogenetic analysis 
and serological data at hand, the Mammarenaviruses are currently divided into two major groups: the 
Old World and the New World arenavirus complex [10] (Fig. 1). For simplicity, I will henceforth use 
the classical term “arenaviruses” synonymous for the entire family and members of the 
Mammarenavirus genus. Where applicable, viruses of the Reptarenavirus genus will be specifically 
referred to. The Old World arenavirus lineage contains the prototypic LCMV that shows world-wide 
distribution [11]. The infection of LCMV in the mouse has served as a veritable Rosetta’s Stone to 
dissect fundamental mechanisms of viral pathogenesis and immunology leading to fundamental 
discoveries in viral immunobiology awarded by several Nobel Prizes [8, 12]. In pediatric medicine, 
LCMV is increasingly recognized as a relevant and under-diagnosed human pathogen and severe 
infections have been observed in immune-compromised transplant patients [13-15]. The highly 
pathogenic Lassa virus (LASV) is widely distributed over large areas of Western Africa, where the virus 
has been endemic for over 1000 years [16, 17]. Lujo virus (LUJV) recently emerged in Southern Africa 
associated with a cluster of fatal infections, but has remained elusive ever since [18]. The African 
arenaviruses Mopeia, Mobala, and Ippy virus have until now not been associated with human disease 
and their pathological potential remains unclear.  
The New World arenaviruses are divided into Clades, A, B, C, and D. Clade D corresponds to 
former Clades A/B or A/rec and may have resulted from recombination events between members of 
Clade A and B [9]. Viruses of Clade B include all human pathogenic viruses, namely Junin (JUNV), 
Machupo (MACV), Guanarito (GTOV), Sabia (SABV), and Chapare (CHAV) virus. Interestingly, these 
viruses do not group within a specific sub-Clade, but cluster phylogenetically with closely related non-
pathogenic viruses such as Tacaribe (TCRV) and Amapari virus (AMPV) [19].  
Arenaviruses are zoonotic pathogens and a short number of closely related rodent species serve 
as reservoirs for each arenavirus species in nature [10, 20]. These reservoir hosts are persistently 
?
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infected, and show no overt signs and symptoms of disease, resulting in a so-called “carrier” state, 
characterized by high levels of viral multiplication in all organs and extensive shedding in urine, saliva, 
and feces [8]. The current phylogenetic diversity among arenaviruses is probably the result of long-term 
co-evolution between these viruses and their host species. Mechanisms that drive arenavirus diversity 
are evolutionary radiation of rodent species, vertical and horizontal transfer of viruses within and 
between populations, as well as recombination and reassortant events [9, 11]. The reservoirs of LASV 
are semi-domestic rodents of Mastomys species [21]. Similar to murine species harboring LCMV (Mus 
domesticus and Mus musculus), M. natalensis invades human dwellings and index cases of Lassa fever 
are related to contacts with infected rodents [16]. Reservoir-to-human transmission is the major route of 
LASV infection in man and occurs mainly via aerosol or close contact with rodent excreta, as well as 
contamination [17, 22]. Human-to-human transmission of LASV has been reported in nosocomial 
outbreaks associated with high case fatalities [23]. JUNV causing Argentine haemorrhagic fever (AHF) 
occurs seasonally with a peak between April and June linked to the dymanics of the feral populations of 
Calomys field voles [24, 25]. Human transmission of JUNV and MACV results from inhalation of 
contaminated dust or consumption of contaminated food [26]. Abnormally low rainfall, combined and 
excessive use of insecticide, decimated cats, allowing rapid expansion of MACV-infected Calomys 
rodents. TCRV was initially isolated from bats [7] and has recently been detected in host-seeking 
Amblyomma americanum ticks  [27]. It is however unclear if the presence of virus in ticks is the 
consequence of passive spill-over or active viral replication in arthropod tissues.  
 
 
Figure 1. Geographic distribution of human pathogenic arenaviruses. The year of the first description 
is indicated in brackets. 
 
Structure and life cycle of arenaviruses 
The Arenaviruses are enveloped negative-strand RNA viruses that form spherical to pleomorphic 
particles with diameters of 50–300?nm [28] (Fig. 2). The viral genome is comprised of two RNA 
segments. The large (L) segment of ca. 7.3?kb and the small (S) segment of ca. 3.5?kb) contain each two 
?
?
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open reading frames (ORF) in opposite orientation, separated by a noncoding intergenic region with a 
predicted hairpin structure. The S RNA segment encodes the nucleoprotein (NP) and the envelope 
glycoprotein precursor (GPC). The L RNA encodes the viral RNA-dependent RNA polymerase L, as 
well as the viral matrix protein Z. The viral GPC is synthesized as a single polypeptide chain and 
posttranslationally cleaved by the cellular proteases signal peptidase and subtilisin kexin isozyme-1/site-
1 protease (SKI-1/S1P) to yield an unusually stable signal peptide (SSP), the mature virion glycoproteins 
GP1 and GP2 [29]. The mature SSP/GP1/GP2 complex forms a trimer and represents the functional unit 
of virus-cell attachment and virus fusion [30]. The N-terminal GP1 engages cellular receptors, and 
decorates the tip of the virion spike [31, 32]. The C-terminal GP2 resembles fusion-active envelope GPs 
of other viruses and is implicated in viral fusion [33]. 
 
 
Figure 2: Virion structure (A) and genome organization (B) of Arenaviruses. For details, please see 
text. 
 
The arenavirus life cycle is non-lytic and confined to the cytoplasm [30, 34-40]. As for every virus, the 
first step of arenavirus infection requires attachment of the virion to one or more cellular receptor(s) 
(Fig. 3A). Most Old World arenaviruses, including LCMV and LASV, as well as the Clade C New 
World viruses Latino and Oliveros use dystroglycan (DG), a ubiquitously expressed receptor for 
proteins of the extracellular matrix (ECM), as a high affinity receptor (Fig. 3B) [41, 42]. In developing 
and adult tissues, DG provides a molecular link between the ECM and the actin-based cytoskeleton. 
Initially encoded as a single polypeptide, DG is cleaved into the extracellular α-DG and membrane 
anchored β-DG [43]. In mammals, α-DG is subject to complex post-translational modifications that are 
essential for its function as a receptor for ECM proteins and arenaviruses [44-46]. Unusual protein O-
mannosylation of α-DG is followed by synthesis of [Xyl-α1-GlcA-3-β1-3] co-polymers by the dual-
specific glycosyltransferase like-acetyl glucosaminyl transferase (LARGE) [47, 48]. The LARGE-
derived [Xyl-α1-GlcA-3-β1-3] polysaccharide is nown as “matriglycan” and recognizes ECM proteins 
and arenavirus GP1 [44, 49, 50]. The recently solved high-resolution X-ray structure of the pre-fusion 
conformation of LASV GP indicates that multiple residues located at the trimeric interface engage the 
DG-derived matriglycan polymers with high avidity [32]. The DG core protein is ubiquitously expressed 
in most mammalian cells similar to house-keeping genes. However, functional glycosylation of DG by 
?
?
??
LARGE is subject of tight tissue-specific control [49]. This makes DG appear as a “tunable” receptor, 
whose virus-binding affinity critically depends on LARGE modification and greatly varies between 
tissues.  
Upon receptor attachement, Old World arenaviruses use an endocytotic pathway resembling 
macropinocytosis for cell entry [38, 51, 52].  Subsequently, the virus passes through the multivesicular 
body and reaches the late endosome [53]. At the late endosome, LASV GP1 undergoes a unique 
“receptor switch”. Acidic pH (<5.5) induces major conformational changes in LASV GP1, resulting in 
dissociation from DG-linked matriglycan. A triad of His residues characteristic of the low pH 
conformation of LASV GP1 engages the late endosomal/lysosomal protein (LAMP)-1, followed by 
fusion triggering [54]. Fusion of the viral membrane with the limiting membrane of the late endosome 
by the fusion-active GP2 creates a “fusion pore”. Within the arenaviruses, the dependence on LAMP-1 
for cell entry is unique for LASV [55, 56] and represents an interesting analogy to the filoviruses Ebola 
virus, whose fusion depends on the late endosomal protein Niemann-Pick C1 [57]. 
New World arenaviruses of Clade B use transferrin receptor (TfR)-1, a highly conserved cargo 
receptor involved in iron metabolism, and clathrin-mediated endocytosis (CME) for cell entry [58]. The 
ability of a Clade B New World arenavirus to use the human orthologue of TfR1 is linked to its potential 
to cause hemorrhagic fever in human [59, 60]. In contrast, non-pathogenic viruses use TfR1 orthologues 
from other species. More recently, the Tyro3/Axl/Mer (TAM) receptor tyrosine kinases Axl and 
Tyro3/Dtk, T cell Immunoglobulin Mucin (TIM) proteins 1 and 4, as well as the C-type lectins DC-
specific ICAM-3-grabbing nonintegrin (DC-SIGN) and LSECtin have been identified as novel 
candidate receptors for arenaviruses [61-65], but their exact role is currently unclear.  
At the fusion pore, the arenavirus capsid disassembles to free the viral ribonucleoprotein (RNP) 
by an unknown mechanism of “uncoating”. According to the negative-strand genome, the arenavirus 
RNP is comprised of viral RNA, NP, and the polymerase L, comprising the minimal unit of viral 
transcription and replication. Viral transcription is initiated by the L polymerase at the incoming RNP, 
resulting in expression of NP and L. As NP accumulates, the viral polymerase progressively shifts to a 
replicase mode, generating full-length antigenomic RNA in positive-strand orientation that serves as 
template for the transcription of GPC and Z as well as synthesis of further copies genomic RNA [66]. 
Newly synthesized NP assembles the viral replication-transcription complexes (RTC) that become 
initially apparent as discrete puncta at the light microscopy level that grow in size and progressively 
coalesce into larger structures distributed throughout the cytosol [67, 68]. Arenavirus RTC are 
membrane-associated structures that contain cellular lipids and proteins, including translation factors of 
the eIF4F complex, suggesting the formation of membrane-associated “platforms” for viral transcription 
and replication [67, 68].   
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In the final stages of the arenavirus life cycle, progeny particles assemble and are released by 
budding from the plasma membrane. The key factor in the budding process is the small RING finger Z 
protein that functions as a bona fide matrix protein in arenavirus particle assembly [36, 69]. As with 
other matrix proteins of enveloped viruses, arenavirus Z interacts with the cytosolic tail of GP2 [70] and 
specific cellular factors of the endosomal/multiple vesicle body pathway to drive the budding of viral 
particles from “budding zones” [34, 36, 39, 69].  
 
 
Figure 3: LASV receptor and life cycle. (A) The life cycle of LASV. (B) Schematic representation the 
LASV receptor DG found in muscle cells associated with the ECM protein laminin (Dr. Renzi Han, 
Loyola University).  
 
Structure-function relationship of the LASV and MACV attachment glycoproteins 
During maturation, processing of the arenavirus GPC precursor by SKI-1/S1P yields the N-terminal 
GP1, which is implicated in binding to the cellular receptors [71] and the transmembrane GP2 that 
mediates fusion and resembles class I viral fusion proteins [33, 72, 73] (Fig. 4A). Arenavirus GPC 
contain a remarkably stable signal peptide (SSP) of 58 amino acids that contains two hydrophobic 
domains and undergoes myristoylation at its N-terminus [74-77]. In the mature tripartite complex 
SSP/GP1/GP2 that forms the trimeric virion spike, SSP interacts with the GP2 subunit (Fig. 4B). 
Examination of LASV particles in electron cryomicroscopy combined with tomography revealed that 
the trimeric SSP/GP1/GP2 complex undergoes significant changes when exposed to low pH [78].  
Resolution of the X-ray structures of the GP1 of LASV, MACV, and JUNV revealed a similar 
compact α/β fold, despite significant sequence variation [79-81]. High-resolution structures of MACV 
GP1 in complex with its receptor TfR1 revealed that the GP1 monomer represents the functional unit of 
receptor recognition and that trimerization is not required for receptor binding [60, 82]. In these studies, 
MACV GP1 was found to bind to the apical surface of hTfR1 without competing with transferrin 
binding. More recent crystallographic studies resolved the structure of the pre-fusion conformation of 
the mature envelope GP of the prototypic Old World arenavirus LCMV [31]. Within the pre-fusion 
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trimer, LCMV GP1 and GP2 undergo extensive interactions, involving ionic bonds. In contrast to the 
New World arenaviruses, monomeric LCMV GP1 is unable to bind the receptor DG with high affinity, 
suggesting that either avidity or the quaternary structure of the pre-fusion trimer is required. Recently, 
the crystal structure of the ectodomain of LASV GP in its trimeric, pre-fusion conformation was solved 
in complex with a nAb from a human survivor [32] (Fig. 5). These studies illuminate the structural basis 
for neutralization of LASV by a nAb that clamps two of the monomers together at the base of the trimer. 
The nAb may neutralize by blocking conformational changes taking place within the trimer that are 
required for receptor binding, the late endosomal receptor switch mentioned above, and fusion. In an 
elegant study, Pinschewer et al, provided evidence for an inherently low immunogenicity of LASV GP1 
as a consequence of extensive glycan shielding, [83], which is similar to the situation with other viruses 
like human immunodeficiency virus (HIV)-1. In line with this, the exposed surfaces at the side and lower 
portions of the LASV GP trimer are extensively shielded by N-glycans, leaving only a few “cracks in 
the armor” vulnerable to Ab binding.  
Once delivered to the late endosome, low pH sets off a series of conformational changes leading 
to shedding of GP1, engagement of LAMP-1, and triggering of fusion of the viral and cellular membrane 
mediated by GP2 (Fig. 4C). The post-fusion conformation of arenavirus GP2 is similar to the six-helix 
bundle conformation common to a number of class I fusion proteins of enveloped viruses [33, 73]. The 
SSP is crucial for transport and processing of arenavirus GPC [74-76, 84, 85]. Both N- and C-termini of 
SSP are located in the cytosol [86] and SSP associates non-covalently with a zinc-binding domain within 
the cytoplasmic tail of GP2 [87, 88]. The SSP-GP2 interactions critically modulate pH-induced 
activation of membrane fusion [89, 90] and are targeted by a range of potent arenavirus fusion inhibitors 
[91, 92], pinpointing this unique feature of arenavirus fusion as a target for the development of anti-viral 
therapeutics. 
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Figure 4. Maturation and trimerization of arenavirus GP. (A) The arenavirus GPC precursor is 
comprised of the stable signal peptide (SSP), GP1, and GP2. The transmembrane domain and the site of 
SKI-1/S1P cleavage are indicated (scissors). (B) Sequential processing of arenavirus GPC in the 
secretory pathway by signal peptidase (SPase) and SKI-1/S1P. The mature tripartite complex 
SSP/GP1/GP2 forms the mature trimeric GP spike (C) The mature GP trimer decorates the virion surface 
and engages cellular receptors. Under acidic pH, GP1 dissociates and liberates the fusion peptide of 
GP2, triggering fusion between the viral and the cellular membrane.  
 
Figure 5: Cartoon representation of the LASV GP extodomain trimer from the front, side, and top [32]. 
The GP1 subunit of each monomer is in a light shade and the GP2 subunit in a dark shade. In the top 
view, spheres indicate positions of the C-terminus of GP1 and the N-terminus of GP2 at the trimeric 
interface. (B) The crystal structure of the LASV GP trimer (cartoon) docked into the tomographic 
reconstruction of the LASV GPC spike from fixed virions in the same orientations as shown in (A).? 
Pathogenesis and immune response to pathogenic arenaviruses infection 
After an incubation period of 7-18 days Lassa fever manifests initially with non-specific, flu-like signs 
and symptoms, including fever, weakness and general malaise [16]. Signs of increased vascular 
permeability such as facial and lung edema, as well as mucosal bleeding are associated with poor 
prognosis [1, 93, 94]. Contagiousness initiates with the onset of symptoms and increases with disease 
severity, consistent with the presentation of pharyngeal shedding, vomiting, diarrhea and bleeding, 
together with high levels of viral load in body fluids. The virus is shed in urine for six weeks and up to 
six months in semen. In severe cases, patients develop progressive symptoms of shock, accompanied by 
internal bleeding. Those recovering develop a robust cellular anti-viral immune response during the 
second week of disease and clear the virus. A highly predictive factor for disease outcome in human 
Lassa fever is the serum viral load [95]. Patients with fatal disease have higher initial viral loads (>106 
PFU/ml) and are unable to limit viral spread. Survivors have lower initial viremia and control infection 
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progressively. In contrast to the persistent infection in their rodent reservoir hosts, there is no evidence 
for persistence of arenaviruses in man and survivors clear the virus completely [25, 96], although there 
is recent evidence for protracted infections [17]. 
 A widely known particularity of fatal LASV infection is virus-induced suppression of the host’s 
innate defense, in particular the type I interferon (IFN) response, that represents an early and decisive 
barrier against viral infections.  The ability of LASV to efficiently suppress innate immunity is linked 
to the NP. The NPs of all known arenaviruses contain a 3’-5’ exoribonuclease function in their C-
terminal domain, which may be involved in degradation of viral RNA, thereby removing the viral 
“danger signal” recognized by the host cell’s pathogen recognition receptors (PRR) of the RIG-I helicase 
and Toll-like receptor (TLR) family [97]. More recent studies identified the Z protein as an additional 
IFN-I antagonist that targets RIG-I and prevents IFN-I induction [98, 99]. Interestingly, only Z proteins 
of human pathogenic viruses, but not non-pathogenic viruses, can bind to human RIG-I, pinpointing Z 
as a classical virulence factor. Following productive viral infection at the site of entry, the virus rapidly 
enters the bloodstream to reach lymph nodes, spleen, and liver. In lymphoid organs, LASV efficiently 
targets antigen presenting cells (APC), in particular dendritic cells (DCs), which represent the most 
important class of professional APC in primo infection. Instead of being recognized and presented as a 
foreign antigen, LASV establishes productive infection in DCs and perturbs their capacity of antigen 
presentation [100, 101], contributing to immunosuppression in severe infection. Examination of fatal 
Lassa fever cases revealed little tissue damage and inflammation, suggesting a weak anti-viral immune 
response [93, 102]. Considering existing clinical and experimental data, it appears that LASV uses a 
dual strategy to suppress adaptive immunity on the one hand blocking antigen presentation by DCs and 
on the other hand promoting exhaustion of anti-viral CD8 T cells. The pathophysiology of the terminal 
hemorrhagic shock syndrome is largely unknown. Blood loss in Lassa fever is minimal and there is little 
evidence for a “cytokine storm” observed in classical hemorrhagic fevers [16]. The terminal shock 
syndrome in Lassa fever may involve functional changes in vascular endothelial cells preceding shock 
and death, combined with alterations in liver, adrenal gland, and other organs [1, 93]. In survivors, anti-
viral CD8 T cells represent a major correlate of protection, indicating a pivotal role of cellular immunity. 
Neutralizing antibodies to LASV appear only late in convalescence and are frequently of low titers. 
Their role in protection against re-infection is currently unclear. However, if provided at sufficiently 
high titers, nAb to LASV proved to be protective in post-exposure prophylaxis in animals [103, 104], 
and in human cases [105, 106], providing proof-of-concept. 
 In contrast to LASV that efficiently evades and suppresses the cellular IFN-I and cytokine 
response, infection with New World arenaviruses like JUNV and MACV results in elevated cytokine 
levels [107, 108]. Indeed, patients with exacerbated disease consistently show elevated levels of TNF-
α  and INF-I. To what extend these enhanced cytokine levels reflect simply higher viral loads is currently 
unknown. In contrast to LASV, JUNV and MACV elicit a robust nAb response in the second week of 
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disease that correlates with positive disease outcome [24]. The strong nAb responses against New World 
arenaviruses points out that the viral GP1 is immunogenic and a recombinant vaccine capable of 
inducing sufficient nAb titers seems feasible. The reasons for the noticeable difference in quality of the 
antibody response between LASV and JUNV/MACV lie, at least in part, in the differential glycosylation 
of the GP1 moieties that represent the targets for nAb [83]. 
 
Current diagnostics and therapy against arenaviruses 
Molecular diagnostics based on real-time quantitative PCR, nucleic acid hybridization, and more 
recently next generation sequencing (NGS) proved invaluable for etiological diagnostics in the clinic 
[109-112]. In recent years, highly sensitive PCR-based molecular diagnostics tests for arenaviruses have 
been developed, including reverse-transcription (RT)-PCR assays for the detection of LASV by 
targeting conserved regions of the L gene, an improved RT-PCR for Lassa virus amplifying the 5’region 
of the S RNA, and an RT-PCR assay coupled with oligonucleotide array hybridization [113].With these 
recent developments, RT-PCR has become the method of choice for the detection of LASV. A recent 
study performed in Nigeria demonstrated that the establishment of a laboratory routine based on 
molecular diagnostics significantly improved Lassa fever case management [114]. For the South 
American viruses, molecular diagnostics is less developed and the design of virus-specific RT-qPCR 
routines faces the problem of extensive sequence variation between geographic isolates.   
Complementary to molecular diagnostics, serology remains crucial for etiological diagnosis and 
sero-epidemiological studies of human arenavirus infection. Common antibody detection systems used 
in routine diagnostics include immunofluorescence assay (IFA), enzyme-linked immunosorbent assay 
(ELISA), and different formats of neutralization tests. Serology by IFA has been the classical method 
for arenavirus diagnostics for several decades and is still in use today. In this method, infected 
monolayers of Vero cells are inactivated by ultraviolet (UV) light, treated with acetone, or irradiated 
with gamma-rays. Drops of cell cultures mounted onto glass slides are then incubated with the patients’ 
serum and a specific antibody reaction is detected by IFA. The threshold is defined as a signal above 
background at a serum dilution of 1:4, which is difficult to assess. Moreover, the major viral antigen 
detected within acetone-fixed infected cell specimens is the viral NP, which results in serological cross-
reactions in the IFA test, in particular among New World arenaviruses [115, 116]. Greatest cross-
reactivity is observed between the closely related MACV and JUNV, followed by TCRV, which 
represents a major limitation of the method. ELISA using recombinant viral proteins has lately been 
developed as an alternative to IFA for early and rapid serological diagnosis, but face essentially the same 
restrictions for New World arenavirus diagnostics [117]. The neutralization test is considered specific 
for all members of the Arenaviridae. However, cross-reactivity was observed with high-titer reference 
sera between JUNV and MACV, which is a major problem and quantification of neutralizing antibodies 
(nAb) can therefore vary greatly (Dr. Delia Enria, personal communication). 
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 For routine isolation of virus from clinical samples and reservoir rodents in surveillance study, the 
E6 clone of Vero cells is used as a suitable cell line. However, a cytopathic effect is often difficult to 
detect, and definitive detection of virus in inoculated cultures requires examination by IFA or ELISA. 
A major limitation for the detection New World viruses is again the current lack on specific antibodies 
capable to distinguish in particular MACV from JUNV, which represent the major pathogens among the 
South American hemorrhagic fever viruses. 
Only one licensed drug for treatment of human arenavirus infection is the broad spectrum guanosine 
analogue ribavirin (Rib) (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) [118]. Rib reduces both 
morbidity and mortality in humans associated with LASV infection [119], and experimentally in MACV 
[120] and JUNV [25] infections, only when administered early during disease. Major problems with Rib 
are the limited bioavailability and the unwanted side-effects, in particular hemolytic anemia, and 
restriction of its use in some patient groups, e.g. pregnant women. Several experimental treatments are 
currently being evaluated for Arenaviruses, including antivirals, molecules targeting host cells and 
immunomodulators. However, none of these have undergone extended human trials. Due to space 
limitations, I therefore refer to recent reviews [121, 122]. Immune plasma transfer therapy for JUNV 
arenaviruses have been prove highly effective [25], but is frequently associated with a self-limiting 
neurological syndrome [24], whose pathophysiology is currently not understood. These potential 
complications underscore the need for alternative therapies.  
Current status of arenavirus vaccine development 
The only existing vaccine for the prevention of Argentine hemorrhagic fever caused by JUNV is the 
live-attenuated vaccine Candid 1 that was developed in the 1980s [123]. Candid 1 has been used in 
selected risk groups in Argentine, predominantly agricultural workers, where it turned out to be safe and 
with high efficiency. When the Argentine National Immunization Plan included the Candid 1 vaccine, 
morbidity and mortality rates dropped down significantly in the area. However, there are considerable 
concerns about the safety of the vaccine for the general population and Candid 1 has not yet been 
approved outside of Argentina. Considering the magnitude of the public health problem and its nature 
as an endemic disease, an effective LASV vaccine is of urgent need for the general population, 
healthcare and laboratory workers and military personnel. When in first place early trials with killed 
LASV vaccines did not succeed at eliciting a protective immune response [124], then, following efforts 
focused mainly on the development of live vaccines. Initially, in a vaccine called ML29, LASV was 
attenuated by generating genetic reassortants with the less pathogenic Mopeia virus [125]. This 
reassortant vaccine, showed efficacy in guinea pigs [126] and small non-human primates [127]. 
However, despite the attenuation of ML29 and Candid1, the use of these live vaccines in population of 
the affected areas encounters large limitations due to safety concerns and the prevalence of 
immunosuppressive conditions, making them not suitable from broad vaccine campaigns. Evaluation of 
recombinant viral platforms for antigen delivery, including vaccinia virus [128], vesicular stomatitis 
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virus [129, 130], and the Yellow Fever virus vaccine strain 17D [131] revealed that the solely presence 
of arenavirus GP was necessary and sufficient to confer protection in different live models. One of the 
imitations of recombinant viral platforms is the host immunity elicited against the vector backbone and 
the biosafety concerns related to life replicating agents. A promising safety profile is the most appealing 
feature of inactivated (‘killed’) vaccines or other non-replicating vaccine approaches, such as virus-like 
particles (VLPs), peptide-based, and DNA vaccines. Although these vaccine approaches induced 
specific immune responses in animal studies, they had in general low immunogenicity and efficacy 
[132]. Another approach undertaken in LASV vaccine development are epitope-based vaccines. Using 
computer-assisted algorithms, protective MHCI-restricted CD8 T cell and MHCII-restricted CD4 T cell 
epitopes have been identified in LASV GP and NP that confer cross-protection against viral challenge 
with LCMV [133]. However, while application of a peptide vaccine in naive individuals might be safe, 
administration to individuals previously exposed to the pathogen, may trigger re-activation of memory 
CD8 and CD4 T cells, which could result in immunopathology. This is of particular concern for LASV 
due to locally high seroprevalence of up to 40% among adults in some parts of Western Africa [134]. 
Alphavirus replicon technology is a convenient solution between ‘killed’ vaccines and replication-
competent platforms due to its safety and immunogenicity profiles. Particles derived from alphavirus 
replicons, while they are unable to spread beyond the first infected cells, they can deliver and transduce 
the genes of interest in target cells and stimulate similar immune responses as those elicited by 
alphavirus-vectored vaccines and inactivated vaccines. RNA replicon vectors derived from an 
attenuated Venezuelan equine encephalitis virus (VEEV) were successfully applied to express LASV 
GPC and NP proteins, and protect guinea pigs against fatal Lassa fever [135]. Up to this point, the 
previously presented vaccine platforms haven’t been developed any further nor underwent human 
vaccine trials. 
Antiviral antibody responses 
Immune control of viruses frequently requires a cooperation of the cellular and humoral responses of 
the adaptive immune system. In higher vertebrates, the immune response to viral infection includes the 
production of antibodies capable of recognizing a remarkably diverse array of antigens, including 
glycoproteins decorating viral particles [5, 136]. The antibody response plays an important role in 
protection against viral infections and this protection combines virus neutralization and effector-
mediated destruction of virions and infected cells, which prevents infection spread and lowers viral load 
and clinical symptoms. Neutralizing antibodies represent therefore a major immunological correlate of 
protection in many successful vaccines [136]. Even though neutralization is probably the most powerful 
function antibodies exert against viruses, the neutralizing activity of a given serum or monoclonal 
antibody is essentially an operational definition that strongly depends on the assays used. This is 
illustrated by a very recent collaborative study aiming at the standardization of antibody neutralization 
tests for Ebola virus to establish an International Reference Reagent through WHO that included to 16 
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laboratories and 22 different assays [137]. Across the board, quantitative correlation was generally poor, 
with only five of the 22 assays giving a correlation coefficient of 0.7 or greater. Notably, among the five 
best assays ranged a VSV pseudotype neutralisation test similar to the one used in my studies. The 
correlation between neutralizing titers assessed in vitro with protection in vivo is challenging and 
requires careful standardization. Moreover, there is evidence from work on LCMV that non-neutralizing 
antibodies to GP1 can confer some degree of protection, e.g. by preventing persistent viral infection 
[138]. Mechanistically, protecting activity requires antibodies to be of relativity high affinity/avidity for 
the exposed structures on the viral surface. If such antibodies cover the virion surface to a sufficient 
degree, they can prevent viral infectivity by interfering with receptor binding and cell entry. For many 
viral systems, this simple model proposed by Parren and Burton in 2001 is supported by available 
experimental data on virus neutralization [3, 139]. Moreover, the process of viral entry may require 
conformational changes of viral surface proteins and antibody binding can prevent viral entry by 
interfering with such conformational changes. During co-evolution with their vertebrate reservoir hosts, 
many viruses developed strategies to evade an effective humoral anti-viral immune response. The 
envelope glycoproteins of many viruses form oligomers in which a considerable proportion of the 
monomeric surface of the viral attachment protein is hidden at the inner face of the multimer, limiting 
antibody accessibility. Enveloped viruses including major pathogens such as HIV-1, Ebola, and LASV, 
use extensive “glycan shielding” to avoid antibody recognition [136, 140]. The host cell-derived N- and 
O-glycans present on viral GPs decrease immunogenicity since they are recognized as “self”. Mature 
LASV GP has 11 potential N-linked glycosylation sites on each of the monomers, whereas MACV GPC 
has only 5 glycosylation sites in total [83]. In addition, other factors can influence the antigenicity of 
native viral surface including the accessibility of the antibody to the antigenic sites as mentioned above, 
the structural arrangement of the glycoproteins on the surface and the host’s B-cell repertoire specificity 
for epitopes in the accessible sites (Fig. 6).   
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Figure 6: Overview of the factors influencing the immunogenicity of viral surfaces. A) Accessibility of 
the antigenic site is determinant for the immunogenicity of viral surfaces. B) Organization of antigens 
in the viral surface can modulate T cell antibody production. C) B-cell repertoire determines the quality 
of the antibody response. [141]. 
Subunit vaccines  
Increasing knowledge in the field of vaccinology allowed defining the immunogenic components of 
existing vaccines that are responsible for eliciting protective immune responses. This permits to isolate 
specific antigenic parts from a pathogen, avoiding the inclusion of virulence factors that could 
potentially promote disease. Subunit vaccines are formulated based on such synthetic or biosynthetic 
antigenic components, combined with immunostimulatory compounds (adjuvants) to induce protective 
immunity. Subunit vaccines have the advantage that they can be reproducibly produced in bulk amounts 
[142] and lack exogenous materials that are often present in heat- or chemically-inactivated preparations 
of classical killed vaccines. For this reason, subunit vaccines are a priori safer than live-attenuated or 
killed vaccines and offer a controlled and targeted mode of immunization. A major drawback of 
recombinant vaccines is their reduced immunogenicity compared to life vaccines, especially in 
generating robust CD4+ and CD8+ T cell responses and the requirement of several boosts to achieve 
immunity [143]. To improve the induction of T cell responses, recombinant immunogens can be 
conjugated to nanocarriers of different chemical composition [144]. Vaccine parameters such as the 
administration route, delivery method, and adjuvant selection should be carefully chosen in order to 
enhance not only the magnitude, but also the quality of the immune response to novel subunit vaccine 
candidates. 
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The initial step during an immune response is the antigen uptake by APCs, followed by its 
presentation to T cells. Macrophages, B cells and dendritic cells (DCs) are traditionally known as 
professional APCs. In particular DCs have the capacity to efficiently present endogenous and exogenous 
antigen in the context of MHCI and MHCII, respectively, thus playing a crucial role in mounting both 
CD8 and CD4 T cell responses in primo infections [145-148]. The use of subunit vaccines capable of 
targeting DCs appears as a promising strategy to enhance their potency. Upon activation, DCs migrate 
to secondary lymphoid organs such as lymph nodes, where the immune response is initiated by antigen 
presentation [147, 149] followed by T cell differentiation and B cell class switching and maturation 
[149]. A widely used method to target subunit vaccines to lymph nodes is intradermal administration. 
Lymphatic capillaries in the skin take up macromolecules from the periphery, which reach afferent 
lymphatic vessels that drain into local lymph nodes where subunit vaccines are transported either by 
migratory DCs or in a cell-independent manner [150]. 
 
Antigen delivery via nanoparticulated platforms 
Vaccine delivery systems use biomaterials to mimic various properties of pathogens to increase 
immunogenicity of otherwise weak antigens. This is achieved by the design of vaccines that mimic size, 
geometry, antigen presentation kinetics, and molecular patterns of viral antigens. Other key feature of 
these nanocarrier platforms is the ability to protect the antigen from early degradation. Examples of 
particulate delivery systems include polymeric nanoparticles, micelles, dendrimers, immune stimulating 
complexes and polymersomes (PS) [151, 152]. Lately, nanoscaled capsules like PS have been 
successfully developed for entrapment and targeted transport of a broad range of active payloads with 
sustained controlled release. The regulation of unique features such as mechanical stability, shell 
permeability, monodispersity, and biocompatibility is key for the successful implementation of these 
artificial vesicles as sophisticated delivery vehicles for tunable immune responses. The so-called “smart 
polymersomes” are able to respond to various external stimuli as pH, temperature, redox potential, 
magnetic fields, or light in order to carry out a controlled release of the payloads. Their chemical nature 
frequently allows co-delivery of suitable adjuvants that provide the “danger signals” for local innate 
immune stimulation.  
Our laboratory recently developed a new PS nanocarrier systems based on the assembly of an 
amphiphilic block copolymer composed of polyethylene glycol (PEG) and polypropylene sulfide (PPS) 
shown in Fig. 7. These PS present several benefits as a vaccine platform. The aqueous interior allows 
secure transportation of hydrophilic molecules including immunogens and adjuvants avoiding chemical 
modification of the loaded molecules, while the surrounding membrane of the self-assembled bilayer 
vesicle can retain hydrophobic molecules [153]. The vesicle-like arrangement is determined by the ratio 
of the hydrophobic to hydrophilic composition of the block copolymers, and the solely presence of small 
amounts of oxidation power to oxidize PPS to the sulfoxide in the PS, is required to initiate the 
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destabilization of the vesicular aggregates into micelles which results in the release of the encapsulated 
content [154]. Moreover, the aggregates resulting from oxidation are sufficiently small for renal 
clearance [154].  
Recent strategies for developing preventative and therapeutic vaccines have focused on the 
ability to deliver antigen to DCs in a targeted and prolonged manner. Nanoscale biomaterials loaded 
with different molecules transit through the lymphatic system and are taken up by DCs localized in 
draining lymphnodes, processes that are dependent on particle size. Empirically, in vivo delivery to 
lymph node-resident DCs is optimal with nanoparticles with a diameter smaller that 200 nm [155], 
whereas particles bigger that 45 nm drain most efficiently through the tissue interstitium into the 
lymphatic system [150] [156]. Nanocarriers with approximately 100 nm diameter, e.g. PS, undergo 
efficient lymphatic transport followed by rapid endocytosis by DCs. In addition, PS have the ability to 
enhance CD4 T cell responses, which is beneficial for the induction of antibodies. Lastly, the 
encapsulation process is a straightforward procedure that does not require any chemical treatment of the 
protein immunogen, thus preserving its native conformation. In sum, the novel PS platform combines 
unique features that make it promising for the development of a safe recombinant vaccine and platform 
for the rapid production of specific monoclonal Abs against pathogenic viruses [157, 158]. 
 
Figure 7. Schematic representation of PEG-bl-PPS block copolymers and vesicles. Block copolymers 
composed of PEG and PPS self-assemble into oxidation-sensitive polymersomes in aqueous solutions. 
Hydrophobic and hydrophilic regions are shown in blue and red, respectively. 
Enhancing the efficacy of subunit vaccines - Adjuvants 
In subunit vaccines, recombinant antigens are formulated with adjuvant molecules that mimic pathogen-
associated molecular patterns (PAMPs), or “danger signals”, that function as agonists for TLRs. 
Adjuvanted vaccines could potentially offset the lack of stimulation and enhance pathogen-specific 
responses involved in protection. The first commercially available adjuvant used in order to improve the 
immunogenicity of vaccine against diphtheria was aluminum-based [159]. Together with aluminum, oil-
in-water emulsions were for a long time the sole compounds to be widely accepted. Adjuvants are used 
as part of a strategy to improve vaccine outcomes through synthetic or endogenous molecules that tune 
the immune effect which results in an enhanced and prolonged pathogen-specific immune response. In 
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addition, adjuvants can modulate the nature of the immune response by skewing towards a particular 
phenotype, favoring certain types of immunoglobulin classes or inducting different types of cytotoxic 
or T helper cell responses (Th1 vs. Th2). The low immunogenicity of certain antigens can be improved 
and the type immune response optimized, while reducing the amount of antigen required. Accordingly, 
succeeding the administration of different adjuvants cytokine responses of different nature can be 
observed. Generally, addition of TLR agonists to vaccine emulsions tunes the response towards a Th1 
phenotype. Small molecule adjuvants (SMA) involve, among others, natural products such as 
monophosporyl lipid A (MPLA), a derivative of bacterial lipopolysaccharides (LPS), which has a much 
safer profile than LPS while still retaining its immunomodulatory properties [160]. MPLA is known to 
be effective at promoting both CD8 and CD4 T cell responses, as well as inducing long-lasting humoral 
responses [161]. Currently, MPLA is included in several vaccines undergoing phase III clinical trials 
[162]. SMA also includes synthetic drug-like molecules such as imidazoquinolines, including 
resiquimod (R-848) [163] and gardiquimod [164], which act as TLR7/8 agonists. CpG-based adjuvants, 
often synthetic, are other examples of SMAs which act as TLR9 agonists. CpGs are immunostimulatory 
DNA sequences containing unmethylated CpG dinucleotides found naturally in bacterial DNA that are 
recognized by TLR9. CpG-B is the most used and best-characterized TLR9 agonists and acts on a broad 
range of APCs, improving antigen uptake and presentation, as well as cytokine secretion [165, 166].  
Preclinical studies in humans have demonstrated that a combination of adjuvants can synergize 
if united in the same vaccine formulation, making adjuvants more attractive for vaccine development. 
Innate receptors agonists could potentially become toxic at certain concentrations, thereby they must be 
administered carefully, in a manner that optimizes immunogeneicity but reduces counteractive local and 
systemic inflammatory reactions. 
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OUTLINE OF THE THESIS 
 
In a first part of my thesis described in chapter 2, we evaluated oxidation-sensitive PS for their ability 
to enhance humoral immunity against the poorly immunogenic GP1 surface antigen of LASV. Based 
on structural information, we designed a recombinant immunogen derived from LASV GP1 which was 
successfully encapsulated into the aqueous core of polymersomes and delivered in combination with a 
well-established adjuvant. Mice immunized with LASV GP1-loaded PS showed enhanced quality of the 
humoral response, including in particular antibodies binding to GP1 displayed at the surface of intact 
virion particles. The better quality of the antibody response correlated with an increase in polyfunctional 
anti-viral CD4 T cells and anti-LASV GP1 IgG-secreting B cells.  Peptide array analysis demonstrated 
a significantly broader epitope range of anti-viral IgG elicited by the polymersomes.  
In chapter 3, we applied our findings from chapter 2 to design a novel strategy to rapidly develop specific 
mAbs against newly emerging viral pathogens without the need of virus isolation or culture.  Starting 
from sequence information only, we provide proof-of-concept by developing a novel panel of “first in 
class” specific mAb to MACV GP1. The novel specific MACV GP1 mAbs were characterized for their 
potential use in diagnostics and research using established techniques. 
Chapter 4 summarizes structural studies on LASV GP1 that I performed during my stay of three month 
in the highly respected laboratory of Prof. Erica Ollman Saphire at the Scripps Research Institute in La 
Jolla, CA. Specifically, I undertook an attempt to obtain the crystal structure of the purified LASV GP1 
immunogen and performed antigen binding to a newly isolated human nAb.  
Finally, in Chapter 5 we summarize our findings, discuss about the implications of our results and 
present the future prospects of our studies.  
In collaboration with Marcela Rincon-Restrepo, I contributed to the demonstration of the efficacy of a 
peptide vaccine based on nanoparticles (NPs) to stimulate CD8 T cell responses upon intradermal 
delivery. Here, we provide evidence that PS loading has a strong impact on the quality of the immune 
response, skewing memory CD8 T cells to an effector-like memory phenotype. 
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ABSTRACT  
Lassa virus (LASV) causes severe hemorrhagic fever with high mortality, yet no vaccine currently 
exists. Antibodies targeting viral attachment proteins are crucial for protection against many viral 
infections. However, the envelope glycoprotein (GP)-1 of LASV elicits weak antibody responses due to 
extensive glycan shielding. Here, we explored a novel vaccine strategy to enhance humoral immunity 
against LASV GP1. Using structural information, we designed a recombinant GP1 immunogen, and 
then encapsulated it into oxidation-sensitive polymersomes (PS) as nanocarriers that promote 
intracellular MHCII loading. Mice immunized with adjuvanted PS (LASV GP1) showed superior 
humoral responses than free LASV GP1, including antibodies with higher binding affinity to virion 
GP1, increased levels of polyfunctional anti-viral CD4 T cells, and IgG-secreting B cells. PS (LASV 
GP1) elicited a more diverse epitope repertoire of anti-viral IgG. Together, these data demonstrate the 
potential of our nanocarrier vaccine platform for generating virus-specific antibodies against weakly 
immunogenic viral antigens.  
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INTRODUCTION  
Lassa virus (LASV) is an Old World arenavirus that causes a severe viral hemorrhagic fever with high 
mortality in humans [1, 2] and is currently considered one of the most important emerging pathogens 
by WHO [3]. Endemic in Western Africa from Senegal to Cameroon, LASV causes several hundred 
thousand infections per year with thousands of deaths. In nature, LASV is carried by persistent infection 
of reservoir rodent host of Mastomys species, semi-domestic rodents that invade human dwellings [1]. 
Reservoir-to-human transmission represents a major route of human infection [4] and human-to-human 
transmission has been reported in nosocomial outbreaks [5]. Due to its transmissibility via aerosol [6] 
and high lethality, LASV is further considered a category A select agent by the Centers of Disease 
Control [7]. There is currently no licensed vaccine available and the standard of care is limited to 
supportive measures and the use of ribavirin, which reduces mortality when delivered early in infection 
[8]. Severe Lassa fever in humans is characterized by extensive viral replication and spread, resulting in 
high viremia and progressive signs and symptoms of shock. Viral load early in disease is predictive for 
fatal disease outcome, indicating competition between viral spread and replication and the patient’s 
immune system [9]. Control of primary LASV infection in survivors seems mainly mediated by the anti-
viral CD8 T-cell response, whereas neutralizing antibodies appear late during convalescence and are 
generally of low titers [10].  
Antibodies represent a major immunological correlate of protection in many successful 
vaccines. These protective antibodies control the initial burst of viral replication by neutralizing free 
virus, thus limiting viral spread. The consequent reduction in viral load provides the host’s immune 
system a window of opportunity to develop a timely adaptive response capable of controlling the 
pathogen [11]. Studies in numerous viral systems demonstrated that antibodies targeting viral 
attachment proteins are of particular importance, as they can neutralize free virus by preventing host cell 
attachment and entry [12-14]. Recently, recombinant monoclonal antibodies (mAb) targeting viral 
attachment proteins showed promise for protection in prophylactic, post-exposure, and therapeutic 
settings, as illustrated in groundbreaking studies with recombinant antibody cocktails against Ebola 
virus [15]. Specific antibodies to viral surface proteins are further of great importance in viral serology 
diagnostics and epidemiology, in particular in the context of newly emerging or re-emerging pathogens.  
Initial trials with killed LASV vaccines failed to elicit protective immunity [16], and the 
development of a safe and efficacious LASV subunit vaccine capable of inducing robust antibodies titers 
remains an unsolved problem [17]. A major challenge is the low immunogenicity of the LASV envelope 
GP1 which decorates the virion spikes, is involved in host cell attachment, and represents the main target 
for protective antibodies [18-20]. A recent elegant study in a mouse model demonstrated that the 
inherently low immunogenicity of LASV GP1 is a consequence of extensive epitope shielding by N-
linked glycans [21]. This is reminiscent of the surface GPs of other major human pathogens, including 
human immunodeficiency virus (HIV)-1 and hepatitis C virus (HCV) [11, 22]. 
?
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To enhance immunogenicity of subunit vaccines, a range of antigen nanocarriers have been 
developed, including polymer-based nanoparticles, liposomes, polymersomes, dendrimers, 
cyclodextrin-containing polymers, carbon nanotubes, and gold nanoparticles [23]. We recently 
developed a novel watery-core polymersome (PS) nanocarrier system designed to efficiently deliver 
antigen to lymph nodes, enhance uptake by dendritic cells (DCs), and promote antigen presentation [24, 
25]. Polymersomes are stable vesicles composed of self-assembling oxidation-sensitive block co-
polymers, in particular hydrophobic polypropylene sulfide (PPS) in combination with hydrophilic 
polyethylene glycol (PEG) [25]. Hydrophilic molecules such as soluble recombinant protein antigens 
and some adjuvants can be incorporated into the watery core of PEG-bl-PPS PS, whereas hydrophobic 
molecules can associate with the leaflet of the membrane bilayer. Previous studies demonstrated that 
incorporation of model protein antigens into the aqueous core of PS enhances antigen presentation by 
dendritic cells in vitro [25]. In vivo, PS induced robust T cell immunity against protein antigens with 
enhanced frequencies of antigen-specific CD4 T cells [24]. 
In our present study, we evaluated a new vaccine, consisting of our PS nanocarrier platform in 
combination with a newly developed immunogen, for its ability to enhance the humoral immune 
response to the weakly immunogenic LASV GP1 in a mouse model.  
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RESULTS  
Immunogen design, production, and characterization  
The LASV glycoprotein precursor GPC is initially synthesized as a single polypeptide that is 
proteolytically processed into the peripheral GP1 and the membrane-associated GP2 (Fig. 1A). The N-
terminal GP1 decorates the tips of the trimeric virion spike and is implicated in receptor binding [26], 
whereas the transmembrane GP2 resembles fusion-active class I envelope proteins of other viruses [27].  
LASV GP1 represents an independent fold with a globular structure [28]. Based on available structural 
information, we engineered a stable, soluble LASV GP1 fragment comprised of amino acids 92-256, 
spanning the putative receptor binding sites [28, 29] and known neutralizing epitopes [20] (Fig. 1A). 
Removal of the 33 N-terminal amino acids of GP1 markedly enhanced expression without affecting the 
overall fold of the protein [30]. To ensure high expression levels and proper folding, recombinant LASV 
GP1 was expressed in mammalian cells as a C-terminal fusion protein with the Fc moiety of human 
IgG1 [31]. To allow efficient removal of the human Fc part after purification, an enterokinase (EK) 
cleavage site was inserted following the C-terminus of LASV GP1, resulting in the construct LASVGP1-
EK-Fc (Fig. 1A). Western blot of the recombinant protein expressed in HEK293E cells revealed the 
expected apparent molecular masses of the GP1-Fc fusion protein that formed the expected dimer (Fig. 
1B). 
Large-scale protein expression was carried out in high-density suspension cultures under serum-
free conditions, followed by the purification strategy outlined in Fig. 1C. Briefly, conditioned cell 
culture supernatant was subjected to protein A affinity chromatography, followed by EK cleavage 
performed on the column, allowing selective elution of LASV GP1 under physiological conditions. 
Eluted LASV GP1 was further purified by ion exchange chromatography followed by gel filtration, 
resulting in > 98% pure protein with the expected apparent molecular mass (Fig. 1D). Our construct 
design resulted in formation of an intermolecular disulfide bond via C230. Accordingly, SDS-PAGE 
under non-reducing conditions revealed that LASV GP1 formed a dimer (Fig. 1E). To further confirm 
the expected molecular mass and dimerization of LASV GP1, we combined size-exclusion 
chromatography with multi angle light scattering (SEC-MALS) (Fig. S1).  From the detected molecular 
mass of the LASV GP1 dimer of 56.1 kDa, only 30.5 kDa corresponded to the predicted polypeptide, 
indicating extensive post-translational modifications, mainly N-glycosylation, in line with previous 
studies [29, 32]. Examination of the glycosylation pattern of LASV GP1 revealed the presence of high 
mannose N-glycans (Fig. S2), similar to GP1 derived from authentic virus [33] and recombinant full-
length GP1 [32]. To assess the correct conformation of our recombinant LASV GP1, we tested binding 
of a panel of previously described conformation-sensitive anti-GP1 mAbs [20] in ELISA. As shown in 
Fig. S3, all mAb tested recognized our LASV GP1. Together, the data suggest that our LASV GP1 
retains at least part of its native conformation and displays a glycosylation pattern similar to GP1 from 
authentic virus, making it a suitable immunogen for our studies. 
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Preparation of polymersomes loaded with LASV GP1 antigen 
PEG-bl-PPS PS (Fig. 2A) were synthesized as outlined in Fig. 2B and described in Materials and 
Methods [24, 25]. To monitor efficiency of immunogen encapsulation, recombinant purified LASV GP1 
was fluorescence labeled with the fluorophore AF594. Considering the small molecule nature of the 
fluorophore, we did not expect a significant impact on the physicochemical nature of our recombinant 
immunogen. After 48 h incubation at 4°C, PS were extruded and purified by gel filtration 
chromatography. A significant proportion of LASV GP1 co-eluted with the PS fraction, indicating 
efficient antigen loading (Fig. 2C). To validate the integrity of the encapsulated antigen, loaded PS were 
lysed with 0.5% Triton-X 100 and analyzed by SDS-PAGE. The antigen recovered from PS migrated 
similar to the input, indicating conservation of the dimeric from during the encapsulation process (Fig. 
2D). Remaining free LASV GP1 was removed by size exclusion chromatography. Nanoparticles in the 
100 nm range ensure efficient lymphatic transport and delivery to antigen-presenting cells in lymph 
nodes upon intradermal or subcutaneous immunization [24]. The resulting PS (LASV GP1) displayed 
an average size range of 163 ±7 nm, with a polydispersity index of 0.1 ± 0.05 (Fig. 2E), which was 
suitable for our immunization studies. 
 
Delivery of LASV GP1 via PS enhances the quality of the antibody response 
To evaluate the capacity of PS to induce an anti-LASV GP1 antibody response, age- and sex-matched 
groups of five adult C57BL/6 mice each were immunized with 10 ? g of antigen as PS (LASV GP1) or 
free LASV GP1, in combination with 10 ? g monophosphoryl lipid A (MPLA), an adjuvant that 
represents a detoxified lipopolysaccaride  derivative [34]. As a ligand for Toll-like receptor (TLR)-4, 
MPLA is capable of enhancing cellular and humoral immune responses and is included in several 
vaccines undergoing phase III clinical trials. Mice received a prime-boost immunization three weeks 
apart with the same immunogen formulation (Fig. 3A). When compared to free antigen, mice that had 
received PS (LASV GP1) showed similar to mildly enhanced titers of anti-LASV GP1-specific IgG on 
days 28, 60, and 105 after immunization, as assessed by ELISA (Fig. 3B). Analysis of the IgG isotypes 
revealed similar trends to those observed with total IgG. On day 28, both groups had high titers of anti-
LASV GP1 IgG2a and IgG2c and robust levels of antigen-specific IgG1, whereas titers of IgG3 were 
generally low (Fig. 3B). As expected, immunization with empty PS did not elicit detectable titers of 
LASV GP1-specific antibodies (data not shown). 
A major immunological correlate of protection in viral infection and anti-viral vaccines are 
antibodies binding with high affinity to the viral attachment protein in its native conformation [11]. To 
detect such virus-binding anti-LASV GP1 antibodies in sera of immunized mice, we employed a solid-
phase virus-binding assay (Fig. 3C). Since LASV is classified as a biosafety level (BSL)-4 agent work 
with live virus is restricted to high containment laboratories. To detect LASV-binding antibodies, we 
used recombinant lymphocytic choriomeningitis virus expressing LASV GP (rLCMV-LASVGP) that 
?
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has been widely used as a BSL2 model for the characterization of LASV tropism and entry in vitro [35-
38] and in vivo [39, 40]. Previous studies revealed that GP1 of rLCMV-LASVGP closely resembles 
authentic LASV [33], making the chimera a suitable tool to detect virus-binding antibodies. The 
rLCMV-LASVGP was produced in BHK-21 cells, followed by purification via ultracentrifugation over 
a renografin gradient as described [41]. Purified virus was immobilized in microtiter plates and 
incubated with serial dilutions of sera derived from vaccinated and control mice. Virus-bound antibodies 
were detected via a secondary antibody in a color reaction. Sera of mice immunized with free antigen 
contained only low titers of virus-binding antibodies (Fig. 3D). In contrast, animals immunized with PS 
(LASV GP1) consistently developed higher titers of virus-binding antibodies that became detectable 
after day 28 and stayed high by day 60 and 105 (Fig. 3D).  
To assess the neutralizing capacity of sera immunized with PS (LASV GP1), we employed a 
well-established pseudotype assay based on recombinant replication-deficient vesicular stomatitis virus 
(VSV) containing a luciferase reporter [42] displaying full-length LASV GP (Fig. S2A). The rVSV-
LASVGP pseudotypes were mixed with sera in presence or absence of complement for one hour at 
37°C. The mix of pseudotypes and antibodies was added to fresh monolayers of A549 cells and infection 
detected by luciferase assay as described [43]. Despite robust titers of virus-binding anti-LASV GP1 
antibodies present in serum of PS (LASV GP1)-immunized mice, we failed to detect significant 
neutralizing activity under our assay conditions on days 28, 60, and 106 (Fig. S2B). This suggests that 
the virus-binding LASV GP1 antibodies were either non-neutralizing or present at insufficient 
concentrations to allow neutralization.           
 
Encapsulation of LASV GP1 antigen in PS enhances follicular helper CD4 T cells, polyfunctional 
CD4 T cells, and antigen-specific B cells. 
Next, we investigated if the increased virus-specific antibody titers in PS (LASV GP1)-immunized mice 
correlated with enhanced CD4 T cell and B cell responses. To this end, we immunized groups of mice 
as shown in Fig. 3A. After 28 d, spleens and draining lymph nodes (LN) were collected and the CD4 T 
cell responses evaluated by ex vivo re-stimulation assay, using purified LASV GP1 antigen. As a control, 
we used purified human Fc to assure that the CD4 T cell responses were indeed directed to the viral 
protein and not remaining traces of Fc. No response was induced upon re-stimulation with human-Fc 
(data not shown), confirming specificity to the LASV GP1 antigen. First, we evaluated whether 
immunization with PS (LASV GP1) enhanced the frequency of antigen-specific CD4 T follicular helper 
(Tfh) cells using the markers CXCR5 and PD1 in flow cytometry [44]. The percentage of CD4 Tfh cells 
was significantly enhanced in LN, but not in spleen of PS (LASV GP1)-immunized animals (Fig. 4A). 
Next, we assessed the surface phenotype of total CD4 T cells using the markers CD25 and CD44 [45] 
and observed a significant increase in the expression of both markers in LN and spleens of mice 
immunized with PS (LASV GP1), suggesting enhanced CD4 T cell activation upon PS immunization 
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(Fig. 4B). Virus-specific CD4 T cells isolated from spleens and LN of PS (LASV GP1)-immunized 
animals secreted significantly higher amounts of IFNγ compared to the group that had received protein 
only (Fig. 4C). Immunization with PS (LASV GP1) likewise enhanced the frequency of TNFα-
producing CD4 T cells, whereas the increase in spleen was not significant (Fig. 3C). Moreover, we 
observed significantly enhanced frequencies of polyfunctional IFNγ/TNFα-secreting CD4 T cells in 
LN, but not in spleen (Fig. 4C).  Next we sought to investigate possible effects of our PS delivery system 
on the frequencies of antigen-specific IgG-secreting B cells. For this purpose we performed ELISpot 
assays using our LASV GP1 as antigen. As shown in Fig 4D, we observed a marked increase in the 
frequency of antigen-specific IgG secreting B cells derived from LN and spleens isolated from mice 
immunized with PS (LASV GP1).  
 
Polymersome-delivery broadens the epitope-range of anti-LASV GP1 antibodies  
The detection of robust titers of virus-binding antibodies (Fig. 2D) and enhanced frequencies of antigen-
specific B cells in animals immunized with PS (LASV GP1) but not free antigen (Fig. 4D), indicated a 
marked effect of PS-delivery on the quality of the antibody response. To quantitatively compare the 
breadth of the anti-LASV GP1 antibody response induced by PS (LASV GP1) vs. free antigen, we 
employed peptide arrays. The custom-made array format consisted of glass slides displaying 20mer 
peptides covering the entire sequence of our antigen with an off-set of one amino acid (Fig. 5A). This 
type of array has been widely used to study the epitope specificity of antibody responses in a reliable 
and quantitative manner [46]. The presentation of linear synthetic peptides may not recapitulate some 
conformational epitopes present on LASV GP1, which is a limitation of the system. In line with the 
detection of important differences in the specific antibody responses towards PS (LASV GP1) compared 
to free antigen, our peptide arrays revealed a significantly broader epitope range of antibodies present 
in sera derived from mice immunized with PS (LASV GP1) (Fig. 5A-C). Based on recently determined 
high-resolution X-ray structures of LASV GP1 [28] and the GP1 of the structurally and genetically 
closely related LCMV [47], we made a first attempt to localize the epitopes recognized by the antibodies 
elicited in our immunization studies (Fig. 5D). Immunization with free antigen induced antibodies that 
bound predominantly to the N-terminal (epitope L95-S111) and C-terminal part (epitope P236-I239) of 
LASV GP1. In contrast, antigen delivery by PS resulted in the generation of antibodies capable to bind 
the core of LASV GP1. Some of the structures recognized were located in the upper face of GP1 that is 
exposed in the context of the mature GP1/GP2 trimer at the viral surface (Fig. 5D). Specifically, epitope 
N114-N119 was located upstream of α-helix 1, while epitope S139-N148 was located within a link 
region between α-helix 1 and the β-3 domain. Epitope N185-N191 mapped to the α-3 domain. Overall, 
the data corroborates that our PS platform enhanced the quality of the immune response to LASV GP1 
by broadening the epitope range of the induced anti-viral antibodies.  
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DISCUSSION 
In the present study, we evaluated a PS-based nanocarrier platform for its ability to improve the antibody 
response against the poorly immunogenic surface antigen of LASV. Delivery of a recombinant LASV 
GP1-derived immunogen via PS enhanced the magnitude and the quality of the antibody response, 
inducing robust titers of virus-binding antibodies. Immunization with PS further enhanced the quality 
of the CD4 T cell and B cell response, resulting in a broader epitope range. 
A large body of clinical and experimental evidence indicates that primary LASV infection in 
humans and animals is controlled mainly via the anti-viral CD8 T cell response, whereas anti-GP1 
antibodies appear only late in convalescence and are generally of low titer [48]. Recent studies in a 
murine model revealed an inherent lack of immunogenicity of LASV GP1 [21], a characteristic shared 
by envelope GPs of other important human pathogenic viruses [14, 22, 49]. The poorly immunogenic 
LASV GP1 was therefore ideally suited as a relevant and well-characterized example for the evaluation 
of our PS platform in a mouse model in vivo, setting the bar rather high. Based on recent structural 
studies, we successfully generated a suitable recombinant LASV GP1-derived immunogen containing 
major antigenic sites involved in receptor binding and neutralization. When expressed in mammalian 
cells, the LASV GP1 fragment retained conformational epitopes and displayed an N-glycosylation 
pattern consistent with the authentic virus-derived antigen [29, 32]. Encapsulation of the immunogen 
into the watery core of PEG-bl-PPS PS was efficiently carried out under physiological pH and ionic 
strength. This mild encapsulation conditions avoided any chemical modification of the protein, ensuring 
conservation of the native conformation.  
 Employing a murine model that has been extensively used to study antibody responses to 
arenaviruses, we investigated the impact of PS encapsulation on the immunogenicity of our LASV GP1 
antigen. Antigen encapsulation into PS enhanced overall LASV GP1-specific antibody titers and 
markedly increased virus-binding antibodies, capable of recognizing GP1 in the context of the authentic 
virion spike. Using a well-established assay based on pseudotypes, similar to the one employed in recent 
studies on human neutralizing mAb to LASV [20], we were however unable to detect significant 
neutralization (Fig S2B). This resembles the situation in human patients and experimental infection in 
non-human primates, where convalescent sera contain generally low titers of neutralizing antibodies 
[50]. In our system, neutralizing antibodies may be present in the serum, albeit at too low titers to be 
detected in our assay. Alternatively, the virus-binding anti-LASV GP1 antibodies may be non-
neutralizing. Interestingly, studies with the closely related LCMV revealed that the generation of non-
neutralizing antibodies directed towards GP1 could contribute to protection in vivo [51]. However, since 
rLCMV-LASVGP infection in the mouse, even at high dose, results in only transient low-level viremia 
[39], this challenge model appears not suitable for viral challenge studies in our context.  
  Delivery of LASV GP1 via PS resulted in higher frequencies of follicular helper CD4 T cells, 
which represent a unique subset of CD4 T cell providing help to B cells within germinal centers, 
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promoting affinity maturation, class switch, plasma cell differentiation, and memory formation. 
Encapsulation of the antigen in PS increased the numbers of antigen-specific CD4 T cells and the 
frequency of polyfunctional IFN-γ /TNF-α secreting CD4 T cells. The higher frequency of antigen-
specific IgG-secreting B cells in spleens of PS immunized mice was in line with the observed increase 
of the humoral response in terms of both magnitude and quality.  
Screening with peptide arrays provided first evidence that the PS-delivered antigen improved 
the humoral immune response by broadening the epitope range. In contrast to free protein, PS (LASV 
GP1) induced the formation of antibodies reactive with the epitopes N114-N119, S139-N148 and N185-
N191. Earlier studies on the related LCMV identified the sequence N114-N119 as a site for 
neutralization [52][189]189189. Recently, Robinson et al. characterized a panel of mAbs isolated from 
human Lassa fever survivors and found neutralizing antibodies directed against the GP1 subunit, 
specifically against GP1-A and GP1-B binding sites, that involve amino acids present in N114-N119 
[20]. In a proof-of-concept study performed in a guinea pig model of Lassa fever, these mAb conferred 
protection in post-exposure prophylaxis [53]. One of the most relevant epitopes identified in this study 
in the LASV GP1 region, is the S139-N148 epitope, which is highly conserved among different LASV 
isolates and Old World arenaviruses and has been proved to be implicated in the interaction of LCMV 
and LASV GP1 with the cellular receptor dystroglycan [47]. The abovementioned epitope locates to the 
interface of the GP1 trimer which is involved in receptor binding. The N185-N191 LASV GP1 peptide 
is likewise highly conserved among Old World arenaviruses [47]. In conclusion, our studies 
demonstrated that PS encapsulation markedly increased the quality and magnitude of the antibody 
response to our newly designed LASV GP1-derived immunogen, including the generation of virus-
binding antibodies. If the augmentation of the specific antibody response observed in our study with the 
poorly immunogenic LASV GP1 is a general feature of our platform is at this point unclear and more 
work including envelope glycoproteins from other viruses will be needed to confirm this.  
The very recently solved structure of the pre-fusion conformation of the LASV GP1/GP2 trimer 
spike highlights the relevance of quaternary structures and the GP1/GP2 interface for receptor binding 
and antibody neutralization [54]. It is at this point unclear if the conformational differences between 
monomeric LASV GP1 crystallized at low pH [28] and GP1 in the context of the mature GP1/GP2 
trimeric spike [54] are due to the different pH, GP1 trimerization, or the presence of GP2. It is therefore 
possible that our LASV GP1 at neutral pH at least in part resembles the conformation within the trimer. 
This is indeed suggested by binding of a panel of conformation-sensitive mAb, as well as the observed 
induction of virus-binding anti-LASV GP1 antibodies by our PS platform. In any case, the novel 
structural insights into the structure of the mature LASV GP virion spike provide novel and promising 
leads for the development of a next generation of improved LASV vaccine immunogens. Candidates 
may then be tested in the context of our platform in order to elicit an optimal neutralizing antibody 
response. Improved vaccine immunogens may further allow a simplified vaccination approach, ideally 
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a “single shot” instead of the prime-boost described here. This would be a decisive advantage for vaccine 
campaigns in remote areas with suboptimal health care infrastructure.    
The advent of powerful next-generation sequencing technologies has greatly accelerated the 
discovery of novel pathogenic viruses [55, 56]. However, such viruses can frequently not be isolated 
and the limited number of clinical cases makes isolation of B cell clones from survivors challenging. A 
decisive advantage of our PS platform in the context of emerging viruses is the use of recombinant 
immunogens that can be designed and produced biosynthetically based on available sequence 
information. The versatile immunization scaffold of PS combined with the antigen production and 
efficient encapsulation method that we present here allows rapid production of specific antibodies. Our 
PS platform may thus allow the development of a “pipeline” to generate recombinant mAb via 
immunization, followed by B cell sorting and cloning of specific IgG using established methodology 
[57] within a few months. Such mAb could be rapidly tested for neutralization and evaluated for 
therapeutic potential. In addition, the availability of specific mAb against novel pathogenic viruses will 
be invaluable for diagnostic purposes to track epidemics.   
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MATERIALS AND METHODS  
Animals  
C57BL/6 female mice, aged 8-12 weeks, were purchased from Harlan (Gannat, France). All animal 
experiments were performed under the approval from the Veterinary Authority of the Canton of Vaud 
(Switzerland) according to Swiss regulations of animal welfare (animal protocol number 2502.1 and 
2235.1). 
Cells and viruses 
Human lung carcinoma epithelial (A549) cells were cultured in Dulbecco modified Eagle medium 
(DMEM) containing10% (vol/vol) fetal bovine serum (FBS), supplemented with glutamine and 
penicillin-streptomycin (Pen/Strep). The generation, growth, and purification of recombinant 
lymphocytic choriomeningitis virus expressing the LASV glycoprotein (rLCMV-LASVGP) has been 
described elsewhere [35]. According to the institutional biosafety guidelines of the Lausanne University 
Hospital, the chimera rLCMV-LASVGP has been classified as a biosafety level (BSL) 2 pathogen for 
use in cell culture. For viral quantification, a previously described immunofocus assay (IFA) was 
performed [58]. 
Construction of the expression construct LASVGP1Δ33-EK-huFc 
For the construction of the expression construct LASVGP1Δ33-EK-huFc pcDNA3.1 IntA, cDNA 
fragments coding for the a LASVGP1 fragment from which residues 58-92 (not starting from the SSP) 
were removed from the N terminal part, were amplified by PCR introducing a 5’-HindIII restriction site 
and a C-terminal enterokinase (EK) recognition sequence (DDDDKI) followed by a 3’ BamHI 
restriction site using the primer sequences 5’-CGC AAG CTT ATG GAG ACA GAC ACA CTC CTG 
CTA-3’ Rev: 5’-ATA AGG ATC CCC GAT CTT GTC ATC GTC ATC GCT TAT GTA GAT GTC 
ACG GGT GCG-3’. The PCR product was then digested with HindIII and BamHI and inserted into the 
expression vector pcDNA3.1 IntA (kindly provided by Dr. Robert Garry, Tulane University) together 
with a cDNA fragment coding for human IgG1 Fc, obtained from the construct DGFc5 pcDNA3 
described previously [59], via digestion with BamHI and XhoI. The final construct was verified by DNA 
sequencing.     
Recombinant protein expression and purification  
Suspension-adapted HEK-293E cells were maintained in serum-free ExCell 293 medium (SAFC 
Biosciences, St. Louis, MO), supplemented with 4 mM glutamine. On the day before transfection, cells 
were seeded in fresh medium at a density of 106 cells/ml.  After 16-14 h, the cells were harvested, 
separated by centrifugation for 5 min and 2 x 107 cells re-suspended in 50 ml of RPMI 1640 containing 
0.1% pluronic F68 (SABiosciences, Qiagen AG, Hombrechtikon, Switzerland) in a 250 ml glass bottle. 
Plasmid DNA of the LASVGP1Δ33-EK-huFc construct (1.5 mg) and 3 mg of linear 25 kDa 
?
?
? ?
polyethylenimine (Polysciences, Eppenheim, Germany) in a solution of 1 mg/ml in water were 
sequentially added to the culture and mixed. The culture was agitated by orbital shaking at 110 rpm in 
an ISF-4-W incubator (Kühner AG, Birsfelden, Switzerland) at 37°C in the presence of 5% CO2.  After 
60 min, the 50 ml transfection mix was transferred into a 2 l glass bottle containing 450 ml of FreeStyle 
medium (Invitrogen, California) supplemented with 4 mM glutamine and 3.75 mM valproic acid. The 
culture was transferred to an incubator shaker at 37°C with 5% CO2 with agitation at 110 rpm.  At 7 
days post-transfection, cell culture medium was recovered by centrifugation at 2,500 rpm for 10 min 
and filtered through a 0.22 μm membrane. 
Conditioned supernatant containing recombinant LASVGP1Δ33-EK-huFc protein was loaded 
onto a protein A sepharose 4B affinity chromatography column (5 ml matrix volume) at a rate of 
0.5ml/min at 4°C. After washing with 40 volumes of PBS, the column was equilibrated with 10 volumes 
of enterokinase (EK) buffer (20 mM Tris/HCl, 50 mM NaCl, 2 mM CaCl2, pH 7.5). Enterokinase (New 
England Biolabs, MA) was diluted in EK cleavage buffer (0.32μg purified enzyme in 5ml) and loaded 
onto the protein A column containing bound LASVGP1Δ33-EK-huFc protein. Cleavage was performed 
at RT for 6 h, followed by elution with EK buffer. Remaining EK in the eluate was inactivated by adding 
trypsin inhibitor conjugated to agarose beads (New England Biolabs, MA). The absence of residual 
human IgG1 Fc from eluates was verified by Western blot analysis as described [59]. 
 For ion exchange chromatography (IEC), the most concentrated factions obtained from the EK 
cleavage above were diluted 20 x with binding buffer (20 mM Tris/HCl, pH 8.0) and loaded onto a 4.7 
ml HiScreen Q-sepharose high performance (HP) column at a flow rate of 1 ml/min. Unbound protein 
was removed by washing with 10 volumes of binding buffer and bound protein eluted with a linear 
gradient (20 volumes) from 0 to 100% elution buffer (20 mM Tris/HCl, pH 8.0, 1 M NaCl) at a flow 
rate of 1 ml/min. Fractions of 2 ml were collected and analyzed by SDS–PAGE and Coomassie blue 
staining. The fractions containing LASVGP1Δ33, henceforth referred to as LASVGP1, were pooled 
and concentrated to 2 ml in an Amicon Ultra-15 centrifugation concentrator with a cut-off of 10 kDa 
(Millipore, Darmstadt, Germany). 
For subsequent size exclusion chromatography, the concentrated pool from the IEC was loaded 
onto a 121 ml HiLoad S200 16/60 Prep Grade Superdex-200 column pre-equilibrated in PBS at a flow 
rate of 1 ml/min. Fractions of 2 ml were collected and analyzed by SDS-PAGE and Coomassie blue 
staining. Fractions containing LASV GP1 were pooled and concentrated in an Amicon Ultra-15 
centrifugation concentrator (10 kDa cut-off), followed by and sterile filtration through a Millipore 0.22 
μm Millex-GP membrane. Overall protein yields were 5 mg/l of starting material and purity was >98%.  
Block-copolymer synthesis and polymersome preparation 
All chemical reagents were reagent grade and purchased from Sigma-Aldrich, MO, unless otherwise 
stated. Polymerosomes (PS) were prepared as described [25]. Briefly, block-copolymers were 
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synthesized using benzyl mercaptan to start the living polymerization of propylene sulfide (PPS). The 
terminal thiolates were capped with PEG-mesylate.  For purification, the co-polymers were precipitated 
two times in cold methanol. The purity and length of the PPS chain were confirmed by gel 
chromatography and NMR. Chains of PEG17-bl-PPSx, containing between x=26-32 PPS units were used 
to form PS. An amount of 30-50 mg was re-suspended in dichloromethane and placed in piranha-etched 
glass vials to desiccate overnight. For the formation of PS with LASV GP1, a thin film of copolymer 
was rehydrated with a solution of 500 μl of LASV-GP1 or fluorescence-labeled LASV-GP1 (2 mg/ml) 
in 50 mM sodium phosphate buffer, and rotated for 48 h at 4°C. Next, the solution was extruded at least 
four times through a 0.2 μm nucleopore track-etched membrane (Whatman, Maidstone, UK) to obtain 
PS ranging between 150-170 nm with polydispersity values < 0.2. Purification of the PS loaded with 
LASV GP1 immunogen from free protein was achieved by size exclusion chromatography through a 
Sepharose CL-6B column. Fractions containing PS were pooled and further concentrated though an 
Ultra-centrifugation filter (Amicon Millipore, Darmstadt, Germany) with a cut-off of 100 kDa. 
Efficiency of LASV GP1 loading into PS was 430 μg/ml calculated by subtracting the amount of the 
unloaded protein from the starting material used. The size of PS was determined by dynamic light 
scattering with a Nano Zs Zetasizer (Malvern Instruments, Malvern, UK). PS were controlled for their 
size and polydispersity, as well as endotoxin levels using the HEK-BlueTM TLR4 cells and QUANTI-
Blue (inVivogen) with endotoxin standard (E-Toxate Endotoxin standard E8029-1VL Sigma-Aldrich) 
for every batch produced. 
SEC-MALS analysis of LASV GP1  
For size exclusion chromatography coupled with multiangle light scattering (SEC-MALS), purified 
LASV GP1 protein was separated on a Superose6 gel filtration column (GE Healthcare, Little Chalfont, 
UK) pre-equilibrated with 20 mM Tris, 150 mM NaCl, pH 7.5 coupled in-line with a mini DAWN Treos 
followed by an Optilab T-rEX refractometer (Wyatt Technologies, CA). Data processing and absolute 
molecular mass calculations were performed using ASTRA software (Wyatt Technologies, CA). 
Western blot  
Protein Samples were mixed 1:1 with 2x SDS-polyacrylamide gel electrophoresis (PAGE) sample 
buffer containing 100 mM DTT and boiled (5 min at 95°C). Samples were separated by SDS-PAGE and 
blotted to nitrocellulose membranes. Membranes were blocked in 3% (w/v) skim milk in PBS and 
proteins detected with primary antibody after overnight incubation at 4°C using HRP-conjugated 
secondary antibodies as described [60]. Monoclonal antibody to human IgG1 Fc (Abcam, Cambridge, 
UK) was used in the dilution 1: 5,000 and polyclonal rabbit anti-mouse-HRP at 1: 3,000. Membranes 
were developed using enhanced chemiluminescence (ECL) using Amersham ECL Prime Western 
Blotting Detection Reagent (GE Healthcare lifesciences Little Chalfont, UK). Signal acquisition was 
performed with ImageQuant LAS 4000Mini (GE Healthcare lifesciences Little Chalfont, UK). 
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Immunization protocol 
All immunizations were administered intra-dermal (i.d.) into the four footpads, under isofluorane 
anesthesia. For all formulations, 10 μg of LASV GP1 was injected per animal, together with 10 μg of 
MPLA (Salmonella minnesota R595, AvantiLipids). All PS and proteins batches were tested negatively 
for endotoxin using a Toll-like receptor activation assay based on HEK-Blue reporter cell lines 
(Invivogen, CA). 
Enzyme-linked immunosorbent assay (ELISA) 
For the detection of antigen-specific antibodies in ELISA, 96-well Nunc MaxiSorp® plates were coated 
with 5 μg/mL of LASV GP1 overnight at 4°C. Plates were washed three times with PBS/ 0.02% (wt/vol) 
Tween-20 and blocked with 2.5% (wt/vol) casein solution in PBS for 2 h at room temperature (RT). 
Serial dilutions of serum in 2.5% (wt/vol) casein/PBS were added and incubated for 2 h at RT. Plates 
were washed four times, following by incubation with HRP-conjugated secondary antibodies specific 
for and IgG1, IgG2a,c, IgG3 or total IgG (Southern Biotech, Birmingham, AL). After incubation for 1 
h at RT, plates were washed four times and developed using 50 μl of 3,3’,5,5’-tetramethylbenzidine 
(eBiosciences, MA). The signal was stopped by adding 20 μl of 2 M H2SO4. Plates were analyzed using 
a plate reader spectrophotometer (Tecan, Mannedorf, Switzerland) by measuring the absorbance at 450 
nm with correction at 570 nm. Specific signals were calculated by subtraction of absorbance obtained 
with samples containing the blocking casein only (background control).  
Virus binding assay 
For the detection of virus-binding specific antibodies, 96-well Nunc MaxiSorp® plates were coated with 
Renografin purified and UV-inactivated rLCMV-LASVGP (107 PFU/ml in PBS) prepared as described 
[61] overnight at 4°C. Plates were washed three times with PBS and blocked for 2 h with a 2.5% (wt/vol) 
casein solution in PBS. Serial dilutions of serum in 2.5% (wt/vol) casein/PBS were added and incubated 
for 2 h at RT. Plates were washed four times, followed by incubation with HRP-conjugated secondary 
antibodies against total IgG (Southern Biotech Birmingham, AL). After incubation for 1 h at RT, plates 
were washed four times and developed and read as described above.   
Preparation of cell suspensions and ex vivo restimulation 
Preparation of cell suspensions and ex vivo restimulation was performed as described [24]. Briefly, 
lymph nodes were digested with collagenase D in DMEM supplemented with 1.2 mM CaCl2, 2% 
(vol/vol) FBS, Pen/Strep (500μg/ml). After digestion, lymph node cell suspensions were pressed 
through a 70 μm nylon cell strainer. For spleens, single cell suspensions were prepared by mechanical 
disruption through a 70 μm nylon cell strainer. Splenocytes were further treated with hypotonic 
ammonium chloride potassium bicarbonate buffer (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) 
to lyze red blood cells. For ex vivo restimulation, 3 x 106 cells were plated in 96-well plates and cultured 
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in DMEM supplemented with 10% (vol/vol) FBS, Pen/Strep (500μg/ml) for 2 h at 37°C in the presence 
of 200 μg/ml of purified LASV GP1. As a negative control, cells were restimulated with the Fc portion 
of human IgG. For detection of intracellular cytokines, 5 μg/ml of Brefeldin A was added to the culture 
and left for 3 h, followed by washing in cold PBS.  
Flow cytometry  
Three million cells were plated in cone-shaped 96 well plates, washed once with HBSS, and stained 
with live/dead fixable cell viability reagent (Life technologies, CA). For surface staining, cells were 
washed once with HBSS supplemented with 0.5% (wt/vol) BSA (Sigma) (staining buffer) and 
resuspended in an antibody cocktail using the panel of mAb listed in Supplementary Table 1. For 
intracellular staining, cells were fixed and permeabilized with the Foxp3/Transcription Factor 
Fixation/Permeabilization kit (eBiosciences, MA) according to the manufacturer’s instructions. Cells 
were stained in permeabilization buffer with the mAb cocktail described in Supplementary Table 1. 
After staining, cells were resuspended in staining buffer for analysis by flow cytometry. Flow cytometry 
was performed using a CyAnTM ADP (Beckman Coulter) and data were analyzed with FlowJo software 
package (Ashland, OR). 
Enzyme-linked immunospot assay (ELISPOT) 
B cell ELISPOT assays were performed using the IgG kit (Mabtech, Nacka Strand, Sweden) according 
to the manufacturer’s instructions. Briefly, serial dilutions of cells derived from lymph nodes were plated 
in duplicates overnight in LASV GP1 coated PVDF 96-well plates (Millipore, Darmstadt, Germany). 
Unbound cells were removed and wells incubated for 2 h with biotinylated anti-mouse total IgG in PBS.  
After several washes, wells were incubated with streptavidin conjugated to alkaline phosphatase (AP) 
for 1 hour. Spots were revealed using 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium 
(BCIP/NBT), and counted with an automatic reader (Bioreader 2000; BioSys GmbH).  Results were 
represented as number of spots corresponding to antibody-secreting cells per 106 total lymph node cells 
and splenocytes. 
Peptide array (CelluspotsTM) 
CelluspotsTM (Intavis AG, Cologne, Germany) were designed based on the LASV GP1 sequence 
spanning from amino acids 92-250 and were comprised of 20mer peptides with an offset of one amino 
acid. Slides were blocked with blocking buffer, followed by 2 h incubation at RT with sera at 1:200 
dilution in blocking buffer. Slides were further washed 3 times with PBS/ 0.02% (wt/vol) Tween-20 and 
incubated with goat anti mouse IgG conjugated to IR dye 800cw (1:10000) from Li-COR Biotechnology 
(Lincoln, NE) in blocking buffer for 1 h. Finally, slides were washed 3 times with PBS/ 0.02% (wt/vol) 
Tween-20. Signals were visualized using the LI-COR Odyssey Infrared Imaging System (LI-COR, Inc., 
Lincoln, NE). 
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Pseudovirion neutralization assay 
Recombinant propagation-defective vesicular stomatitis virus (VSV) encoding the two reporter proteins 
green fluorescent protein (GFP) and firefly luciferase (Luc) was generated as described [42]. 
Recombinant VSV pseudotypes bearing the envelope GP of LASV Josiah were generated as reported 
earlier [62]. For the pseudovirion neutralization assay, sera were diluted 1:20 in complete MEM, 
followed by two-fold serial dilutions. For each well (quadruplicates), serum dilutions (50 μl) were mixed 
with an equal volume of complete MEM containing 4,000 infectious units (IU) of rVSV-LASV GP and 
incubated for 1 h at 37 °C. Following this incubation, the mixture was added to fresh monolayers of 
A549 cells cultured in clear bottom white-walled 96-well plates (Costar). After 1 h, the inoculum was 
removed by washing and fresh medium added. After 20 h at 37 °C and 5% (vol/vol) CO2, luciferase 
reporter activity was detected using the Luciferase Assay System (Promega, WI). A GloMax (Promega, 
WI) microplate reader was used for signal acquisition.  
Statistical Analysis  
One-way ANOVA followed by a Bonferroni post-test was used to assess statistical differences between 
the groups with a p-value < 0.05 was used as criterion of statistical significance. All data was analyzed 
using the GraphPad Prism 5 Software (GraphPad Software Inc., La Jolla, CA). All data presented as bar 
graphs represent the mean ± standard deviation (SD). 
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FIGURES 
 
  
 
Figure 1. LASV GP1 antigen design, production and characterization. A) Schematic 
representation of arenavirus GPC and LASV GP1-Fc: The N-terminal receptor-binding GP1 
subunit, the C-terminal GP2, the transmembrane domain, and the stable signal peptide (SSP) are 
indicated, as well as the EK cleavage site and the human Fc moiety. B) Detection of LASV GP1-EK-Fc 
in Western blot. LASV GP1-EK-Fc was expressed in HEK293T cells by transient transfection. 
Conditioned supernatants were collected, total protein precipitated, separated by SDS-PAGE under non-
reducing (NR) or reducing (R) conditions, and blotted to nitrocellulose. Blots were probed with a human 
IgG Fc-specific antibody combined with an HRP-conjugated secondary antibody and enhanced 
chemiluminescence (ECL). Relative molecular masses are indicated. C) Schematic of the purification 
process. LASV GP1-EK-Fc was expressed in high-density suspension cultures of HEK293H cells in 
serum-free medium. Cleared conditioned supernatants were subjected to protein A affinity 
chromatography. Elution of LASV GP1 antigen was performed by EK cleavage of bound LASV GP1-
EK-Fc on the column under neutral pH. After subsequent ion exchange and size exclusion 
chromatography, purified protein were dialyzed against PBS and concentrated. D) Elution of LASV 
GP1 by EK cleavage. Protein A-bound LASV GP1-EK-Fc was incubated with EK, followed by elution 
under neutral pH. Fractions were analyzed by SDS-PAGE under non-reducing conditions. Fractions 
LASV GP1 F1-3 correspond to the eluate and fractions Fc to the IgG Fc moiety eluted under acidic 
conditions, stained by Coomassie blue. The absence of IgG Fc from LASV GP1 eluate (F1) was verified 
by Western blot. Purified human IgG1 Fc was included as a positive control. Relative molecular masses 
are indicated. E) LASV GP1 forms a dimer. LASV GP1 purified as in (C) was separated by SDS-PAGE 
under reducing (R) and non-reducing (NR) conditions.  
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Figure 2. LASV GP1 polymersomes production and purification. A) Schematic representation of 
PEG-bl-PPS block copolymers and vesicles. Block copolymers composed of PEG and PPS self-
assemble into oxidation-sensitive polymersomes in aqueous solutions. Hydrophobic and hydrophilic 
regions are shown in blue and red, respectively.  B) Flow sheet of the encapsulation process. After 
chemical synthesis, the PEG-PPS polymers were desicated and rehydratated in an aqueous solution of 
LASV GP1. The newly formed PEG-bl-PPS PS were then extruded at 100 nm, purified by size exclusion 
chromatography, and concentrated. C) Encapsulation efficiency into polymersomes. Elution of 
fluorescent-labeled LASV GP1  after mixing with the PEG-PPS block-copolymers from a size-exclusion 
column. PS-associated protein (orange spheres) appeared in fractions 7-10, whereas free protein eluteed 
in fractions 18-22. Fraction numbers are plotted against arbitraty raw absorbance units (RAU). D) 
Encapsulated protein was recovered from PS by detergent treatment, followed by SDS-PAGE under 
non-reducing conditions. Recovered protein (PS (GP1)) was compared to reference free protein (GP1). 
The band corresponding to dimeric LASV GP1 is indicated. The signal corresponding to the apparent 
high molercular mass aggregates (*) was likely the result of a loading artifact of PS-recovered material 
that we consistently observed. E) Size and polydispersity of loaded polymersomes were determined as 
described in Material and Methods. Data shown represent absorbance plotted against paricle diameter. 
The maximum peak corresponds to 163 ±7 nm.  
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Figure 3. Polymersomes induce virus-binding anti-LASV GP1 antibodies. A) Schedule of 
immunization, blood draws, and composition of the immunization cocktail. B) Detection of anti-LASV 
GP1 specific IgG in ELISA. Microtiter plates were coated with purified LASV GP1 antigen. After 
blocking, plates were incubated with sera  in 10-fold serial dilutions for 2 h at RT. For the detection of 
LASV GP1-specifig IgG, bound primary antibodies were detected by HRP-conjugated secondary 
antibodies to total IgG and the indicated IgG isotypes in a color reaction. Data are OD 450 nm (n = 5+ 
SD).  C) Schematic of the virus-binding assay. For details, please see text. D) Detection of virus-binding 
anti-LASV GP1 antibodies. Microtiter plates were coated with the purified rLCMV-LASV GP, followed 
by blocking and incubation with sera as in (B). Virus-bound total IgG was detected with a HRP-
conjugated secondary antibody in a color reaction. Data represent individual animals. One out of three 
independent experiments is shown. 
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Figure 4. LASV GP1 antigen delivery via PS enhances antigen-specific follicular helper CD4 T 
cells,  polyfunctional CD4 T cells, and IgG secreting B cells. Mice were immunized as in (3A) with 
PS (LASVGP1) or free LASV GP1 combined with MPLA. One week after the last immunization, lymph 
node cells (LN) and splenocytes (spleen) were isolated and restimulated ex vivo using LASV GP1 
antigen. The percentage of follicular dendritic CD4 T cells among total CD4 T cells was detected using 
the markers CXCR5 and PD1 in flow cytometry (A) and the frequency of activated CD4 T cells assessed 
by staining for CD25 and CD44 (B). Data are from one out of two independent experiments, n = 5+ SD. 
P-values are indicated, ns = not significant. C) Detection of IFNγ-producing and polyfunctional 
IFNγ/TNFα-secreting CD4 T cells by intracellular cytokine staining after ex vivo restimulation with 200 
μg of LASV GP1 in the presence of Brefeldin A. Data are from one of two independent experiments, n 
= 5+ SD. P-values are indicated, ns = not significant.  D) Detection of specific IgG secreting B cells 
assessed by ELISpot as detailed in Materials and Methods.  Data are from one of two independent 
experiments, n = 5+ SD. with p-values indicated.   
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Figure 5. Polymersomes enhance the epitope-range of the anti-LASVGP1 antibody response. A) 
LASV GP1 peptide array analysis. The peptide array consists of spots of 20mer peptides spanning the 
entire LASV GP1 sequence (off-set of one amino acid) starting from the N terminus (A1) and ending 
with the C-terminal peptide (G1). Peptide arrays were probed with sera at a dilution of 1:200, follwed 
by detection with a HRP-conjugated secondary antibody to total IgG. Slides were developed using ECL. 
Displayed is a represenative LASV GP1 and PS (LASV GP1) example with luminescence signal 
intesities shown in false colors with red representing the more intense and light blue the less intense 
signals. B) Data from (A) plotted as relative intensity (y axis) of each spot (PS (LASV GP1) blue bars 
and control LASV GP1 (red bars) in the array with its position relative to the protein sequence (x axis). 
C) The peptide sequences corresponding to the spots detected in (A). D) Identified peptide sequences 
recognized by LASV GP1 antibodies in PS (LASV GP1) vaccinated mice in (A) superimposed on a 
structural model of LASV GP1 taken from (44). 
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SUPPLEMENTARY INFORMATION 
 
 
 
Figure S1. The elution profile of purified LASV GP1 was determined by size exclusion chromatography 
coupled with multiangle light scattering (SEC-MALS) as detailed in Materials and Methods. The 
horizontal line corresponds to the calculated mass for LASV GP1, 56.1 kDa, of which, only 30.5 kDa 
corresponded to the predicted polypeptide, indicating extensive post-translational modifications.  
 
 
Figure S2. Analysis of the glycosylation pattern of recombinant LASV GP1. The glycosylation 
pattern of LASV GP1 was examined using the DIG glycan differentiation kit (Roche, Switzerland) 
according to the manufacturer's instruction. Briefly, purified LASV GP1 and internal controls supplied 
with the kit were separated using 10% SDS–PAGE and transferred to PVDF membranes. The 
membranes were blocked in 20 ml of blocking solution supplied by the manufacturer for 30 min. After 
two washes with PBS, membranes were incubated with digoxigenin-labeled lectins Galanthus nivalis 
agglutinin (GNA), Sambucus nigra agglutinin SNA), Datura stramonium agglutinin (DSA), Maackia 
amurensis agglutinin (MAA), and peanut agglutinin (PNA) for 1 h. After two washes with PBS, the 
lectin binding pattern was visualized with an AP-conjugated anti-digoxigenin antibody using ECL 
according to the manufacturer’s instructions. 
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Figure S3. Purified LASV GP1 binds to different LASV GP1 mAbs. Binding to different LASV 
GP1 mAb isolated from human LASV survivors [33] was tested by ELISA. Microtiter plates were 
coated with 5 μg/ml of purified LASV GP1 followed by incubation with 5 μg/ml of purified mAbs. 
Bound primary antibody was detected with a HRP-conjugated secondary antibody in a color reaction. 
Data is optic density (OD) at wavelength 540 nm. 
 
 
Figure S4. Detection of neutralizing anti-LASV GP1 antibodies in a pseudotype neutralization 
assay. A) Schematic representation of recombinant VSV pseudotypes. The replication-deficent 
rVSVΔG*-GFP-Luc lacking the endogenous glycoprotein (G) protein was pseudotyped by trans-
complementation with either the cognate VSV G glycoprotein (rVSVΔG*-VSVG) or full-length LASV 
GP Josiah (rVSVΔG*-LASVG). Sera were diluted 1:20 (quadruplicates) and mixed with an equal 
volume of complete MEM containing VSV pseudotypes at 4,000 infectious units (IU) per well of a 96-
well plate in presence and absence of complement. As a positive control we used the DNA aptamer 
Rep9 that targets arenavirus GP and acts like a neutralizing antibody [63]. This mixture was incubated 
for 1 h at 37 °C and added to fresh monolayers of A549 cells. Luciferase reporter activity was detected 
after 48 h. Only the samples treated with the poitive control aptamers showed marked neutralization, 
whereas neutralization in serum-treated samples did not reach statistical significance.   
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Supplementary table 1. Antibodies used for the FACS staining as detailed in Materials and Methods.  
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ABSTRACT  
The advent of powerful next-generation sequencing greatly accelerated the discovery of novel 
pathogenic emerging viruses. Virus-specific monoclonal antibodies (mAb) represent crucial tools for 
research and diagnostics on such novel pathogens. However, lack of suitable culture systems and limited 
numbers of clinical cases frequently prevent isolation of the live virus or of virus-specific B cell clones 
from convalescent individuals for mAb production. Here we describe a novel approach for the 
generation of virus-specific mAb using biosynthetic immunogens based only on sequence information 
using the New World arenavirus Machupo (MACV) that causes Bolivian hemorrhagic fever as an 
example. Despite several efforts, the generation of mAb specific for MACV remains an unmet 
challenge. We produced a suitable recombinant immunogen derived from the MACV envelope 
glycoprotein that was encapsulated into oxidation-sensitive polymersomes serving as nanocarriers for 
antigen delivery. This versatile immunization scaffold facilitates intracellular MHCII loading and 
promotes a potent antibody response. Mice were immunized with adjuvanted antigen-loaded 
polymersomes in a prime-boost scheme and individual antigen-specific memory B cells isolated by 
single cell sorting. Pairs of mouse immunoglobulin heavy and light chains were PCR amplified and 
inserted into expression vectors, followed by expression in mammalian cells. Using this approach, we 
identified a novel set of MACV-specific mAb that show exquisite specificity in ELISA, Western blot, 
immunofluorescence assay, and flow cytometry. Their negligible cross-reactivity even with closely 
related New World arenaviruses makes these new mAb unique and powerful tools for research and 
diagnostics on this important and largely understudied emerging human pathogen.   
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INTRODUCTION  
Over the past decades, emerging or re-emerging viral infectious diseases have caused numerous serious 
outbreaks. The majority of emerging human pathogenic viruses are zoonotic pathogens. Current climate 
changes affecting reservoir population dynamics, urbanization, and almost unrestricted global trade 
promote human contacts with novel and unknown animal species, increasing the risks of zoonotic 
infections. The successful control of epidemics caused by novel pathogens critically depends on the 
availability of rapid and sensitive diagnostic methods to detect, identify, and trace the agent in the clinic, 
at the community level, and in the environment. Molecular diagnostics based on real-time quantitative 
PCR, nucleic acid hybridization, and more recently next generation sequencing (NGS) proved 
invaluable for the discovery of novel pathogens, routine clinical diagnostics, and outbreak control [1, 
2]. As a second pillar, serology is crucial for both etiological diagnosis and seroepidemiological studies. 
Antibody detection systems include immunofluorescence assay (IFA), enzyme-linked immunosorbent 
assay (ELISA), and different formats of neutralization tests. Virus-specific monoclonal antibodies 
(mAb) are of great importance for detection of viral antigens and examination of antigenic relationships 
of emerging viruses in research and diagnostics. However, lack of suitable cell culture systems and the 
often limited numbers of clinical cases occurring in remote areas frequently prevent isolation of the virus 
or of virus-specific B cell clones from convalescent individuals. Moreover, close structural relationship 
to other viruses sometimes prevented the generation of species-specific mAbs. In our present study, we 
developed a novel strategy for the rapid, efficient, and cost-effective production of recombinant mAb 
using biosynthetic immunogens designed “from scratch” based exclusively on available sequence 
information. To assess feasibility of our approach, we performed a proof-of-concept study taking the 
highly pathogenic New World arenavirus Machupo (MACV), as an example.  
The arenaviruses are a large and diverse family of emerging viruses that include causative agents 
of severe viral hemorrhagic fevers (VHF) in humans and represent important public health problems 
[3]. Based on their geographical distribution, mammalian arenaviruses are divided into Old World and 
New World viruses that are carried mainly by rodents [4]. Since the 1950s, the Clade B New World 
arenaviruses MACV, Junin (JUNV), Guanarito (GTOV), Sabia (SABV), and Chapare virus (CHAV) 
have emerged as causative agents of severe VHF in the Americas with case fatality rates of 30-50% [5]. 
Currently, there are no FDA approved vaccines available and treatment options are limited. In their 
reservoir species, the viruses are maintained by persistence and human infection occurs mainly by 
zoonotic transmission through inhalation of contaminated rodent excreta [6, 7]. After an incubation 
period of 1-3 weeks, patients initially develop flu-like symptoms followed by gastrointestinal 
manifestations, mucosal bleeding, and in some cases neurological problems. The varied and non-specific 
early clinical signs and symptoms of the South American VHF render clinical diagnosis often difficult 
[6]. Rapid pathogen detection is therefore imperative to prevent the risk of human-to-human 
transmission, in particular in nosocomial settings. Although MACV has been discovered in the 1960s, 
?
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all attempts to generate specific mAb have failed so far, severely limiting research and development of 
diagnostic tests [8-10]. In our proof-of-concept study, we tried to close this gap, generating a first set of 
MACV-specific mAb for use in diagnostics, research, and development. Our novel approach, outlined 
schematically in Figure 1 is based on newly developed polymersomes (PS) used as antigen nanocarrier 
for the enhancement of humoral immunity. Our PS are non-infectious, stable vesicles composed of 
biopolymers which can efficiently deliver antigen to lymph nodes, enhance uptake, and promote antigen 
presentation. Soluble biosynthetic immunogens combined with suitable adjuvants can be incorporated 
into the watery core without further modification. Following immunization with the PS nanocarrier, 
single antigen-binding B cells are isolated from spleen of immunized mice by flow cytometry (FACS).  
Single-cell RNA is extracted, reversely transcribed, and paired heavy and light chains amplified by PCR 
using specific primer sets. The resulting amplicons are cloned into expression vectors, allowing 
recombinant IgG production in mammalian cells. Using this approach, we were able to isolate a set of 
“first-in-class”, species-specific recombinant mAb against MACV.  
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RESULTS  
Generation of polymersome nanocarriers delivering the MACV GP1 immunogen 
Among New World arenavirus proteins, GP1, decorating the tips of the virion spike, shows the least 
conservation and represents therefore the most promising candidate for the development of species-
specific mAb. Available structural data reveal that MACV GP1 represents an independent fold with a 
globular structure (Fig. 2A) [11]. The GP1 monomer is necessary and sufficient for binding to the 
cellular receptor human transferrin receptor (TfR1) [20, 21] and represents the target for neutralizing 
antibodies [6]. The co-crystal structure of MACV GP1 with hTfR1 revealed that the interaction between 
GP1 and TfR1 involves several contacts via extended GP1 loops and extensive hydrogen-bonding 
networks [20]. The soluble recombinant MACV GP1 fragment used as immunogen in our study is 
comprised of amino acids 87-257, spanning the known receptor binding sites, as well as neutralizing 
epitopes.  
For antigen delivery, we chose PEG-bl-PPS (Fig. 2C), capable of enhancing CD4 T cell 
responses [22] and humoral responses to weakly immunogenic viral surface antigens (Galan et al, 2017 
in press). Polymersomes were synthesized and loaded with immunogen as described in detail in 
Materials and Methods [13, 22]. Nanoparticles with diameters in the 100 nm ensure efficient lymphatic 
transport and delivery to antigen-presenting cells in lymph nodes upon intradermal or subcutaneous 
immunization [22]. The resulting PS (MACV GP1) displayed an average size range of 150 nm, with a 
polydispersity index of 0.1. (Fig. 2D), making them suitable for our purposes. Our previous studies 
identified the Toll-like receptor (TLR)-4 ligand monophosphoryl lipid A (MPLA) [23] as a suitable 
adjuvant capable of enhancing the humoral response to PS loaded with a poorly immunogenic viral 
surface antigen (Galan et al., 2017). Age- and sex-matched C57BL/6 mice were immunized with PS 
(MACV GP1) in combination with 10 μg MPLA. Mice received a prime-boost immunization three 
weeks apart with the immunogen formulations indicated in Fig. 3A. All immunized mice showed robust 
titers of anti-MACV GP1-specific IgG on day 60 after immunization, as assessed by ELISA using our 
recombinant MACV GP1 as antigen, (Fig. 3B).  
Sorting of single antigen-specific memory B cells and cloning of anti-MACV GP1-specific IgGs 
Next, we sought to isolate antigen specific memory B cells form immunized mice. For this purpose, the 
5 mice showing the highest anti-MACV GP1 IgG titers, as assessed by ELISA (Fig. 3B) were selected 
and boosted with the PS (MACV GP1) + MPLA formulation. After 10 days, serum titers of anti-MACV 
GP1 were again measured and animals that reached a 1:1,000,000 endpoint dilution in ELISA were 
sacrificed. Total splenocytes were obtained and IgG expressing B cells isolated as outlined in Fig. 4A.  
To ensure specificity of B cells to MACV GP1 and minimize cross-reactivity, IgG expressing B cells 
were sorted after binding to fluorescence labeled recombinant MACV GP1 and the GP1 of the closely 
related JUNV that is notorious for cross-reactivity. Using flow cytometry, we separated MACV GP1-
?
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specific IgG1 producing B from cross-reactive cells. Out of the 960 single cells that were sorted, 384 
cells were selected for total RNA extraction and cDNA synthesis, by reverse transcriptase using random 
hexamer priming. Then, 17 pairs of mouse Ig heavy and light chains were amplified with primers chosen 
based on previous publications [16]. The variable heavy- and light-chain domains were then amplified 
by nested PCR. The first PCR uses a primer mix that anneals to the V(D)J leader sequences and an Ig 
constant region reverse primer. The second PCR is performed with primers annealing to the 5? end of 
the variable (V) genes and a nested reverse primer to an Ig constant region. The PCR products were then 
purified, sequenced, and inserted into eukaryotic expression vectors, followed by transient co-
transfection in HEK293T cells. Recombinant IgG from conditioned supernatants were purified by 
protein G affinity chromatography. Finally, 14 purified candidate mAb were tested for their ability to 
bind MACV GP1 in ELISA, resulting in the identification of 6 MACV GP1binding mAb, 10G7, 7C11, 
8F4, 8B9, 8G8, and 8B7 (Fig. 5A).  
Characterization of the recombinant anti-MACV GP1 mAb 
In a first step to characterize the newly obtained candidate mAb to MACV GP1, we defined their IgG 
isotype in ELISA using isotype-specific secondary antibodies. All candidate antibodies belonged to 
class IgG1 (Fig. 5B). A major goal of our study was to identify species-specific anti-MACV GP 
antibodies. To validate their specificity for MACV GP1, we performed ELISA using analogous 
recombinant GPs fragments of the related New World arenaviruses JUNV, GTOV, and OECV 
(Ocozocoautla de Espinosa virus) antigens. As a negative control, we included the GP1 of the only 
distantly related Old World arenavirus Lassa (LASV). All candidate mAbs were highly specific for 
MACV GP1 with negligible cross-reactivity to the other GP1s (Fig. 5A), providing fist evidence of 
species-specificity of our mAb.  
             The GP1 of MACV represents a compact globular fold that is stabilized by intramolecular 
disulfide-bonds. To probe possible conformation-dependence of our candidate mAb, we heated our 
recombinant MACV GP1 in presence or absence of 100 mM DTT, followed by SDS-PAGE under 
denaturing conditions. Proteins were blotted to nitrocellulose and probed with our candidate mAb in 
Western blot. All mAb recognized MACV GP1 in Western blot performed under reducing-denaturing 
conditions (Fig. 6A), suggesting that intact disulfide bonds are not required for binding. Although we 
cannot exclude the possibility of some re-folding of the immobilized protein, the observed strong 
binding in reducing Western blot suggests that our mAb may recognize non-conformational epitopes.     
           A major application of species-specific mAb in diagnostics and research will be IFA. Since 
MACV and most of the closely related Clade B New World arenaviruses, in particular JUNV and 
GTOV, are BSL4 pathogens, work with live viruses is restricted. To assess specificity of our mAb in 
IFA we therefore tested them against recombinant full-length GPC expressed in mammalian cells. First, 
a plasmid expressing MACV GPC-Flag was transfected into HEK 293T cells. After 48 h, cells were 
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fixed with paraformaldehyde and either permeabilized with saponin or left untreated. Cells were then 
stained with our candidate mAb in combination with a fluorophore-conjugated secondary antibody. The 
mAbs 10G7, 7C11, 8F4, and 8B9 gave a characteristic cell-surface staining on non-permeabilized cells 
well above background (Fig. 7A), whereas mAbs 8D8 and 8D7 gave weaker staining and were not 
further pursued (data not shown). To verify the specificity of mAbs 10G7, 7C11, 8F4, and 8B9 in IFA, 
they were tested against the full-length GPC of the closely related JUNV. In line with our ELISA and 
Western blots, the mAbs proved to be specific for MACV GP1 with no detectable cross-reactivity for 
the GP1 of related viruses under our assay conditions (Fig. 7B).  
            In addition to IFA, we verified reactivity and specificity of our mAbs in flow cytometry. To this 
end, HEK 293T cells were transfected with a plasmid expressing MACV GPC-Flag. Live non-
permeabilized cells were stained with mAbs 10G7, 7C11, 8F4, and 8B9 in staining buffer containing 
sodium azide in order to prevent internalization of GPC. After fixation, bound mAbs were detected with 
a florescence-labeled secondary antibody. Analysis by flow cytometry revealed robust and specific 
staining in MACV GPC transfected cells, but not mock-transfected controls (Fig. 8).  
Our initial characterization revealed that our mAb 10G7, 7C11, 8F4, and 8B9 were highly 
specific for MACV GP1 with possible applications in ELISA, Western blot, IFA, and flow cytometry, 
making them valuable tools for research and diagnostics. In a next step, we assessed neutralizing activity 
of the mAbs, employing a well-established pseudotype assay based on recombinant replication-
competent, propagation-deficient vesicular stomatitis virus (VSV) lacking the G protein (VSVΔG) 
containing a luciferase reporter [18] displaying full-length mature MACV GP (Fig. S1A). Briefly, 
VSVΔG-MACVGP pseudotypes were mixed with mAb at 20 μg/ml for one hour at 37°C. The mixture 
of pseudotypes and antibodies was added to fresh monolayers of VeroE6 cells and infection detected by 
luciferase or GFP assay as described [24]. Despite robust binding to MACV GP1, none of the mAbs 
achieved significant neutralizing activity under our assay conditions, whereas soluble hTfR1 included 
as a positive control lead efficiently blocked infection (Fig. S1B).  
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DISCUSSION  
Hemorrhagic arenaviruses are classified as BSL4 pathogens and high containment facilities are required 
to handle live virus samples for diagnostic purposes. To circumvent these restrictions, serological assays 
based on recombinant viral antigens have been developed, including direct IgG-ELISA, IFA, and 
capture-ELISA [8, 25, 26]. These serological assays are highly sensitive and specific for LASV [26] and 
JUNV [8]. However, the current lack of specific mAb to MACV [8-10] so far prevented the development 
of specific tests for MACV, severely restricting research and development. The current lack of mAb to 
MACV is likely explained by the high antigenic relatedness in particular to JUNV, which shows higher 
prevalence. Examination of available sequences revealed that the GP1 moiety involved in host cell 
attachment shows the largest variation, possible reflecting selective pressure exerted by the humoral 
immune response of the host [27, 28]. However, several lines of evidence support the notion that the 
arenavirus GP1 are inherently weak antigens due to glycan shielding [29], similar to the envelope GPs 
of other human pathogens, such as human immunodeficiency virus (HIV)-1 or hepatitis C virus (HCV) 
[30-32]. Using a recombinant receptor-binding fragment of the GP1 of the Old World arenavirus LASV, 
we recently showed that mice immunized with adjuvanted PS (LASV GP1) showed superior humoral 
responses than free antigen, including antibodies with higher binding affinity (Galan-Navarro et al., 
2017). This was reflected by increased levels of polyfunctional anti-viral CD4 T cells and IgG-secreting 
B cells, as well as a more diverse epitope repertoire of anti-viral IgG. Considering the extensive 
glycosylation found of envelope GPs of major families of emerging viruses, including filoviruses, 
Bunyaviruses, and arenaviruses, we employed our PS platform for antigen delivery. Recombinant 
MACV GP1 was synthesized based on the available sequence information [33] and encapsulated into 
PS. For immunization, PS (MACV GP1) were applied following a prime-boost protocol, which induced 
robust anti-MACV GP1 IgG responses. Using purified recombinant immunogen, we achieved isolation 
of 960 single antigen-specific B cells. Total RNA was extracted from 384 cells, followed by cDNA 
synthesis. Amplification using specific primers and subsequent filtering of data resulted in the 
identification of 17 pairs of mouse immunoglobulin heavy and light chains. Expression in HEK293T 
cells yielded 14 recombinant IgG that were screened for antigen specificity using ELISA. Six mAb were 
selected based on their specificity and high binding affinity in ELISA. 
Since research and diagnostic applications involve a range of techniques, we validated the 
sensitivity and specificity of our mAb in ELISA, Western blot, IFA, and flow cytometry. Examination 
in ELISA against a panel of recombinant arenavirus GP1, including the closely related Clade B viruses 
JUNV and GTOV revealed exquisite sensitivity. Examination of mAb in Western blot under reducing 
conditions revealed strong binding of our mAb to denatured antigen, making them suitable for the 
examination of fixed specimens that had undergone virus inactivation, which would be a decisive 
advantage considering the requirement of BSL4 to handle unfixed native samples. Since IFA remains a 
major diagnostic technique and is widely used in research, we validated specificity of our anti-MACV 
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GP1 mAb using the full-length GPC of MACV and the closely related JUNV. In contrast to all mAb 
isolated so far [9, 10], our set of mAb was highly specific for MACV GP1 in fixed cell specimens. 
Staining of non-permeabilized cells revealed the characteristic cell surface staining associated with the 
expression of full length GPC in infected or transfected cells. Lastly, examination of our mAb in flow 
cytometry performed on live, non-permeabilized cells confirmed the high specificity for MACV GP1 
over JUNV GP1. Initial examination of our mAb in a neutralization test based on pseudotypes of 
vesicular stomatitis virus (VSV) [18, 24] revealed little neutralizing activity (Sup. Figure 1). Combined 
with the observed ability of our mAb to strongly bind reduced denatured MACV GP1 in Western blot, 
this suggests that they are directed against, non-conformational epitopes, possibly located at the non-
neutralizing face of the protein. We are currently screening a larger number of antigen-specific B cells 
in order to isolate neutralizing mAb.     
Despite some sequence variation, MACV and JUNV have a nearly identical overall GPC 
architecture and share the host cell receptor TfR1uisng a conserved binding mode. The capacity of our 
polymersomes to induce specific mAb against MACV GP1 is therefore unprecedented and demonstrates 
the potential of this versatile immunization scaffold. As previously shown in our studies on the 
notoriously weakly immunogenic LASV GP1, the platform may further promote the quality of antibody 
responses against otherwise poor antigens. This may enhance the probability of successful mAb 
isolation, removing an important bottleneck. Considering that the clinical signs and symptoms of 
Bolivian VHF caused by MACV in humans are virtually indistinguishable from those of classical 
Argentine VHF associated with JUNV, our virus-specific mAb may be useful for the direct detection of 
the virus in tissue specimens using IFA. In addition, we are currently developing a capture-ELISA 
format for the rapid and sensitive detection of MACV antigen in serum and CSF samples.  In sum, we 
used a versatile PS-based immunization scaffold to rapidly generate recombinant mAb to MACV GP1 
that show exquisite specificity in ELISA, IFA, Western blot and flow cytometry. These mAb represent 
valuable tools for research and development for the biomedical research comunity and clinical 
diagnostics.   
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MATERIALS AND METHODS  
Animals  
C57BL/6 female mice, aged 8-12 weeks, were purchased from Harlan (Gannat, France). All animal 
experiments were performed under the approval from the Veterinary Authority of the Canton of Vaud 
(Switzerland) according to Swiss regulations of animal welfare (animal protocol number 2502.1 and 
2235.1). 
Recombinant MACV GP1  
Purified recombinant MACV GP1 was obtained as described [11]. The globular domain of MACV GP1 
glycoprotein responsible for attachment to human transferrin receptor 1 (residues 87 to 257 from the 
complete mature GP; GenBank accession number AAS77647.1) was cloned into the pHLsec vector 
containing the chicken RPTP signal sequence (5). MACV GP1 was expressed in HEK 293T cells 
transfected with 2 mg DNA/liter of cell culture in the presence of 5 M kifunensine, which prevents 
extension of N-glycans, resulting in protein bearing oligomannose-type glycans. MACV GP1 protein 
was purified from the cell supernatant by using immobilized metal affinity chromatography (IMAC) 
followed by size-exclusion chromatography (SEC). Protein yields were 2.0 mg MACV GP1/liter of cell 
culture at purity of >98%. LASV GP1 (residues 58-92) and JUNV GP1 (residues 87–231) antigens used 
here were described in previous studies in Galan-Navarro et al. 2017 and [12]. 
Block-copolymer synthesis and polymersome preparation 
All chemical reagents were reagent grade and purchased from Sigma-Aldrich, MO, unless otherwise 
stated. Polymersomes (PS) were prepared as described [13]. Briefly, block-copolymers were 
synthesized using benzyl mercaptan to start the living polymerization of propylene sulfide (PPS). The 
terminal thiolates were capped with PEG-mesylate. For purification, the co-polymers were precipitated 
two times in cold methanol. The purity and length of the PPS chain were confirmed by gel 
chromatography and NMR. Chains of PEG17-bl-PPSx, containing between x=26-32 PPS units were used 
to form PS. An amount of 30-50 mg was re-suspended in dichloromethane and placed in piranha-etched 
glass vials to desiccate overnight. For the formation of PS with MACV GP1, a thin film of copolymer 
was rehydrated with a solution of 500 μl of MACV GP1 or fluorescence-labeled MACV GP1 (2 mg/ml) 
in 50 mM sodium phosphate buffer, and rotated for 48 h at 4°C. Next, the solution was extruded at least 
four times through a 0.2 μm nucleopore track-etched membrane (Whatman, Maidstone, UK) to obtain 
PS ranging between 150-170 nm with polydispersity values < 0.2. Purification of the PS loaded with 
MACV GP1 immunogen from free protein was achieved by SEC through a Sepharose CL-6B column. 
Fractions containing PS were pooled and further concentrated though an ultra-centrifugation filter 
(Amicon Millipore, Darmstadt, Germany) with a cut-off of 100 kDa. Efficiency of MACV GP1 loading 
into PS was 430 μg/ml calculated by subtracting the amount of the unloaded protein from the starting 
material used. The size of PS was determined by dynamic light scattering with a Nano Zs Zetasizer 
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(Malvern Instruments, Malvern, UK). PS were controlled for their size and polydispersity, as well as 
endotoxin levels using the HEK-BlueTM TLR4 cells and QUANTI-Blue (inVivogen) with endotoxin 
standard (E-Toxate Endotoxin standard E8029-1VL Sigma-Aldrich) for every batch produced. 
Western-blot  
Protein Samples were mixed 1:1 with 2x SDS-polyacrylamide gel electrophoresis (PAGE) sample 
buffer containing 100 mM DTT and boiled (5 min at 95°C). Samples (1μg of purified MACV GP1) 
were separated by SDS-PAGE and blotted to nitrocellulose membranes. Membranes were blocked in 
3% (w/v) skim milk in PBS and proteins detected with primary antibody after overnight incubation at 
4°C using HRP-conjugated secondary antibodies as described [14]. Monoclonal antibodies to MACV 
GP1 were used at 1 μg/ml and polyclonal rabbit anti-mouse-HRP at 1: 3,000. Membranes were 
developed using enhanced chemiluminescence (ECL) using Amersham ECL Prime Western Blotting 
Detection Reagent (GE Healthcare lifesciences Little Chalfont, UK). Signal acquisition was performed 
with ImageQuant LAS 4000Mini (GE Healthcare lifesciences Little Chalfont, UK). 
Immunization protocol 
All immunizations were administered intra-dermal (i.d.) into the four footpads, under isofluorane 
anesthesia. For all formulations, 10 μg of MACV GP1 was injected per animal, together with 10 μg of 
MPLA (Salmonella minnesota R595, AvantiLipids). All PS and proteins batches were tested negatively 
for endotoxin using a Toll-like receptor activation assay based on HEK-Blue reporter cell lines 
(Invivogen, CA). 
Enzyme-linked immunosorbent assay (ELISA) 
For the detection of antigen-specific antibodies in ELISA, 96-well Nunc MaxiSorp® plates were coated 
with 5 μg/mL of MACV GP1 overnight at 4°C. Plates were washed three times with PBS/ 0.02% 
(wt/vol) Tween-20 and blocked with 2.5% (wt/vol) casein solution in PBS for 2 h at room temperature 
(RT). Serial dilutions of serum in 2.5% (wt/vol) casein/PBS were added and incubated for 2 hrs at RT. 
Plates were washed four times, following by incubation with HRP-conjugated secondary antibodies 
specific for and IgG1, IgG2a,c, IgG3 or total IgG (Southern Biotech, Birmingham, AL). After incubation 
for 1 h at RT, plates were washed four times and developed using 50 μl of 3,3’,5,5’-tetramethylbenzidine 
(eBiosciences, MA). The signal was stopped by adding 20 μl of 2 M H2SO4. Plates were analyzed using 
a plate reader spectrophotometer (Tecan, Mannedorf, Switzerland) by measuring the absorbance at 450 
nm with correction at 570 nm. Specific signals were calculated by subtraction of absorbance obtained 
with samples containing the blocking casein only (background control).  
Flow cytometry  
For detection of full-length MACV GP on transfected HEK293T cells, 3x106 cells were plated in cone-
shaped 96 well plates, washed once with HBSS, and stained with live/dead fixable cell viability reagent 
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(Life technologies, CA). For surface staining, cells were washed once with HBSS supplemented with 
0.5% (wt/vol) BSA (Sigma) and resuspended in HBSS, 0.5% (wt/vol) BSA containing primary 
antibodies at the indicated concentrations. Bound primary antibodies were detected with a 
phycoerythrine (PE)-conjugated goat anti-mouse IgG secondary antibodies (1:100) in HBSS, 0.5% 
(wt/vol) BSA. After staining, cells were resuspended in staining buffer for analysis by flow cytometry. 
Flow cytometry was performed using a CyAnTM ADP (Beckman Coulter) and data were analyzed with 
FlowJo software package (Ashland, OR). 
Single memory B cell sorting  
Staining and single-cell sorting of memory B cells was performed as described [15]. Briefly, mice were 
sacrificed and fresh total splenocytes harvested were sequentially incubated with different specific 
antibodies (Supplementary table 1). For antigen specific-staining Streptavidin fluorescent proves were 
used (Alexa488-SA: 53370D, Alexa647-SA: 54050D and PE-SA). Then, Washed cells were subjected 
to single cell sorting to isolate CD4−, CD8−, Gr-1−, F4/80−, B220+, CD38−, IgM−, IgG+, and MACV 
GP1+ memory B cells into 96-well plates using a FACSAria III sorter (Becton Dickinson) according to 
von Boehmer et al., 2016 detailled descrition. The cells were then lysed with 4 μl lysis buffer containing 
RNASin (Promega) 40 U/μl (0,3 μl), DPBS (Dulbecco) 10 x (0.2 μl), DTT (Invitrogen) 100 mM (0.4 
μl) and nuclease-free water (3.1 μl). The sorted plates were stored at −80 °C until further processing. 
Cloning and expression of Ig genes as a recombinant antibody 
Cloning of recombinant IgGs was performed as reported earlier [16]. Briefly, total RNA of each antigen-
specific sorted B cell was extracted and cDNA synthesized using reverse transcription (RT) with random 
hexamer primining. IgH and IgK or Igλ light chain genes were amplified in separate nested PCR 
reactions using cDNA as a template and water as a negative control. The PCR products were sequenced 
and subjected to IGBLAST to determine the V and J region of IgH and IgK or Igλ, respectively. Specific 
primers of V and J genes with restriction sites were used to amplify and clone the specific products into 
corresponding expression vectors. Vectors to express variable heavy chain and light chain of the 
antibody were transfected into HEK293T cells. Cell supernatant were collected after 48?h of 
transfection.  
Immunofluorescence assay (IFA) 
The immunofluorescence assay was described previously [17] . Briefly, A549 cells were seeded in a 96-
well plate (3 × 104 cells/well). After 19 h, cells were transiently transfected with expression constructs 
for the indicated full-length arenavirus GPC and lipofectamine. At 48 h postransfection, cells were fixed 
with 4% paraformaldehyde (PFA). The cells were permeabilized with 0.01% (wt/vol) saponin in PBS 
containing 3% (wt/vol) BSA] and reacted first with each MACV GP1 mAb, followed by an Alexa Fluor 
568-labeled (green) or rhodamine (red) anti-mouse secondary antibodies and counterstaining of nuclei 
(DAPI, blue). Specimens were examined by FLoid Cell imaging station form Life Sciences, CA.  
?
?
? ?
Pseudovirion neutralization assay 
Pseudotyped propagation-defective vesicular stomatitis virus (VSV) encoding the two reporter proteins 
green fluorescent protein (GFP) and firefly luciferase (Luc) was generated as described [18]. VSV 
pseudotypes bearing the envelope GP of MACV were generated as reported earlier [19]. For the 
pseudovirion neutralization assay, sera were diluted 1:20 in complete MEM, followed by two-fold serial 
dilutions. For each well (quadruplicates), serum dilutions (50 μl) were mixed with an equal volume of 
complete MEM containing 4,000 infectious units (IU) of VSV-MACV GP and incubated for 1 h at 37 
°C. Following this incubation, the mixture was added to fresh monolayers of A549 cells cultured in clear 
bottom white-walled 96-well plates (Costar). After 1 h, the inoculum was removed by washing and fresh 
medium added. After 20 h at 37 °C and 5% (vol/vol) CO2, luciferase reporter activity was detected using 
the Luciferase Assay System (Promega, WI). A GloMax (Promega, WI) microplate reader was used for 
signal acquisition.  
Data collection and Statistical Analysis  
1-way ANOVA (analysis of variance) followed by a Bonferroni post-test was used to assess statistical 
differences between the groups with a p-value < 0.05 was used as criterion of statistical significance. 
All data was analyzed using the GraphPad Prism 5 Software (GraphPad Software Inc., La Jolla, CA). 
All data presented as bar graphs represent the mean ± standard deviation (SD). 
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FIGURES 
 
Figure 1. Workflow of our approach developed to rapidly produce recombinant mAb against newly 
emerging pathogens. When a disease caused by an unknown pathogen emerges, subtractive NGS 
approaches can be used to determine the nucleotide sequence of the pathogen’s genetic material without 
the need to isolate the agent. Biocomputational analysis frequently allows the classification of the novel 
agent and the identification of putative ORFs coding for its structural and non-structural proteins that 
represent possible targets for antibodies. Based on this information, new candidate antigens can be de 
novo synthesized or produced in recombinant form based on cDNA sequences and purified. These 
antigens can then be encapsulated into PS nanocarriers (PHASE I). Antigen loaded PS combined with 
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a suitable predetermined adjuvant formulation can be used to immunize mice and obtain an enhanced 
polyclonal antigen-specific humoral immune response (PHASE II). Upon immunization following a 
prime-boost scheme, splenocytes are isolated form responding animals, followed by sorting of antigen-
specific B cells using recombinant antigen as a bait in flow cytometry. Total RNA is extracted from 
individual antigen-specific B cells and specific primers used to amplify corresponding heavy and light 
IgG chains. Paired heavy and light chains are inserted into a mammalian expression vector in order to 
produce the recombinant monoclonal Abs (PHASE III). Finally, the candidates recombinant mAbs can 
be characterized in order to use them as therapeutic or diagnostic tools (PHASE IV). 
 
 
Figure 2. MACV GP1 antigen structure and PS (MACV GP1) production and immunization. A) 
Structure of MACV GP1. Left panel with cartoon diagram of MACV GP1 colored as a rainbow with 
the N terminus shown in blue and the C terminus in red. The N and C-termini are marked with blue and 
red spheres, respectively. Right panel with view of MACV GP1 rotated by 90° [33]. B) Sequence 
alignment of residues observed in the MACV GP1 crystal structure. Secondary structure elements are 
shown with an arrow and helices are shown as spirals, with α-helices shown in bold. Residues which 
are highlighted red are fully conserved with other related NW arenavirus GP1, residues which are 
colored red are partially conserved, and residues which are black are not conserved. Amino acids which 
correspond to predicted N-linked glycosylation sites are marked with blue boxes. C) Schematic 
representation of PEG-bl-PPS block copolymers and vesicles. Block copolymers composed of PEG and 
PPS self-assemble into oxidation-sensitive PS in aqueous solutions. Hydrophobic and hydrophilic 
regions are shown in red and blue, respectively. D) Size and polydispersity of loaded PS were 
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determined as described in Material and Methods. Data shown represent absorbance plotted against 
particle diameter. Maximum peak corresponds to 163 ±7 nm. 
 
 
Figure 3. Immunization with PS (MACV GP1) induces a humoral response against MACV GP1. 
A) Schedule of immunization, blood draws, and composition of the immunization cocktail. Mice were 
immunized with either 10 μg of PS (MACV GP1) or 10 μg of MACV GP1. 10 μg of MPLA were 
constantly provided in the formulation. Mice were boosted 21 days after prime immunization and bleed 
on days 14 and 28 after prime immunization and every two weeks onwards. B) Detection of polyclonal 
anti-MACV GP1 and anti-JUNV GP1 specific IgG present in mice serum 60 days post immunization 
with specific ELISA test. Plates were coated with 5 μg of purified MACV GP1 or JUNV GP1 
respectively. Data are OD 450 nm (n = 5+ SD).  
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Figure 4. Sorting of single antigen-specific B cells and cloning of anti-MACV GP1-specific IgGs. 
A) Gating strategy for isolation of antigen-specific single B cells. Antigen-specific IgG memory B cells 
are obtained by gating for B220+, CD38+, IgG+IgM− cells excluding cells expressing CD8, F4/80, CD4 
and Gr-1 (DUMP). Gating for antigen-binding cells yielded three different populations, MACV GP1 
specific (purple), JUNV GP1 specific (green) and cross-reactive MACV-JUNV GP1 specific B cells 
(orange). B) Work flow of the strategy followed for the cloning and expression of antigen specific IgG. 
Briefly, after single memory B cell isolation, V(D)J transcripts were amplified by RT-PCR. Fragments 
were then combined with linearized expression vectors, assembled in vitro as part of a sequence- and 
ligation-independent cloning reaction and then transformed into Escherichia coli.  Purified vectors were 
then used to transfect HEK293 suspension cells and produce and isolate mAb. 
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Figure 5. The mAbs 10G7, 8G8, 7C11, 8F4, 8B7, and 8B9 are specific for MACV GP1. A) Microtiter 
plates were coated with purified MACV, JUNV, GTOV, OECV and LASV GP1s purified antigens. 
After blocking, plates were incubated with each MACV GP1 mAb in 10-fold serial dilutions for 2 hrs 
at RT. For the detection, bound primary antibodies were detected by HRP-conjugated secondary 
antibodies to total IgG. B) IgG isotype determination of MACV GP1 mAb in a color reaction. Data are 
OD 450 nm (n = 5+ SD). 
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Figure 6. Specificity of MACV GP1 mAbs to MACV GP1 in Western Blot. A) The mAbs 10G7, 
8G8, 7C11, 8F4, 8B7, and 8B9 recognize MACV GP1 in Western blot under reducing/denaturing 
conditions. For Western blotting, purified MACV GP1 and JUNV GP1 protein were subjected to SDS-
PAGE under reducing and not reducing conditions, and the separated proteins transferred to a 
nitrocellulose membrane. After blocking, the membrane was incubated with each of the mAbs, followed 
by incubation with HRP-conjugated secondary antibody and development by ECL. Molecular mass 
markers are indicated.  
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Figure 7. mAbs 10G7, 7C11, 8F4, and 8B9 are specific for MACV GP1 in IFA. Immunofluorescence 
assay with mAbs 10G7, 7C11, 8F4, and 8B9.  HEK293T cells were transfected with MACV GPC-Flag, 
(A) JUNV GPC-Flag (B) or mock transfected, cells fixed and then treated with saponin for 
permeabilization (intracellular staining) or left untreated (surface staining) and incubated with the 
indicated mAbs. Bound mAbs were detected with a secondary antibody conjugated to GFP and the flag 
tag was detected with a secondary antibody conjugated to rhodamine-red. Bar = 10 μm. 
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Figure 8. MACV GP1 mAbs bind to MACV GP1 in live cells. A) Detection of MACV GP1 on live 
non-permeabilized cells in flow cytometry. HEK 293T cells were transfected with MACV GPC-Flag 
and live, non-permeabilized cells stained with the indicated mAbs. After fixation, bound primary 
antibodies were detected in flow cytometry using PE-conjugated or Alexa 488 secondary antibodies.  
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SUPPLEMENTARY INFORMATION 
 
  
Fig S1. Detection of neutralizing anti-MACV GP1 antibodies in a pseudotype neutralization assay. 
A) Schematic representation of VSV pseudotypes. The replication-deficent VSVΔG*-GFP-Luc lacking 
the endogenous glycoprotein (G) protein was pseudotyped by trans-complementation with either the 
cognate VSV G glycoprotein (VSVΔG*-VSVG) or full-length MACV GP (VSVΔG*-MACVG). mAbs 
were diluted up to 20μg/ml (quadruplicates) and mixed with an equal volume of complete MEM 
containing VSV pseudotypes at 4,000 infectious units (IU) per well of a 96-well plate in presence and 
absence of complement. As a positive control we used purified hTfR1 which acts like a neutralizing 
antibody [34]. This mixture was incubated for 1 h at 37 °C and added to fresh monolayers of A549 cells. 
Luciferase/GFP reporter activity was detected after 48 h. Only the samples treated with the poitive 
control showed marked neutralization, whereas neutralization in antibody-treated samples did not reach 
statistical significance.   
 
 
Supplementary table 1. Antibodies used for the B cell sorting staining as detailed in Materials and 
Methods. 
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CHAPTER 4 
 
 
Conclusions, implications and future 
directions 
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CONCLUSIONS 
In the first part of my thesis a PS-based nanocarrier platform was evaluated for its ability to improve the 
antibody response against the poorly immunogenic surface antigen GP1 of LASV. We were able to 
demonstrate that antigen encapsulation into PS enhanced overall LASV GP1-specific antibody titers and 
markedly increased virus-binding antibodies, capable of recognizing GP1 in the context of the authentic 
virion spike. Delivery of the poorly immunogenic LASV GP1 via PS resulted in higher frequencies of 
follicular helper CD4 T cells, increased the numbers of antigen-specific CD4 T cells and the frequency 
of polyfunctional IFN-γ /TNF-α secreting CD4 T cells. An enhanced frequency of antigen-specific IgG-
secreting B cells correlated with a broadened epitope-range. Together, the data indicate that PS 
encapsulation enhanced the humoral response in terms of both magnitude and quality. 
During the second part of my studies, we took an additional step and applied the obtained 
knowledge to develop a novel approach for the rapid production of antigen-specific recombinant mAb 
using biosynthetic antigens that can be generated based on sequence information only. In a proof-of-
concept study, we combined our PS platform with single B cell sorting and molecular cloning of 
recombinant IgGs, to generate a unique panel of “first in class” mAb specific to MACV GP1 which 
showed exquisite selectivity for MACV in ELISA, Western blot, IFA, and flow cytometry. These novel 
mAbs will be invaluable for research and development of novel diagnostic tests against this devastating 
and understudied emerging pathogen.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
?
?
? ?
IMPLICATIONS AND FUTURE DIRECTONS 
Towards a new vaccine against Lassa virus 
Lassa virus currently causes several hundred thousand infections per year with thousands of deaths, 
affecting some of the poorest countries in the World. Incomplete knowledge of the virus and the disease, 
the requirement for BSL4 facilities to work with live virus, and lack of suitable platforms prevented so 
far the development of an efficient and safe vaccine. The limited therapeutic options, overall weak public 
health infrastructure in affected regions, and the rapid geographical spread of this hemorrhagic fever-
causing virus, makes progress in the field indispensable and of immediate importance. A series of recent 
reports emphasized the promise of protective antibodies in treatment and prevention of Lassa fever and 
provided novel insights into the mechanisms of antibody-mediated neutralization of LASV [1-4]. 
Research on the fundamental virology of Lassa virus further shed light on the molecular mechanisms of 
viral attachment and entry that are the key targets for protective antibodies [5-10]. Compilation of these 
published studies with our work presented here and studies that I contributed to (Fedeli et al., manuscript 
attached) could pave the way for the development of a protective LASV vaccine as well as novel 
immunotherapeutics.  
A major drawback of our current PS (LASV GP1) vaccine formulation is its apparent inability 
to elicit potent neutralizing antibodies (nAb) defined operationally by our VSV-pseudotype-based in 
vitro neutralization test. Notably, the same neutralization test format proved to be very powerful in 
recent applications for the Ebola vaccine development [11], suggesting an inherent limitation in our 
vaccine system rather than an experimental artefact. Novel insights into the molecular mechanisms of 
antibody-mediated neutralization of LASV provide a possible explanation for this. Examination of a 
large panel of nAb isolated from Lassa fever survivors revealed specificity for conformational epitopes 
that frequently depended on GP1/GP2 quaternary structures [1]. The very recently reported high 
resolution structure of LASV GP in its pre-fusion conformation bound to one of these newly isolated 
nAb further highlighted the relevance of quaternary structures during immunization, emphasizing that 
the GP1/GP2 interface is essential for receptor binding and antibody neutralization [2]. To 
experimentally address this issue, I propose to design a new improved LASV immunogen retaining key 
structural elements of the quaternary structure of the prefusion GP trimer, in particular features of the 
GP1/GP1 trimer and GP1/GP2 heterodimer interface. A major challenge will be the stabilization of the 
trimeric structure of the LASV GP ectodomain in absence of the membrane anchor. In their structural 
studies, Hastie et al. achieved this stabilization by “clamping” the soluble LASV GP ectodomain into 
its trimeric form with an antibody [2]. Similar stabilization of the trimeric ectodomain of a trimeric class 
I viral fusion protein was achieved with a smaller biosynthetic trimerization domain used in studies on 
the influenza A virus 1918 hemagglutinin [12]. We expect that delivery of an immunogen containing at 
least parts of the crucial molecular interfaces of the trimer via our PS platform would markedly increase 
the probability to obtain nAb.     
?
?
? ?
Many nAb target viral envelope GPs in their pre-fusion conformation and interfere with binding 
to receptors or co-receptors [13, 14]. This would be the case for at least some of the nAb elicited by the 
newly improved antigen derived from the LASV GP prefusion trimer outlined above. Interestingly, upon 
entry via its cellular receptor DG, LASV is rapidly delivered to the late endosome, where the virus 
undergoes a “receptor switch” and engages the late endosomal/lysosomal resident protein LAMP-1 that 
is essential for efficient fusion [5, 7, 8]. Although most Old World arenaviruses can use DG as a receptor, 
the ability to hijack LAMP-1 as a late endosomal entry factor is unique for LASV [9]. Our unpublished 
data further show that LASV entry via the alternative receptor Axl likewise depends of LAMP-1, 
suggesting convergence at the level of the late endosomal entry factor (Fedeli et al., manuscript 
attached). The use of an essential intracellular entry factor by LASV is shared by the filovirus Ebola that 
hijacks the late endosomal protein Niemann-Pick1 (NPC1) to penetrate the limiting endosomal 
membrane [15]. A current model of the sequence of events during this late endosomal receptor switch 
is presented in Fig. 1. Please note that the dissociation from the cell surface receptor is followed by a 
lag-phase during which the free LASV GP undergoes protonation, preventing fusion until it engages 
LAMP1 that provides the fusion-triggering signal. Very recent experimental studies performed in our 
laboratory by my colleague Dr. Chiara Fedeli revealed a duration of this lag-phase of circa 5-10 min. 
Considering the fast on-rates of high affinity nAb, pre-loading of cells with nAb targeting the specific 
conformation of LASV GP1 required for LAMP-1 binding appears as a promising “second hit” strategy 
to prevent viral fusion at the level of the late endosome. Recent cryo-tomography studies on authentic 
LASV particles indicated drastic conformational changes of LASV GP1 under acidic pH (< 5.5) [16]. 
Performing crystallization of LASV GP1 under acidic pH, the structure of the low pH conformation was 
resolved [7]. As expected this stable low energy conformation of LASV GP1 bound LAMP-1 with high 
affinity, but was unable to recognize the cell surface receptor DG. Since the low pH conformation of 
LASV GP1 represents an attractive second target for anti-viral nAb, I propose to deliver both, LASV 
GP in its pre-fusion conformation and the low pH form of GP1 in a combined PS-based vaccine. The 
resulting antibody response would include “classical” nAb targeting LASV GP in its pre-fusion 
conformation, thus preventing host cell attachment, and a second type of nAb that would enter the scene 
once the virus has overcome the barrier of the plasma membrane and reaches the late endosomal 
compartment in search for its entry factor LAMP-1. As all RNA viruses, LASV has a high mutation 
rate, rendering this pathogen highly plastic. A major concern of recombinant LASV vaccines based on 
biosynthetic immunogens is the possibility of the virus to escape nAb by acquisition of specific 
mutations in immunodominant B cell epitopes. Targeting in addition the secondary endosomal receptor 
binding would still block such putative escape variants, reducing the risk of vaccine failure. Moreover, 
LASV enters human cells via macropinocytosis [10], which is the major pathway of bulk liquid 
transport. As a consequence, both virion and nAb would reach the same cellular compartment, the late 
endosomes, where viral fusion takes place. Conceptually, a similar strategy is currently explored against 
Ebola virus targeting NPC1 at the level of the late endosome.  
?
?
? ?
 
Figure 1. Current model for the late endosomal “receptor switch” of LASV. At the cell surface, 
LASV GP1 engages the O-linked matriglycan polysaccarides displayed by α-DG, followed by 
endocytosis via an unusual pathway related to macropinocytosis. Progressive acidification of late 
endosomes induces a structural change in LASV GP1, which dissociates from DG and adapts a low pH 
conformation displaying a histidine-triad. Protonation of residue H230 “locks” GP1 in the pre-fusion 
state, preventing premature fusion. Engagement of LAMP1 neutralizes the positive charge on H230 of 
GP1 and triggers efficient fusion with the limiting membrane of the late endosome/lysosome. Taken 
from [17].      
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A novel approach for the production of mAb against novel emerging human pathogens 
Regarding pathogenic novel emerging viruses their classification as BSL3 or BSL4 pathogens 
frequently limits diagnostics, in particular in remote areas with limited public heath infrastructure. 
Reliable, specific, inexpensive, rapid, and high-throughput, point-of-care, virus-free serology assays, 
are critical tools for the decision-making process during the initial steps of an emerging health crisis in 
order to contain the outbreak. The necessity for sensitive and specific diagnostic tests for the detection 
of emerging and re-emerging pathogens is dramatically illustrated by the ongoing outbreak of Zika virus. 
The only transient viremia in individuals infected with Zika virus limits the positive predictive value of 
RT-PCR and other molecular diagnostic tests. The lack of a specific serological test for Zika caused 
extensive misdiagnosis of early cases that were erroneously taken for Dengue, a very abundant pathogen 
in many of the affected countries. Due to the persisting cross-reactivity with multiple flavivirus antigens 
and the lack of specific serology-based assays, laboratory diagnosis of Zika virus still relies on laborious 
and time-consuming virus isolation or RNA detection techniques with the abovementioned limitations. 
As more structural information becomes available on the E proteins of Zika and other relevant 
flaviviruses, the design of candidate biosynthetic antigens that may be capable of eliciting specific mAb 
to Zika becomes feasible. Our novel approach would allow rapid testing of panels of biosynthetic 
immunogen candidates using our PS platform. In case a specific response is obtained, B cells could be 
isolated, followed by cloning and production of recombinant mAb. Such mAb could then be directly 
used in etiological diagnostics in the clinic, e.g. IFA of infected tissue specimens or sandwich-ELISA 
for direct pathogen detection, as well as references for seroepidemiological studies. An example for such 
an assay is a highly specific sandwich-ELISA based on mAbs developed for the detection of JUNV 
currently used in Argentina in endemic regions [18, 19]. The advent of powerful next-generation 
sequencing technologies has greatly accelerated the discovery of novel pathogens, but their isolation is 
frequently not possible. Another decisive advantage of our novel approach based on the PS platform in 
the context of emerging pathogens is the use of recombinant biosynthetic immunogens that can be 
designed and produced based on available sequence information only. In our proof-of-concept study, 
we showed that the versatile immunization scaffold of PS allows rapid production of specific antibodies 
via immunization, followed by B cell sorting, and cloning of specific IgG within a few months. Such 
mAb can be rapidly tested for specificity and evaluated for diagnostic as well as therapeutic potential.  
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Contribution to manuscripts: 
 
Review Torriani et al. JVI 
In this invited Gem review article of the Journal of Virology, I participated in the discussions, the 
development of concepts, and writing of the article.  
 
Manuscript Fedeli et al., JVI 
This manuscript is currently under revision at the Journal of Virology. 
In this project, I developed the specific protocols for virus production and purification that were 
instrumental for the study, specifically experiments shown in Fig. 2, 4, 6, and 7. I further optimized 
existing experimental protocols for IFA detection and quantification of virus used throughout the 
study.  
 
Manuscript Rincon-Estrepo et al., 
In this manuscript I have amplified and quantified the LCMV virus for the challenge experiments. I 
have helped with performance of the animal work in mice, both in during immunization and during i.v 
challenge with the virus. I have also collaborated in the bleeding and organ collection of mice 
throughout the experiments. I participated in the discussions, the development of concepts exposed in 
the article.  
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STRUCTURAL STUDIES ON LASV GP1 ANTIGEN 
BACKGROUND AND MOTIVATION 
During the first years of my doctoral thesis I evaluated a novel vaccine platform based on polymersomes 
(PS) coupled with biosynthetic antigens for its potential to elicit a protective antibody response against 
Arenaviruses. For this purpose, a LASV immunogen derived from the receptor-binding domain of the 
viral envelope glycoprotein (GP) 1 was engineered. To achieve sufficient expression levels and to ensure 
proper folding, LASV GP1 was expressed as a C-terminal fusion with human IgG1 containing an 
enterokinase processing site, allowing cleavage of the protein. When expressed in human cells, the 
LASV GP1 immunogen showed an N-glycosylation pattern similar to authentic LASV GP1 present on 
the virus. Using a solid-phase binding assay previously developed to assess LASV-receptor binding [1], 
we observed binding to the LASV receptor DG. These features and the high purity of the protein 
obtained, in addition to the fact that it can be produced in high amounts in mammalian cells, made this 
antigen an interesting candidate to obtain structural information on LASV GP1 in its putative pre-fusion 
conformation that represents the primary target for nAb.  Structural data at atomic resolution for viral 
proteins is key for understanding their function at the molecular level and can facilitate novel avenues 
for combating viral infections. A detailed structure of an antigen or a complex of an antigen with specific 
antibodies could give insight not only into viral entry mechanisms, but as well provide information about 
antibody neutralization or protection, information which could provide a template for vaccine design. 
            The only known high-resolution structure of LASV GP1 up to beginning of 2017 was obtained 
from a truncated, underglycosylated variant produced in insect cells that crystallized under low pH (5.0) 
[2]. This form of LASV GP was unable to bind to dystroglycan but recognized the late endosomal 
resident protein LAMP-1 that represents an intracellular receptor for LASV.  
             During 2016, I spent three months as a visiting graduate student in Prof. Erica Ollmann 
Saphire’s laboratory, one of the world’s leading structural biologist working on emerging viruses and 
who has made crucial advances in the field of hemorrhagic fever viruses such Ebola virus and 
arenaviruses. An important goal in Prof. Saphires laboratory was the structural characterization of the 
LASV GP1 antigen via crystallization of LASV GP1 protein. Since crystallization of the heavy 
glycosylated viral antigen in its native conformation is sometimes challenging, the viral GP was 
complexed with Fab fragments isolated from human LASV survivors [3] that bind conformation-
dependent epitopes.  These can stabilize GP1’s conformation and therefore facilitate the formation of 
regular crystals that show sufficient X-ray diffraction patterns to obtain robust datasets and predict 
protein structure.  Among the experiments performed during this internship, the first was to further 
characterize the purified LASV GP1 antigen using Size Exclusion Chromatography with Multi-Angle 
Light Scattering Detection (SEC-MALS). Static Light Scattering (SLS) is an optical technique that 
measures the intensity of the scattered light in dependence of the scattering angle to obtain information 
?
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on the scattering source. A typical application is the determination of the average molecular weight of a 
macromolecule such as a polymer or a protein. Performing MALS experiments on LASV GP1 helped 
us to determine the protein fraction of the sample in comparison with the modifier, (the glycans) and 
gave us information about the polydispersity of both, the protein fraction and the modifier (Figure 1A). 
A panel of different LASV GP1 human mAb was isolated from patients surviving Lassa fever, 
including three neutralizing mAb against LASV GP1 [3]. A first screen to confirm binding of Fab 
fragments of some of these mAb to LASV GP1 protein was performed by direct ELISA (Figure 1 B). 
The six best binding Fab candidates were used to generate LASV GP1-Fab complexes, namely 10.4B, 
19.5E, 5.6H, 19.5A, 2.4F and 3.3B. After the Fabs were produced and purified, complexes with LASV 
GP1 protein were made (Figure 1C left panel) and SEC purified (Figure 1C right panel), followed by 
crystallization with different conditions suitable for the formation of protein crystals. The method used 
was always the vapor diffusion-sitting drop technique in 96 well plates (Figure 1 D). For the trays setup, 
an automated microseeding apparatus (Orwex) was used to seed exact drop ratios within a tray. All 
complexes were then tested with four commercial screening 96 well trays, including TOP 96, Index, 
PEG-ION and PEG II. Initial hits were followed up by optimization of the initial leading condition. In 
order to obtain bigger crystals of better diffracting quality, parameters like precipitant concentration, 
pH, complex concentration, drop ratio well/complex solution, PEG concentration and other conditions 
were tested.  
 
OPTIMIZATION PROCEDURE FOR LASV GP1-10.4B FAB COMPLEX CRYSTALS  
The most promising hit was obtained with the nAb 10.4B.  The leading condition (0.1 M sodium 
malonate, pH 6, 12% PEG 3350) was optimized by varying parameters as precipitant concentration, pH, 
drop protein: mother liquor solution ratio, PEG- or complex concentration (Figure 1 D). Crystals were 
also transferred to bigger drops in 24 well trays. First optimization consisted in a small variation of the 
salt concentration between 0.1 and 0.15 M sodium malonate, increasing the percentage of PEG 3350 
(10-14%), different pH (5, 6 and 7) and two different complex concentrations (5/10 mg/ml). First 
optimization revealed that the pH was a critical factor as crystals only grew at pH 7. High concentration 
of PEG 3350 resulted in too high nucleation which resulted in an undesired microcrystal shower. 
Crystals in 0.1 M sodium malonate grew also better. The drop ratio between the well condition and the 
protein solution is an important factor that could be determining. Hence, two different drop ratios were 
tested (0.15:0.15 and 0.22:0.22) which gave similar crystals. It is crucial that the selected conditions are 
both reproducible and allow crystal stability, preventing the crystal to melt over time. The next step for 
the optimization was to obtain bigger crystals by translating the conditions from 96 well plates to 24 
well plates using the hanging drop technique. Translation to bigger crystals could be a critical step to 
improve diffraction. However, some crystals resist to the translation and do not grow using a different 
?
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technique than the initial leading one. Fortunately, crystals translated well to bigger drops and bigger 
crystals were grown. Next, different concentrations of complex (5, 10 and 6.8 mg/ml) were tested. As 
expected, crystals grew faster with higher complex concentrations. In order to speed up the crystal 
growth, new drops were seeded with previously grown crystals. LASV GP1-10.4B Fab complexes seeds 
were collected from 0.1 M sodium malonate 12% PEG 3350 condition and diluted into 0.12 M sodium 
malonate 13.2% PEG 3350. After crystals were mechanically crushed, the solution was diluted 10-4 times 
and used as seeds for new crystals.  
Several initial hits were sent to the Stanford Synchrotron Radiation Laboratory (SSRL) for an 
initial X-ray diffraction analysis (Figure 1E left panel) while others leading hits were condition-
optimized to get better diffracting patterns. In order to avoid ice at the crystal surface and protect the 
crystal form changing temperatures, crystals were frozen in the leading solution with different 
concentrations of additives cryoprotectants as PEG 400, glycerol, ethylene-glycol and mineral oil since 
different cryoprotectant compounds could affect the quality of the crystal during the freezing process. 
Diffraction patterns obtained confirmed to be protein crystals and moreover we could confirm that the 
protein crystallized was the complex GP1-Fab and not only the Fab fraction since both proteins would 
have distinct unit cells volumes. However, the resolution obtained was only 10-15 Å. Indexing into the 
correct space group was therefore not possible at this point and further optimization will be needed 
(Figure 1 F). The next step towards the optimization would be an additive screening where single 
components are added to the leading optimized condition in order to improve in the quality of the crystal.  
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FIGURES 
 
Figure 1. Structural studies of LASV GP1 antigen. A) LASV GP1 antigen characterization. The 
elution profile of LASV GP1 was determined by SEC-MALS. The horizontal line corresponds to the 
calculated mass for LASV GP1, of 56.1 kDa. B) Purified LASV GP1 binds to different LASV GP1 
mAbs. Binding to different LASV GP1 mAb isolated from human LASV survivors was tested by 
ELISA. Microtiter plates were plated with 5 μg/ml of purified LASV GP1 followed by incubation with 
5 μg/ml of purified mAbs. Bound mAb were detected with a HRP-conjugated secondary antibody in a 
color reaction. Data are optical densities, means, n = 2. C) LASV GP1 antigen forms complexes with 
the Fab of nAb 10.4B that recognizes a conformational epitope [3]. In left panel, free stain blot to analyze 
LASV GP1-Fab complexes of different Ab Fab fragments. In the right panel, one LASV GP1-Fab 
complex is purified through SEC. D) Schematic of the vapor diffusion-sitting drop technique for protein 
crystallization. Image adapted from http://www.douglas.co.uk E) Example of crystals obtained during 
the process of optimization of crystallization conditions for the LASV GP1-10.4B Fab complex with 
different PEG 3350 concentrations. F) Crystals of LASV GP1-10.4B Fab complex analyzed by X-ray 
diffraction in the Stanford Synchrotron Radiation Laboratory (SSRL) (left panel). X-ray diffraction 
panel obtained from LASV GP1-10.4B Fab complex crystal. Cell dimensions: a, b, c (Å): 142.06 195.39 
234.71 α, β, γ (°): 90.093 90.091 90.686. Resolution (Å): ≈10. Outer green ring is ~6.5Å. (right panel). 
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ABSTRACT 
Viral entry represents the first step of every viral infection and is a determinant for the host-range and 
disease potential of a virus. Here we review the latest developments on cell entry of the highly 
pathogenic Old World arenavirus Lassa, providing novel insights into the complex host cell interaction 
of this important human pathogen. We will cover new discoveries on the molecular mechanisms of 
receptor recognition, endocytosis, and the use of late endosomal entry factors.     
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Lassa virus is a significant human pathogen 
Among the arenaviruses, Lassa virus (LASV) represents the most prevalent human pathogen with 
several hundred thousand infections per year [1]. Carried by persistent infection of the reservoir rodent 
host Mastomys natalensis, LASV is endemic in large parts of Western Africa. Arenaviruses are 
enveloped negative-strand RNA viruses with a non-lytic life cycle confined to the cytosol. The 
arenavirus genome is comprised of a small (S) RNA segment encoding the envelope glycoprotein 
precursor (GPC) and the nucleoprotein (NP), and an L segment coding for the matrix protein (Z) as well 
as the viral polymerase (L) [2]. The GPC is synthesized as a single polypeptide and undergoes 
processing yielding a stable signal peptide (SSP), the N-terminal GP1, and the transmembrane GP2. The 
GP1 binds to cellular receptors, whereas GP2 mediates viral fusion and structurally resembles class I 
viral fusion proteins.Upon receptor binding, LASV enters the host cell via receptor-mediated 
endocytosis with subsequent transport to late endosomal compartments, where fusion occurs at low pH 
[3, 4]. Arenavirus fusion has been covered by an excellent recent review [5] and will therefore not be 
detailed here. By an unknown mechanism of “uncoating”, the viral ribonucleoprotein is released into 
the cytosol where viral transcription and replication takes place. The assembly and release of arenavirus 
infectious progeny is orchestrated by the matrix protein Z, which recruit ESCRT proteins that are crucial 
for virion budding.  
Human LASV infection occurs mainly via reservoir-to-human transmission [6] that likely 
involves inhalation of contaminated aerosolized rodent excreta and ingestion of contaminated food [1]. 
Following early viral multiplication at the site of entry, the virus disseminates via the bloodstream 
reaching lymph nodes, spleen, and liver, where productive infection is established. A predictive factor 
for disease outcome is the viral load early in infection, indicating a close competition between viral 
spread and replication and the patient’s immune system [7]. The pathophysiology of the fatal shock 
syndrome is not well understood and may involve functional changes in vascular endothelial cells, liver, 
adrenal gland, and other organs [8]. Current treatment is limited to supportive care and the antiviral drug 
ribavirin that reduces mortality when given early in disease [9]. Due to its proven transmissibility via 
aerosol [10] and high lethality, LASV is considered a Category A agent by the Centers of Disease 
Control [11]. The lack of a licensed vaccine and limited treatment options make the development of 
novel therapeutic strategies against LASV an urgent need. Anti-viral drugs capable of reducing 
multiplication and spread of LASV may provide the patient’s immune system a window of opportunity 
to develop an anti-viral immune response. A major challenge for the development of drugs against 
LASV is however the limited structural information available on the pathogen. As all viruses, LASV 
critically depends on the molecular machinery of the host cell for its multiplication. Targeting viral entry 
appears further as a promising strategy for therapeutic intervention as it allows blocking the pathogen 
before it can take control over the host cell. The identification of cellular factors required for productive 
LASV entry and their evaluation as possible targets for therapeutic anti-viral intervention is therefore of 
great interest.  
? ? ?
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Lassa virus shows complex receptor use 
The first LASV receptor was identified as dystroglycan (DG), a ubiquitously expressed conserved 
cellular receptor for extracellular matrix (ECM) proteins [12]. In mammals, DG is found in most tissues, 
where it provides a molecular link between the ECM and the actin cytoskeleton. Apart from LASV, DG 
can serve as a receptor for most isolates of the prototypic arenavirus lymphocytic choriomeningitis virus 
(LCMV), the African arenaviruses Mopeia and Mobala, as well as Clade C New World arenaviruses 
[12, 13]. The DG core protein is initially synthesized as a single polypeptide chain that undergoes 
autoprocessing, yielding the peripheral α-DG interacting with ECM proteins and the transmembrane β-
DG. At the cytosolic face, β-DG associates with the cytoskeletal adaptor proteins dystrophin and 
utrophin, anchoring the DG complex to the actin cytoskeleton [14]. During biosynthesis, α-DG 
undergoes remarkably complex O-glycosylation that is essential for its biological function [15]. The 
functional glycosylation of α-DG starts with the biosynthesis of the unusual O-linked trisaccaride [O-
Man-β1-4-GlcNAc-β1-3GalNAc] that undergoes phosphorylation at the O-mannosyl residue [16]. A 
ribitol moiety links the trisaccaride to [Xyl-α1-GlcA-3-β1-3] co-polymers synthesized by the dual-
specific glycosyltransferase like-acetylglucosaminyltransferase (LARGE) [17, 18]. The LARGE-
derived [Xyl-α1-GlcA-3-β1-3] polysaccaride is called “matriglycan” and recognizes LG domains of 
ECM proteins via an unusual lectin-type binding [15, 19, 20]. Modification of DG by LARGE is also 
crucial for arenavirus binding [21, 22] and a recent elegant haploid screen revealed that LASV GP1 
strikingly mimics the mechanisms of receptor recognition of host-derived ECM proteins [23]. While the 
DG core protein is ubiquitously expressed in most mammalian cells, functional glycosylation by 
LARGE is under tight tissue-specific control [19]. Dystroglycan therefore appears as a “tunable” 
receptor [19], whose virus-binding affinity is influenced by the length of the LARGE-derived glycans 
[21]. Genome-wide association studies in human populations revealed positive selection for specific 
LARGE alleles in populations from Western African [6, 24, 25]. Although the exact role of the selected 
LARGE alleles in LASV susceptibility of carriers is not yet clear, the data suggest a role of DG’s post-
translational modifications in virus-host co-evolution.  
Binding of viruses to their receptor(s) frequently induces signaling that functions as a “knock 
on the door” to facilitate entry [26]. The cytosolic domain of β-DG can associate with signaling 
molecules, including the adaptor Grb2 [27], MAP kinases MEK and ERK [28], and focal adhesion 
kinase [29]. Engagement of cellular α-DG by LASV GP induced tyrosine phosphorylation of β-DG’s 
cytosolic domain, resulting in dissociation from the cytoskeletal adaptor utrophin, which may promote 
internalization of the virus-receptor complex [30]. Virus-receptor binding further affected signaling 
cross-talk of DG with α6β1 integrins, another widely expressed family of ECM receptors that can 
functionally cooperate with DG [31, 32]. However, since β1 integrins are dispensable for LASV entry, 
the role of this phenomenon for viral infection is currently unclear.   
More recently, the Tyro3/Axl/Mer (TAM) receptor tyrosine kinases Axl and Tyro3/Dtk, as well 
as the C-type lectins DC-specific ICAM-3-grabbing nonintegrin (DC-SIGN) and LSECtin have been 
? ? ?
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identified as novel candidate receptors for LASV and LCMV [33, 34]. Tyro3 and Axl are broadly 
expressed receptors for the phoshatidylserine (PS)-binding serum proteins Gas6 and protein S and are 
involved in removal of apoptotic cells [35, 36]. Over the past years, TAM kinases have been implicated 
in viral entry by “apoptotic mimicry”, which involves recognition of PS displayed in the viral lipid 
envelope by cellular PS receptors and is used by a broad range of enveloped viruses [37-42]. The co-
expression of DG with TAM receptors in tissues infected by LASV suggests complex receptor use. 
However, conflicting data have been reported on the roles of TAM receptors in Old World arenavirus 
infection. A role for Axl and Tyro3 in LASV entry was initially discovered by expression cloning using 
a LASV pseudotype platform [34]. Antibody perturbation experiments supported a contribution of Axl 
to LASV entry into cells lacking functional DG [34]. However, other studies found no enhancement of 
LASV or LCMV entry by over-expression of TAM kinases and the authors concluded that these PS 
receptors are unable to mediate productive infection [43]. Notably, mice deficient in Axl remained 
highly susceptible to LCMV infection in vivo [44]. More work will be needed to define the exact roles 
of TAM kinases in LASV entry into specific human target cells and their role in vivo.  
Based on their more restricted expression patterns, DC-SIGN and LSECtin may contribute to 
LASV entry into specific cell types, including dendritic cells (DC) that represent important early targets 
during infection [45]. In vitro studies on monocyte-derived human DC revealed that high mannose N-
glycans displayed on LASV GP1 could engage DC-SIGN during attachment [46]. However, DC-SIGN 
seemed dispensable for subsequent viral entry. This seems in stark contrast to arthropod-borne 
Phleboviruses and Dengue virus [40, 47] that use DC-SIGN as true entry receptor in DC. However, the 
candidate receptor expression pattern of monocyte-derived DC in vitro may differ from authentic DC 
populations in vivo putting limitation to this model.  
 
Dystroglycan-mediated LASV entry involves an unusual pathway of macropinocytosis 
Initial studies suggested that Old World arenaviruses enter via an unknown clathrin- and dynamin-
independent pathway [48-50]. More recent genome-wide RNA interference silencing screens identified 
sodium hydrogen exchangers (NHE) as host factors involved in the multiplication of LCMV [51]. Based 
on these findings, de la Torre and colleagues validated NHE as entry factors for LCMV and LASV and 
demonstrated for the first time a link between arenavirus entry and macropinocytosis [52]. Employing 
a panel of “diagnostic inhibitors” for macropinocytosis proposed by Mercer and Helenius [53, 54], 
LASV entry into human epithelial cells was investigated. In line with earlier studies, functionally 
glycosylated DG served as the main receptor for LASV in epithelia, whereas other candidate receptors 
were either absent or dispensable [55]. Consistent with previous studies [52], LASV entry was 
independent of dynamin, dependent on NHE, and required the dynamics of the actin cytoskeleton. The 
small GTPase Cdc42 and its downstream effectors PAK1 and N-Wasp were required for the regulation 
of LASV entry, whereas Rac1, RhoA, the Arp2/3 complex, myosin II, and myosin light chain kinase 
seemed dispensable in the cell types tested. The identification of PAK1 as a LASV entry factor was 
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further in line with a recent screen for anti-LASV drugs that identified the PAK1 inhibitor OSU-03012 
as a hit [56].  
Macropinocytosis is a major pathway of cell entry used by >20 different viruses and the 
pathogens seem to recruit specific sets of regulatory proteins according to their needs [54, 57]. In line 
with this, LASV entry requires a limited subset of the known regulators of “classical” macropinocytosis. 
In most cells, macropinocytosis is not constitutively active, but needs to be activated [53]. A series of 
classical studies on other viruses, including the poxvirus vaccinia (VACV), respiratory syncytial virus, 
influenza A virus, Echovirus 1 [58], and African swine fever virus revealed that the pathogens are able 
to activate the pathway [42, 58-61]. As a consequence, virus attachment to the plasma membrane induces 
membrane “blebbing”, triggers actin-depolymerization, and increases bulk fluid uptake. In contrast, 
LASV entry only minimally affected the host cell’s membrane- and actin-dynamics, [55], possibly due 
to distinct receptor use and/or differences in virion size. Several kinases implicated in macropinocytosis 
are required for LASV entry, including protein kinase C (PKC), phosphoinositol 3 kinase (PI3K), 
epithelial growth factor receptor (EGFR), and hepatocyte growth factor receptor (HGFR) [55, 56]. The 
data at hand suggest that DG can link LASV to a pathway related to macropinocytosis that causes only 
minimal perturbation of the host cell, which may be a required for its non-lytic life cycle and the ability 
to persist in its rodent reservoir.  
 
LAMP-1 is a late endosomal entry factor for LASV that facilitates viral fusion 
Similar to other early endosomal compartments, early macropinosomes undergo maturation [62]. Recent 
studies revealed that macropinosome maturation is crucial for productive VACV entry [63], but it is 
unknown to what extent this applies for LASV. Moreover, the fate of late macropinosomes is unclear 
and may involve fusion with classical late endosomes and lysosomes. Since LASV passes through late 
endosomes and depends on the endosomal sorting complex required for transport for entry [49], it will 
be of interest to see if and at which point incoming LASV “merges” into the classical late endosomal 
route. Using an unbiased haploid screening approach, Jae et al. identified the lysosome-associated 
membrane protein (LAMP) 1 as a late endosomal entry factor required by LASV [64]. Under the acidic 
conditions of the late endosome, the virus dissociated from its high affinity receptor DG and engaged 
LAMP1, which triggered efficient fusion. Recent structural analysis of LASV GP1 combined with 
functional studies provided insights into the mechanisms underlying this “receptor switch” (Fig. 1). X-
ray analysis revealed the existence of a stable low pH conformation of LASV GP1 displaying a triad of 
histidine residues that form a binding site for LAMP1 and is conserved among Old World arenaviruses 
[65]. Recent electron cryotomography studies on authentic LASV particles revealed conformational 
changes in GP1 to occur under pH 5, in line with the X-ray data [66]. Although LAMP1 is crucial for 
productive LASV entry [64], LAMP1 binding is not strictly required for fusion per se, evidenced by 
mutations within the histidine-triad that were still able to undergo fusion albeit at lower pH [67]. Elegant 
functional studies demonstrated that residue H230 within the histidine-triad on LASV GP1 undergoes 
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protonation around pH 5.5, when GP1 starts dissociating from DG (Fig. 1). A positive charge at residue 
H230 had an inhibitory effect on LASV GP fusion activity, preventing premature fusion. Engagement 
of GP1 protonated at H230 with LAMP1 may neutralize the positive charge via a countercharge 
provided by LAMP1, promoting fusion triggering [67] (Fig. 1). These studies reveal a remarkable role 
of the histidine-triad in orchestrating fusion activity of LASV GP with the timing and location of the 
receptor switch from DG to LAMP1. This scenario further suggests a division of labor between DG and 
LAMP1 in LASV entry. Functional DG appears to serve as a high affinity receptor that efficiently 
captures free virus at the cell surface via its matrigylcan polysaccharides that likely reach above the 
gylcocalyx, followed by rapid endocytosis. Whether DG requires assistance by other yet unknown co-
receptor(s) for virus internalization is currently unknown. Engagement of the late endosomal receptor 
LAMP1 likely guarantees optimal spatial conditions for fusion in proximity to the limiting membrane 
of the late endosome. The use of late endosomal entry factors by LASV has further interesting parallels 
to filoviruses and may reflect a more common strategy of late-penetrating viruses, as discussed in an 
excellent recent review [68].    
 
Perspectives and challenges 
Recent developments on LASV entry provided novel insights into the complex interaction of this 
pathogen with the host cell. At the same time new questions arose that need to be addressed. As pointed 
out above, several lines of evidence support the notion that DG’s function as a LASV receptor critically 
depends on post translational modification. However, the tissue tropism of the virus does not always 
correlate with the extent of DG’s functional glycosylation. This is illustrated by skeletal muscle that 
expresses DG with long matriglycan chains and high LASV binding affinity [19], but seems largely 
resistant to infection by LCMV [69] and LASV [70, 71]. Recent studies revealed that the resistance of 
differentiated myotubes against LCMV lies at the level of viral entry [72], suggesting that expression of 
functionally glycosylated DG per se is insufficient for productive infection. Considering the complex 
interaction pattern of DG with cellular proteins, cell-type specific DG complexes likely represent the 
“functional units” of virus entry. Pre-existing “steady-state” interactions of DG with specific cellular 
factors may thus influence DG’s ability to function as a viral receptor. Moreover, some data at hand 
suggest that virus binding to DG induces receptor signaling and affects the molecular composition of 
the complex. It is therefore conceivable that virus engagement of the receptor induces a dynamic pattern 
of protein-protein interactions involved in the entry process, as recently illustrated in a ground-breaking 
study on hepatitis C virus entry [73]. The advent of unbiased “shotgun” proteomics approaches, 
including sensitive label-free quantification, provides new and powerful techniques to address these 
questions [74].  
   Cell entry of LASV critically depends on cellular kinases [55, 56], indicating a role of signaling 
in LASV entry. The virus may actively induce cellular signaling to promote entry, as well as to “prime” 
the host cell to facilitate subsequent steps of infection. Since viruses are opportunistic and may “create” 
? ? ?
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their own pathways by re-shuffling cellular factors according to their needs, focusing on specific 
signaling pathways may face some limitations. Recently, quantitative phosphoproteomics was 
successfully used to dissect the complex signaling events following attachment of human 
immunodeficiency virus-1 [75], paving the way for similar studies on emerging viruses. Candidate 
signaling pathways involved in productive LASV entry could be integrated into a “LASV entry 
network” allowing the identification of promising drug targets. Since candidate signaling molecules may 
represent already known drug targets in other human disorders, clinically approved drugs or drug 
candidates in advanced stages of development may be “re-purposed” to combat this important human 
pathogen. 
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FIGURE 1 
 
Current model for receptor use, cell entry, and late endosomal “receptor switch” of LASV [64, 65, 
67]. At the cell surface, LASV GP1 engages the O-linked matriglycan polysaccarides displayed by α-
DG, followed by endocytosis via an unusual pathway related to macropinocytosis. Progressive 
acidification of late endosomes induces a structural change in LASV GP1, which dissociates from DG 
and adapts a low pH conformation displaying a histidine-triad. Protonation of residue H230 “locks” GP1 
? ? ?
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in the pre-fusion state, preventing premature fusion. Engagement of LAMP1 neutralizes the positive 
charge on H230 of GP1 and triggers efficient fusion with the limiting membrane of the late 
endosome/lysosome (for details, please see text  
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ABSTRACT  
The induction of protective T cell immunity is a major goal of many prophylactic and especially 
therapeutic vaccines.  We describe a nanoparticle (NP) vaccine for delivery of a synthetic peptide 
representing the MHCI-restricted epitope GP33-41 derived from lymphochoriomeningitis virus (LCMV) 
and show their superior efficacy in eliciting CD8 T cell responses following a prime-boost 
immunization. NP vaccination in combination with a Toll-like receptor 9 adjuvant promoted generation 
of a robust pool of memory CD8 T cells with an effector-like phenotype, characterized by high 
expression of killer cell lectin-like receptor G1 (KLRG1) and low expression of CD43, CD27, CD127, 
and CD62L.  These T effector memory (Tem) cells displayed protective and proliferative capability 
against a later LCMV challenge, in a comparable manner to T memory cells induced by a dendritic cell-
based vaccination with T central memory traits.  Moreover, we show the importance of antigen retention 
promoted by the NP carrier in shaping the differentiation of CD8 T cells. These studies demonstrate that 
the peptide conjugate NP vaccine can be exploited for inducing robust and long-lasting CD8 T memory 
cells, emphasizing the importance of the antigen carrier for tuning the quality and the magnitude of the 
immune response.  
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INTRODUCTION 
In recent years, there has been an increasing interest in the use of synthetic vaccines able to induce 
protective cellular immunity1–3. Particularly, nanoparticles have proved to be promising delivery 
platforms for low molecular weight subunit components, such as peptides, as these carriers are able to 
amplify the immunogenicity of such small compounds, thus augmenting antigen (Ag)-specific cellular 
immune responses4–8. Along those lines, our laboratory has developed a platform based on ultra-small 
synthetic nanoparticles, 25-40 nm in size, composed of propylene sulfide (PPS) cores surrounded by a 
polyethylene glycol (PEG) corona (herein referred to as NP)9,10. We have previously demonstrated that 
conjugating Ag through a disulfide bond to the PEG corona of the NP can promote induction of high 
numbers of polyfunctional and cytotoxic CD8 T cells. Mechanistically, our NP design allows for 
endosomal escape of the Ag into the cytoplasm, enhancing cross-presentation7,8,11–13 . 
The development of efficacious recombinant vaccines requires generation of long-lasting memory 
responses14,15. The CD8 T cell memory compartment is heterogeneous, composed of cell populations 
that differ in their trafficking properties and functionality15. Currently, there is growing interest in the T 
effector memory (Tem) subset, as this subpopulation shows enhanced ability to circulate compared to T 
central memory (Tcm) cells, which reside in lymphoid organs, thus demonstrating enhanced protection 
against systemic infections16–20. Moreover, there is evidence that differentiation of CD8 T cells into Tem 
cells occurs during protracted or chronic viral infections that involve persistent levels of antigen in 
lymphoid organs, maintaining T cells in a effector differentiation state21–23. Indeed, during chronic viral 
infections with the immunosuppressive lymphocytic choriomeningitis virus (LCMV) isolate clone-13 
or cytomegalovirus, the levels of antigen stimulation are strongly correlated with the frequency of cells 
that display high expression of killer cell lectin-like receptor G1 (KLRG1) and low expression of 
CD62L, characteristics of the Tem subset24,25. Similarly, Tem biased differentiation has been reported 
following vaccination with viral vectors and synthetic carriers that promote antigen retention at the sites 
of immunization16–20,26,27. Since particulate carriers are suggested to enhance cellular immunity by 
augmenting antigen retention in lymphoid organs28–30, we set out to evaluate the impact of NP antigen 
delivery on the differentiation state of memory CD8 T cells, including surface-receptor expression, 
effector function and anatomical localization. 
To this end, we conjugated the well-characterized MHCI H-2Db-restricted GP33-41 epitope derived from 
the envelope glycoprotein (GP) of LCMV to our NP. Infection of LCMV in the mouse represents one 
of the most powerful experimental models to study anti-viral T cell immunobiology and has provided 
insight and fundamental concepts applicable to other viruses and pathogens31,32. We employed as 
adjuvant a well-studied TLR9 ligand, CpG-B, which has been shown to augment protective CD8 T cell 
immunity to subunit vaccinations12,33,34. 
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To benchmark the NP formulation, we included a well-established peptide vaccine that uses dendritic 
cells (DC) as a vehicle35–37, to qualitatively compare T cell memory differentiation upon the two regimes 
of immunization. In contrast to soluble peptides, our NP platform significantly enhanced the magnitude 
of CD8 T cell responses. Delivery of the LCMV GP33-41 epitope by NP increased Ag persistence in 
lymphoid organs and promoted the survival of a robust population of CD8 memory T cells. These cells 
adopted an effector-like phenotype, characterized by the expression of KLRG-1, and lack of CD62L, 
CD43 and CD27. When compared on a per-cell basis with memory T cells induced by a well-established 
DC vaccination, which display central memory-like characteristics, we show that both types of cells 
have similar abilities to respond to a viral challenge, and prevent the establishment of viral persistence. 
Our data further demonstrates that promotion of antigen retention is crucial for the establishment of 
effector memory cells, and suggests that ultra-small PPS-PEG-based NP are a promising platform for 
establishing proliferative and protective effector memory responses similar to those observed with 
vaccination strategies promoting T central memory differentiation.  
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RESULTS 
Nanoparticles enhance cytotoxic and polyfunctional responses to the GP33 epitope compared to 
the soluble form 
First, we sought to determine the extent to which the NP carrier enhances cellular responses to the 
soluble GP33-41, the MHC class I H-2D
b-restricted GP33-41 epitope derived from the envelope glycoprotein 
(GP) of LCMV. For this purpose, groups of age- and sex-matched C57BL/6 mice were immunized with 
a prime-boost immunization regime (Fig. S1a) previously employed in our group, which has shown to 
be efficient in potentiating CD8 T cell immunity8,12,34. The GP33  peptide (2 ? g) was given either in 
soluble form or conjugated onto NP (NP-GP33) via a disulfide link, which is labeled in the endosome. 
For both formulations, we used 10 ? g of the TLR9 ligand CpG-B, which has proven to enhance cellular 
immunity in combination with our platform8,11,34. Five days after the booster immunization given at day 
14, we evaluated the Ag-specific CD8 T cell response by ex vivo re-stimulation with 1 μM of GP33  
peptide.   
In skin-draining lymph nodes (dLNs), the NP-GP33 immunization induced at least 2-fold higher 
percentages of IFN-a expressing Ag-specific CD8 T cells and IFN-a /TNF?? bi-functional CD8 T cells 
(6.5±0.4 and 1.4±0.1) compared to the soluble peptide (1.9±0.6 and 0.7±0.2). Frequencies of cells 
simultaneously secreting IFN-a TNF?? and IL-2 remained low following both immunization regimens 
(Fig.S1b,c). In the spleen, the NP-GP33 immunization likewise induced significantly higher frequencies 
of Ag-specific CD8 T cells producing either IFN-a or IFN-a/TNF? (Fig.S1b,c) Moreover, we noticed 
an increase in the frequency of degranulating CD8 T cells, characterized by the expression of CD107a, 
a surrogate marker of cytotoxic activity (Fig.S1b,d). Together, this data confirmed that the NP platform 
substantially augments the frequencies of cytotoxic T cells to the peptide Ag. 
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Figure S1. Intradermal immunization with NP-GP33 conjugates enhances polyfunctional and 
cytotoxic CD8 T cells responses to the GP33 epitope 
a)  Mice were immunized twice two weeks apart with NP-GP33 or GP33 intradermally (i.d.) together with 
10 μg CpG-B. Draining lymph nodes and spleen were collected five days after a prime boost 
immunization for analysis by flow cytometry. b) Representative flow cytometry plots of cytokine-
secreting CD8 T cells (left) and degranulating CD8 T cells (right) in lymph nodes at day 19, after ex 
vivo restimulation with GP33 peptide. Cytokine expression was assessed by intracellular staining c) 
Frequency of endogenous cytokine-secreting CD8 T cells in lymph node and spleen d) Frequency of 
endogenous cytotoxic CD8 T cells in spleen.  Data are representative of three independent experiments 
with at least n=4 per group. *: p< 0.05; **p<0.01. Mann-Whitney U test.  
 
Nanoparticles promote Ag persistence in secondary lymphoid organs  
Ag persistence has important implications for T cell memory differentiation18,38–40;  hence, we next 
investigated the ability of NPs to promote Ag retention in lymphoid organs. We performed a side-by-
side comparison with a vaccination based on DCs as Ag carriers, for the reason that, similar to the NP 
formulation, the DC vaccine can be administered i.d., together with a selected adjuvant35–37. The dose of 
antigen used for pulsing DCs and DC numbers were selected based on the ability to promote a similar 
expansion of P14 cells in spleen upon a single immunization compared to an immunization with NP-
GP33 (2 ? g) (Fig.S2). The unformulated Ag was used as a negative control as relatively low retention in 
dLNs was expected at the time points studied.  
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Figure S2. Frequency of P14 cells in lymph nodes and spleen after a prime or a prime boost 
immunization with NP-GP33 or DC-GP33 
Naïve CD45.1 P14 CD8 T cells (5x104) were adoptively transferred into host mice and the following 
day, mice were immunized with NP-GP33 (2μg) or DC-GP33 (2x10
6 cells), together with 10 μg of CpG-
B. At day 5, 19 or 90 after immunization, lymphocytes retrieved from draining lymph nodes (dLNs) and 
spleen were collected and analyzed for the frequency of CD45.1 P14 in total CD8 T cells. Data are 
representative of two independent experiments for days 4 and 19, and three independent experiments 
for day 90, with at least n=3 per group 
 
Mice were immunized once with NP-GP33, DC-loaded with GP33 (DC-GP33) or soluble GP33, in each 
case combined with CpG-B. One or three weeks after vaccination, we adoptively transferred CFSE-
labeled Ag-specific CD45.1 P14 CD8 T cells derived from mice transgenic for the LCMV T cell receptor 
(TCR), which recognizes the GP33 epitope in the context of H-2D
b. Three days after, P14 CD8 T cells 
were retrieved from dLNs, and the dilution of the CFSE dye was assessed as a means to detect stored 
Ag in dLNs (Fig.1a). We consistently found higher frequencies of P14 CD8 T cells upon NP-GP33 
immunization at both time points of analysis (Fig.1b), with corresponding levels of cell proliferation. 
The percentage of dividing cells was significantly enhanced in mice that had received NP-GP33 over the 
DC-GP33 and GP33 peptide-only groups (Fig.1c), suggesting that the Ag was retained for longer periods 
of time  (> 3 weeks) when delivered via NP.  
Next, we wanted to determine the cells within the dLN within which Ag is retained upon immunization. 
We administered fluorescently labeled GP33 loaded on NP or delivered via DC. To normalize for the 
amount of Ag, the level of fluorescence of peptide was matched before vaccination between both groups. 
Ten days after i.d. immunization, animals of the NP-GP33 group displayed a higher percentage of Ag
+ 
cells when compared to mice immunized with DC-GP33 (Fig.1d). The frequency of CD45
hi 
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hematopoietic cells within the Ag+ fraction was comparable in both groups. The Ag was mainly 
distributed within major lymphocyte populations (T cells, B cells), and to a lesser extent in LN resident 
DCs, monocytes, or macrophages (Fig.1e-f).  
Interestingly, there were striking differences in Ag retention within the stromal cell (CD45low) 
compartment, where the NP vaccination displayed a considerably higher frequency of Ag+ cells (Fig.1e). 
To define the CD45low subpopulations that were associated with GP33, we employed a gating strategy 
based on PECAM-1 (CD31) and podoplanin (gp38) staining, as described previously41, allowing us to 
differentiate fibroblastic reticular cells (FRCs, CD31lowgp38hi), lymphatic endothelial cells (LECs, 
CD31higp38hi), blood endothelial cells (BECs, CD31hi gp38low), and double negative cells (DN, 
CD31lowgp38low). Analysis of these populations revealed that NP-GP33 was specifically retained within 
LECs, in agreement with previous reports using protein Ag42,43.Conversely, Ag was not detected in any 
of the stromal subsets when delivered via DCs (Fig.1g). These data indicate that Ag delivered by NP 
localizes to both hematopoietic and non-hematopoietic cells in regional dLNs.  
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Figure 1. Nanoparticles promote enhanced antigen retention in draining lymph nodes compared 
to dendritic cell vaccination 
a) Naïve C57BL6 mice were immunized with NP-GP33 (2 μg) or DC-GP33 (2x10
6 cells), together with 
10 μg of CpG-B.  At day 7 or day 21 post immunization, mice received 1x106 CD45.1 P14 CD8 T cells 
that were CFSE labeled. Three days after the transfer, splenocytes were isolated and proliferation of P14 
cells was assessed by CFSE dilution. b) Percent of P14 cells in lymph nodes 3 days after i.v. transfer. c) 
Left, representative histograms; Right, percent of dividing P14 cells, calculated as the frequency of CD8 
T cells that dilute CFSE compared to the initial population (the non-divided P14 cells). (d-g) Naïve mice 
were immunized with 2 μg of fluorescently labeled GP33 as either soluble, or delivered in NPs or DCs, 
together with 10 μg of CpG-B. At day 10, lymph nodes cells were retrieved and analyzed by flow 
cytometry. (d) Percent of GP33 positive cells in total lymph node cells. e) Percent of CD45
hi and CD45low 
populations within the GP33
+ cells. f) Percent of hematopoietic populations within GP33
+ cells. g) Left, 
gating strategy based on the expression of gp38 (podoplanin) and CD31 (PECAM-1) for the 
identification of stromal cell subsets. Fibroblastic reticular cells (FRCs), CD31lowgp38hi; lymphatic 
endothelial cells (LECs), CD31higp38hi; blood endothelial cells (BECs), CD31hi gp38low); and double 
negative cells (DNs), CD31lowgp38low. Right, antigen positive cells within stromal cell subsets.   Data is 
representative of two independent experiments with at least n=3 per group*: p< 0.05; **p<0.01. b-c) 
One way ANOVA, d-f) Mann-Whitney U test. 
 
NP-GP33 vaccination promotes effector T cells with a different phenotype but comparable cytolytic 
ability relative to DC-GP33 
Because antigen retention kinetics due to NP vaccination was distinct from DC vaccination, we 
hypothesized this would generate phenotypically and functionally distinct antigen-specific CD8 T cells. 
Thus, we wanted to investigate how memory CD8 T cells differ between the two immunization regimens 
with respect to functionality, surface phenotype and trafficking properties. For this purpose, we 
adoptively transferred 5x104 congenically marked P14 CD8 T cells into naïve C57BL6 mice. The 
following day, animals were immunized i.d. with 2 ? g of Ag administered as NP -GP33 or DC-GP33. All 
formulations were combined with 10 ? g of CpG-B (Fig.2a).   
Initially, we sought to evaluate P14 CD8 T cells in dLNs during the effector phase after a prime or a 
prime-boost immunization. Surface expression phenotype of effector cells at both times of analysis (day 
4 and 19) indicated differences in activation upon NP or DC vaccination (Fig.2b). There were consistent 
differences in the expression of IL-7R, with the DC-vaccinated group maintaining a higher percentage 
of IL-7Rhi cells (83% and 55% at days 4 and 19) compared to the NP counterpart (32% and 21% at days 
4 and 19), in line with previous observations of accelerated central memory differentiation when 
employing DCs as Ag carriers35,44. Intriguingly, we also found that P14 CD8 T cell from mice vaccinated 
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with NP, but not the DC vaccine, expressed the inhibitory receptor programmed cell death protein (PD)-
1. Instead, L-selectin (CD62L) expression was downregulated and CD44 and KLRG1 were upregulated 
in the majority of the P14 CD8 T cells, regardless of the immunization. In particular, KLRG1 expression 
was considerably higher in both groups after the boost (Fig.2c). This was in agreement with previous 
reports that demonstrated that multiple immunizations augment the expression of effector-like markers 
in responsive CD8 T cells19,45,46 (Fig.2b).  
To determine whether cytokine production and degranulation capability varied between both 
immunizations, we re-stimulated LN cells ex vivo for 5 h with 1 ?M of GP33. There was a considerable 
high expression of CD107a and IFN-a in both groups, whereas the levels of TNF? and Granzyme B 
(GzmB) were lower after NP vaccination. (Fig.2d-f). Nevertheless, effector cells in both groups 
displayed similar cytotoxic activity, as assessed by the ability of primed CD8 T cells to kill splenocytes 
that were previously pulsed with the GP33 peptide in an in vivo killing assay (Fig.2g). The data suggested 
that, despite phenotypical differences, both immunizations drove functional effector CD8 T cells.  
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Figure 2. NP-GP33 and DC-GP33 vaccination promote effector cell subsets that differ in surface 
expression and cytokine secretion, but exhibit comparable killing activity 
a) Naïve CD45.1 P14 CD8 T cells (5x104) were adoptively transferred into host mice. The following 
day, mice were immunized with NP-GP33 (2 μg) or DC-GP33 (2x10
6 cells), together with 10 μg of CpG-
B. At day 4 or 19 after immunization, lymphocytes retrieved from draining lymph nodes (dLNs) were 
collected and analyzed. b) Expression of various surface markers in P14 cells in dLNs after a prime or 
a prime boost immunization with DC-GP33 or NP-GP33. c) Percent of KLRG1
hi P14 cells after a prime-
boost immunization in DC-GP33 and NP-GP33 immunized mice. d) Percent of IFN-a IFN-a/TNFα
+, and 
e) GzmB secreting P14 cells in dLNs, following ex vivo restimulation with GP33. f) Percent of 
CD107a+IFN-a cells following ex vivo restimulation with GP33. g) In vivo cytotoxic assay; GP33-pulsed 
(CFSEhigh) and untreated/unpulsed (CFSElow) splenocytes were transferred intravenously (i.v.) into mice 
previously vaccinated with DC-GP33 and NP-GP33, as described above. As a control, mice were 
vaccinated with soluble 2μg of GP33 or were untreated. After 6 h, the frequency of CFSE
low and CFSEhigh 
cells were assessed by flow cytometry, and the percent of in vivo killing calculated. Data is 
representative of two independent experiments with at least n=3 per group. *: p< 0.05; **p<0.01.  
Mann-Whitney U test.  
 
NP-GP33 vaccination induces long-lasting memory CD8 T cells with an effector memory phenotype  
In order to assess the evolution in surface phenotype of P14 CD8 T cells, we performed a longitudinal 
analysis in blood, examining the expression of CD62L and IL-7R. Based on these two markers, three 
major sub-populations of memory CD8 T cells can be distinguished: T central memory (Tcm, IL-7Rhi 
CD62Lhi), T effector memory (Tem, IL-7Rhi CD62Llow), and T effectors (Teff, IL-7Rlow CD62Llow)47,48. 
The latter sub-population has been proposed to represent recently activated CD8 T cells and has been 
consistently observed upon long-term Ag retention18,47. At day five after prime or a prime-boost 
immunization, circulating memory cells in both groups reflected closely the pattern of expression of 
IL7-R observed in dLNs (Fig.3a). Meanwhile, at later times (day 90) the majority of NP-GP33 -induced 
P14 CD8 T cells consisted of Tem (43±2), followed by Teff (32±2) and Tcm (21±1). The maintenance 
of the Teff subset further supports that Ag persisted for long periods of time upon NP vaccination. On 
the contrary, DC vaccination favored generation of P14 memory cells with Tcm characteristics (61±4), 
while the Tem and Teff subsets were less prevalent (26±3, 3±1) (Fig.3a).  
The striking differences in CD8 T cell phenotype between the two vaccine regimens on day 90 prompted 
us to investigate whether the phenotype of memory P14 CD8 T cells in other organs (liver, spleen, LN, 
lung) resemble those observed in blood. In LNs the majority of GP33-specific CD8 T cells displayed a 
CD62Lhi Tcm phenotype. In contrast, in spleen and peripheral organs such as liver and lung, the memory 
compartment reflected the phenotype of circulating Ag-specific CD8 T, as similar frequencies of Tcm, 
Tem and Teff cells were observed when compared to blood (Fig.3b). We also evaluated memory cells 
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based on a prototypic gating strategy involving KLRG1 and IL-7R21 as well as CD27 and CD4349. 
Employing these gating schemes further illustrated that NP promoted predominantly Tem cells, based 
on the prevalence of KLRG1hi IL-7R and CD43low CD27low populations (Fig.S3a-b).  
We turned to our previous analysis based on CD62L and IL-7R and assessed how markers such as 
KLRG-1, CD43 and CD27 were expressed within the three subsets of memory cells (Tcm, Tem, Teff).  
As expected, the presence of KLRG1 was almost exclusively found in Tem and Teff populations, but 
not in the Tcm subset. On the contrary, CD43 and CD27 varied to some degree within the individual 
populations, with CD43hi and CD27hi being detected exclusively in the Tcm subset, while Teff cells 
displayed low levels of both markers. In comparison, the Tem exhibited heterogeneous expression of 
CD43, and intermediate-to-low expression levels of CD27 (Fig.3c). In summary, P14 cells from NP-
vaccinated mice were prevalently KLRG1hi and CD43lowCD27low, which is consistent with a Tem 
phenotype based on multiple definitions of the phenotype. 
Notably, the PD-1 expression observed in Ag-specific CD8 T cells earlier during the effector phase in 
NP vaccinated mice was also observed at the memory stage (Fig.3d). This suggests that upregulation of 
PD-1 in our system does not represent a transient phenomenon, but may be an “imprinted” characteristic 
of CD8 T cells upon activation in the NP vaccination paradigm.  
Successively, we were interested in the effector functions of memory CD8 T cells in LNs and spleen 
and how it may differ from our earlier observations in the early effector phase. As seen previously, the 
memory CD8 T cells in the NP-vaccinated animals displayed a comparable capacity to express IFN-
a and CD107a than with those cells in DC-immunized mice, although TNF? levels were lower, as 
observed earlier (Fig.3f-g). The frequency of GzmB cells in spleen was also similar between the two 
groups, with a tendency to be higher in the LNs of NP-GP33 treated mice (Fig.3g).  
Finally, we evaluated the cellular homing characteristics of these memory CD8 T cells. Previous studies 
have shown that Tcm cells preferentially reside in the spleen parenchyma, while Tem cell are located 
mainly in the red pulp50. To differentiate between cells located in the splenic red pulp and white pulp, 
we employed an intravascular staining strategy51, consisting of an intravenous injection of an anti-CD8 
antibody (Ab). This technique discriminates between the red and white pulp based on the staining level 
by the injected Ab. Congruent with the other functional analyses, we observed that NP-derived memory 
CD8 T cells with a Tem phenotype were predominantly located in the red pulp. Instead, DC-primed 
CD8 T cells were enriched in the spleen white pulp, as seen by the lack of staining with the injected Ab 
(Fig.3h). Altogether, these data suggest that the NP vaccination preferentially promotes the 
differentiation of CD8 into T cell with characteristics of T effector memory cells. 
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Figure 3. NP-GP33 induce the differentiation of antigen specific T cells into T effector memory 
Naïve CD45.1 P14 CD8 T cells (5x104) were adoptively transferred into host mice and the following 
day immunized with NP-GP33 (2 μg) or DC-GP33 (2x10
6 cells), together with 10 μg of CpG-B. At day 
90, lymphocytes from lymphoid and peripheral organs were retrieved and analyzed. a) Phenotype of 
P14 cells in peripheral blood, based on the expression of CD62L and IL-7R expression. b) Percent of T 
central memory (Tcm, CD62Lhi IL-7Rhi), T effector memory (Tem, CD62Llow IL-7Rhi) and T effector 
(Teff, CD62Llow IL-7Rlow) within CD45.1 P14 cells at day 90 in spleen. c) Surface expression of CD43, 
CD27, KLRG-1 within the Tcm, Tem and Teff memory subsets in the DC-GP33 and NP-GP33 vaccinated 
mice. d) Mean Fluorescence Intensity (MFI) of PD-1 in P14 cells.   e) Percent of IFN-a, IFN-a/TNFα+, 
and f) GzmB secreting P14 cells in spleen at day 90, following ex vivo restimulation with GP33.  g) 
Percent of CD107a+IFN-a cells following ex vivo restimulation with GP33. h) Discrimination of memory 
P14 cells within the red pulp or white pulp by intravital staining with the injection of anti-CD8a i.v. 
Right, pie charts displaying the distribution of memory P14 cells within the spleen after immunization 
with DC-GP33 or NP-GP33. Data is representative of three independent experiments with n=3-4 per 
group, *: p< 0.05; **p<0.01. Mann-Whitney U test. 
 
 
 
Figure S3. Memory differentiation of antigen specific P14 cell upon vaccination with NP-GP33 and 
DC-GP33 
Naïve CD45.1 P14 CD8 T cells (5x104) were adoptively transferred into host mice and the following 
day immunized with NP-GP33 (2μg) or DC-GP33 (2x10
6 cells), together with 10 μg of CpG-B. At day 
90, lymphocytes from lymphoid and peripheral organs were retrieved and analyzed.  Phenotype of P14 
cells in spleen was analyzed based on the expression of a) KLRG1 and IL-7R, or b) based on the 
expression of CD27 and CD43.  Graph bars represent the percent from CD45.1 P14 cells. Data are 
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representative of three independent experiments with at least n=4 per group*: p<0.05; **p<0.01, ***: 
p<0.001.  2way ANOVA with Bonferroni post-test. 
 
Memory cells induced by NP vaccination respond as robustly to viral and bacterial challenges as 
those induced by DC vaccination 
Next, we evaluated the ability of memory CD8 T cells induced by NP-GP33 or DC-GP33 vaccination to 
respond to pathogen challenge. To evaluate protection from viral challenge, we employed the stringent 
LCMV ARM53-variant clone-13 (Cl-13) infection model, which causes persistent infection associated 
with generalized T cell exhaustion and immune suppression52-55. Briefly, three months post vaccination 
we sorted and adoptively transferred 5x104 CD45.1 memory CD8 T cells into age-matched CD45.2 naïve 
hosts. The following day, mice were challenged i.v. with 2x106 PFU LCMV Cl-13. After 14 days, we 
assessed the numbers of CD45.1 cells present in the spleen and the viral load in kidneys (Fig4.a). 
Analysis of cell numbers in spleen showed similar frequencies of GP33-specific CD45.1 cells in both 
groups, indicating that transferred memory T cells deriving from both vaccination schemes proliferated 
extensively upon viral challenge (Fig.4b). Consequently, we measured the viral titers in the kidneys of 
infected mice.  We found that both groups were able to significantly reduce the virus titers in this organ, 
compared to the infection control group, which did not receive any cell transfer. Remarkably, there was 
no difference in virus titers between the two groups, suggesting that cells induced by NP-GP33 or DC-
GP33 vaccination controlled the infection with LCMV Cl-13 to a similar extent (Fig.4c).   
Similar results were observed using a bacterial challenge model involving Listeria monocytogenes 
expressing ovalbumin (OVA; Lm-OVA) in mice vaccinated with OVA257-264 (SIINFEKL), a MHC class 
I H-2Kb-restricted peptide delivered on the two platforms: NP-SIINFEKL and DC-SIINFEKL (Fig.S4).   
Cytokine secretion analysis in the CD45.1 CD8 T cell subset upon LCMV Cl-13 infection demonstrated 
a polyfunctional phenotype present to a comparable degree in both vaccine schemes (Fig.4d). 
Interestingly, when we analyzed the expression of PD-1 at day 14 after challenge, we observed that the 
levels of this marker on the surface of memory CD8 T cells at day 14 after challenge resembled those 
observed before the infection. This was in contrast to the typical high levels of PD-1 seen in the 
endogenous CD8 T cells, a hallmark of functional exhaustion after challenge with Cl-13.  This suggests 
that the transferred cells maintained their PD-1 pattern acquired at earlier times (Fig.4e). Collectively, 
the data demonstrate that memory CD8 T cells derived from NP and DC vaccination, despite their 
surface marker and homing differences, were able to respond actively to a pathogenic Ag challenge. 
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Figure 4.  CD8 T memory cells generated following NP-GP33 and DC-GP33 vaccination display 
similar protective capacity when challenged with LCMV Cl-13 
a) 5x104 memory CD45.1 P14 CD8 T cells sorted from splenocytes of DC-GP33 or NP-GP33 vaccinated 
mice were transferred into age-matched, CD45.2+ naïve hosts. One day after, mice were challenged i.v. 
with 2x106 PFU. of LCMV Cl-13.  b) Two weeks post infection (p.i.), whole spleens were analyzed and 
assessed for the number of CD45.1 P14 cells. c) Viral titers in kidney were assessed by qPCR. d) 
Cytokine secretion (IFN-a, IFN-a/TNFα, left and GzmB, right) by P14 cells at day 14 p.i. was assessed 
by intracellular staining, after ex vivo restimulation with GP33. e) Left, representative histograms; right, 
Mean Fluorescence Intensity (MFI) of PD-1 in transferred P14 cells and endogenous CD8 T cells at day 
14 p.i.  Data are representative of two independent experiments with n=4 per group. *: p< 0.05; 
**p<0.01. Mann-Whitney U test.  
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Figure S4. Tem and Tcm cells induced by NP and DC vaccination promote protection to a 
bacterial challenge 
a) Naïve CD45.1 OTI CD8 T cells (5x104) were adoptively transferred into host mice and the following 
day immunized with NP-SIINFEKL (2 μg) or DC-SIINFEKL(2x106 cells), together with 10 μg of CpG-
B. At day 90, 1x104 CD45.1 OTI cells were sorted from spleens and adoptively transferred into naïve 
C57BL6 mice.  One day later, mice were challenged i.v. with 1x105 CFU of Listeria-monocytogenes 
expressing Ovalbumin (LM-OVA). b) Determination of protection by quantification of CFU in spleens 
of infected mice three days post infection. Data are representative of a single experiment with n=7-8 per 
group. **p<0.01. Mann-Whitney U test. 
Differentiation into Tem is not affected by antigen dose or TLR identity 
The notable differences in the effector phenotypes between our vaccination paradigms prompted us to 
evaluate factors that might instruct CD8 T cells towards a certain phenotype. Specifically, we focused 
on antigen load37,56–58, adjuvant selection36,59,60, and the presence of CD4 T cell help during T cell 
activation48,61–64.   
Antigen does direct the differentiation of CD8 T cells, and thus competition for the antigen by the 
responding cells may play an important role. To test how early antigen availability impacted T cell 
memory differentiation upon DC and NP vaccination, we immunized naïve mice previously adoptively 
transferred with CD45.1 P14 cells with a high and a low dose of peptide (0.5 ? g and 5 ? g) conjugated 
onto NP. For the DC vaccine we varied the concentration of peptide delivered to them in vitro or the 
number of DCs used for immunization, keeping the amount of pulsing peptide constant (Fig.5a). We 
then evaluated the phenotype of the CD8 T cell memory pool generated under these conditions in the 
spleen. Interestingly, none of the doses tested appeared to have a significant effect on the phenotype, as 
similar frequencies of Tcm, Tem and Teff where obtained under the doses tested (Fig.5b).  
Further, we assessed whether the main Tem differentiation upon NP vaccination was restricted to the 
use of the TLR9 ligand, CpG-B, as adjuvant, or whether this phenotype was observed when employing 
other TLR agonists (Fig.5c). We vaccinated mice as detailed above, but instead of CpG-B we used either 
10 ? g of the TLR4 adjuvant MPLA or 20 ? g of the TLR3 ligand Poly I:C. However, P14 CD8 memory 
T cells consistently displayed a T effector memory phenotype, irrespective of the adjuvant administered.  
It has also been proposed that lack of CD4 T cell help can lead to the generation of memory CD8 T cells 
with effector-like phenotype, similar to what we observed in the NP vaccination61,65. Therefore, we 
evaluated whether vaccination with a full protein (containing MHCII epitopes) could modulate the Tem 
phenotype observed upon NP-MHCI vaccination. We analyzed at day 90 memory CD8 T cells from 
mice that received an adoptive transfer of naïve OTI CD8 T cells (5x104), which were vaccinated with 
SIINFEKL or the protein OVA, loaded onto NPs (NP-SIINFEKL or NP-OVA). Mice immunized with 
NP-SIINFEKL displayed equivalent percentage distributions of Tcm, Tem and Teff to those seen in NP-
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GP33. Meanwhile, mice that received OVA displayed enhanced numbers of the Tcm population, 
although Tem cells were still the predominant population at the time of the analysis. Similarly, Teff cells 
were reduced in the NP-OVA group, but were maintained at considerable frequencies in the memory 
phase (Fig.5d). These data indicate that CD4 T cell help certainly has an effect on the differentiation of 
CD8 T cells, as observed in earlier studies 48,61,62. However, the predominant presence of Tem cells 
during NP-OVA vaccination suggests that the unhelped memory differentiation is not the main cause of 
the observed phenotype in NP educated memory T cells.  
 
 
Figure 5. Differentiation into Tem is not affected by antigen dose or TLR identity. Mice that were 
adoptively transferred with 5x104 naïve CD45.1 P14 CD8 T cells were immunized with NP-GP33 or DC-
GP33, together with 10 μg of CpG-B, 20 μg of Poly I:C or 10 μg of MPLA. At day 90, lymphocytes 
retrieved from spleen were isolated for analysis by flow cytometry. a) Mice were vaccinated with 
varying doses of peptide loaded on NPs, with DCs loaded with varying doses of peptide, or varying 
numbers of DCs. b-c) The phenotype of P14 cells was determined based on the expression of CD62L 
and IL-7R as T central memory (Tcm, CD62Lhi IL-7Rhi), T effector memory (Tem, CD62Llow IL-7Rhi) 
and T effector (Teff, CD62Llow IL-7Rlow) b) Frequency of CD45.1 P14 cells in spleen at day 90. c) 
Phenotype of P14 T cells upon vaccination with NP-GP33 or DC-GP33 adjuvanted with Poly I:C or 
MPLA. d) Memory phenotype of CD45.1 OT-I memory cells upon immunization with NP-SIINFEKL 
(2 μg) and NP-OVA (2 μg) together with 10 μg of CpG-B. Data are representative of two independent 
experiments with n=3-4 per group.
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DISCUSSION 
Subunit vaccines delivered as synthetic particles have attracted significant attention in the vaccine field 
due to their capacity to enhance cellular immunity over unformulated antigens. Motivated by this, we 
have designed a PEG-PPS-based nanoparticle vaccine (NP) and evaluated the impact of NP-conjugation 
on the activation of CD8 T cells against the LCMV GP antigen, GP33. 
Using GP33 as model Ag, we confirmed that intradermal immunization with a NP peptide conjugate 
augmented the frequency of polyfunctional and cytotoxic CD8 T cells compared to the soluble GP33 
peptide, as evidenced by the increase in multiple cytokine secreting CD8 T cells, and enhanced 
expression of CD107a, a surrogate marker of cytotoxicity.  This is in agreement with previous studies 
using PEG-PPS NP7,8,11,12,34, underscoring the potential of this platform to augment quantitatively and 
qualitatively cellular immune responses in clinically relevant scenarios.   
The development of successful T cells vaccines relies on the ability to generate long-lasting memory 
responses. To have a more comprehensive understanding of the differentiation of memory CD8 T cells 
upon NP vaccination, we benchmarked our NP platform to a DC-based vaccine, which has proven to be 
an effective immunization approach for promoting protective CD8 T cell memory responses35,36. We 
show that NP promoted a CD8 T cell memory pool with a bias towards an effector memory phenotype, 
characterized by high expression of IL-7R, KLRG-1 and a low/intermediate expression of CD43, CD27 
and CD62L. These cells were polyfunctional (secreted IFN-a TNF-b simultaneously), had higher 
circulatory capability and displayed recall potential to viral (with LCMV Cl-13) and bacterial (with Lm-
OVA) challenges similar to those induced by the DC-based vaccine.  Moreover, we demonstrated that 
NP promoted Ag retention in dLNs when compared to the unformulated peptide or the DC vaccine, 
potentially allowing the proliferation of newly arrived naïve CD8 T cells over an extended period. In an 
effort to define the cells in which Ag is retained, we labeled the GP33 peptide and showed that Ag was 
retained mainly in hematopoietic cells in lymph nodes. Additionally, we also observed antigen 
associated with LECs, in accordance to a previous report with fluorescently labeled protein antigen42, 
indicating that Ag delivered by our synthetic nanoparticles can promote retention in this stromal cell 
subset. 
The importance of Ag persistence on memory differentiation has been extensively described during 
chronic viral infections24. In the context of LCMV Cl-13, high loads of antigen primarily in non-
lymphoid organs drive CD8 T cells towards functional exhaustion and deletion22,39,66,67. These cells are 
characterized by a high expression of the surface marker KLRG1 and their partially or fully impaired 
capability to secrete effector molecules22. Based on this evidence, KLRG1 has been described as a 
correlative marker of senescence68.  Nevertheless, in our system we showed that NP-educated memory 
T cells, in their majority expressing KLRG1, proliferated upon antigen encounter and displayed 
cytotoxic capability. Our data supports previous studies that demonstrated the protective efficacy of the 
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Tem subset17–20,69. For instance, Olson et al19 reported that a Tem population with similar traits to the 
Tem subset generated by the NP vaccine displayed better protective capability to Listeria 
monocytogenes than Tcm cells, despite a lower proliferation recall capacity. Our results are also in 
accordance with those of Reyes-Sandoval et al18 who demonstrated that frequency of blood-circulating 
Tem promoted by antigen-delivery via an adenovirus vector correlated with the level of protection 
against a sporozoite challenge in a malaria model of vaccination. 
In addition to Ag persistence as the main factor promoting Tem differentiation, we wanted to understand 
the contribution of other factors that favor differentiation into Tem cells, such as antigen dose, adjuvant 
selection and CD4 T cell help. We excluded the possibility that the observed phenotype was caused by 
drastic differences in Ag dose between the two vaccination regimes, since tuning peptide doses or DC 
cell numbers did not have an impact in the differentiation of memory CD8 T cells.  We further addressed 
if lack of CD4 T cell help during the immunization could be also responsible for the observed strong 
effector-like phenotype after NP immunization. Studies in MHCII knockout mice or CD4-deficient mice 
reported that unhelped memory CD8 T cells display a similar phenotype as the one we observed with 
NP, characterized by the low expression of CD62L, IL-7R and CD27; and high levels of KLRG148,61,70. 
We showed that vaccination with the model antigen OVA delivered as a full protein conjugated onto 
NP promoted a moderate increase in the frequencies of Tcm cells.  However, the majority of cells still 
displayed the Tem phenotype observed with the immunization with the MHCI-restricted NP-
SIINFEKL, indicating that the lack of CD4 T cell help is not the main responsible factor for the Tem-
biased differentiation. Similarly, modulation of the inflammatory environment using different TLR-
based adjuvants promoted little phenotypic change in memory T cells. Consistent with our hypothesis, 
our data highlights that Ag persistence is a key factor for the generation of Tem cells. 
Interestingly, we observed an increase in PD-1 expression on NP-primed memory CD8 T cells, but not 
other inhibitory receptors, such as LAG-3 (data not shown). Although it is generally believed that not 
all PD-1hi T cells are exhausted, there are few studies addressing the role of this receptor in memory 
differentiation71,72. Hokey et al72 showed  that peptide vaccination in macaques also drives the generation 
of fully active PD-1hi cells, indicating that rather than representing an exhaustion marker, PD-1 
expression may define T cell activation during a primary immune response.  
Future studies should address whether protection by this subset arises by a faster response owing to the 
extra-lymphoid localization and enhanced circulatory potential of this subset. Since it is unlikely that a 
single phenotype is generated by a vaccine regime, it would be important to elucidate how the different 
memory subsets synergize to provide protection against pathogens.  
In summary, we have shown that NP-vaccination and a benchmark DC vaccination each drives a distinct 
memory differentiation; PEG-PPS NP-GP33 vaccination results in Tem differentiation, while, DC 
vaccines preferentially promote Tcm cells.  Antigen retention in both hematopoietic cells and LECs in 
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the dLN appears to be key in inducing the Tem bias. Both NP-educated and DC-educated CD8 T cells 
display protective capacity against viral and bacterial challenge, establishing the NP vector as a 
promising platform for peptide-based T cells vaccines aiming at promoting protective immunity. 
Moreover, these studies highlight the importance of vaccine design in tailoring the quality of the immune 
response. 
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MATERIALS AND METHODS 
Animals  
C57BL/6 female mice, age between 8-12 weeks, were purchased from Harlan (France). CD45.1 P14 
mice, which encode for a T cell receptor that is specific for the LCMV MCHI epitope GP33-41, were 
obtained from the group of Pedro Romero at CHUV. All animal experiments were performed under the 
approval from the Veterinary Authority of the Canton of Vaud (Switzerland) according to Swiss Law 
(protocols VD2502, VD2235.1 ,VD2954 and VD 2992) 
Infections 
Mice were infected intravenously (i.v.) with 2.0x106 PFU of LCMV-Cl13 virus to establish a chronic 
infection. Virus was obtained from the group of Dietmar Zehn, University of Lausanne. Viral titers in 
peripheral organs were measure by qPCR as described by Crotty et al 73. For Listeria monocytogenes 
expressing OVA (Lm-OVA) studies, mice vaccinated with NP-SIINFEKL and DC-SIINFEKL were 
infected at day 90 post immunization with 1x105 colony forming units (CFU) intravenously (i.v.). Three 
days after, the spleen was harvested and homogenized. Various dilutions of the spleen were plated on 
brain heart infusion (BHI) (Sigma-Aldrich) agar plates and incubated overnight at 37oC. The following 
day, CFUs were counted and the amounts of Lm-OVA were calculated with respect to the relative 
dilutions. 
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Peptide activation 
GP33-41 (KAVYNFATC) and SIINFEKL peptides were purchased from Thermo Scientific with a purity 
of >95%.  Peptides were activated by adding a 2-pyridylthiol group (Sigma-Aldrich) to the cysteine 
residue 7. Peptide purity and activation was confirmed by analytical HPLC/MS.  
Nanoparticle preparation 
All chemical reagents were reagent grade and purchased from Sigma-Aldrich unless otherwise stated. 
PPS-PEG nanoparticles (NP) were synthesized as detailed previously 9,10, with some modifications to 
allow for protein loading into the PEG corona. Briefly, OH-PEG (NP-OH, peptide loading) or a mixture 
of 1:3 COOH-PEG / OH-PEG (for NP-COOH, protein loading) were used to prepared the emulsion 
polymerization to form NP. NP-OH were immediately purified by dialysis against MQ H2O for 36 h at 
room temperature, and passed through a filter with a 0.22 ?m pore size (Millipore Corporation). For 
NP-COOH, the remaining thiolates were quenched by the addition of 45 mg of iodoacetamide and stirred 
for 15 min. To functionalize the COOH groups on the NP surface, sulfo-NHS (Life Technologies), 
pyridyl disulfide cysteamine (synthesized in house) and 1ethyl-3-(3-dimethylaminopropyl) (EDC) were 
added to the mixture and let to react for 24 h. Subsequently, NP were purified and filter as detailed 
above. The concentration of the loaded pyridyl disulfide was determined by measuring the absorbance 
at 340 nm after adding TCEP (ThermoScientific) to the NP solution.  
Peptide conjugation was achieved by mixing NP-OH with activated peptide for 16 h at room 
temperature. The concentration of loaded peptide was assessed by measuring the absorbance at 340 nm, 
which represents the release of pyridyl thione from the peptide as it reacts with free thiols on the NP 
core. For OVA conjugation, functionalized NP were mixed with guanidine hydrochloride (GndHCl) to 
achieve a final concentration of 6 M of GndHCl. The solution was filtered through a 0.22 ?m membrane 
(Millipore Corporation) and mixed with OVA for 16 h at room temperature.  Non-conjugated peptides 
and protein were purified by size exclusion chromatography through a Sepharose CL-6B column 
equilibrated in 0.9% saline solution (Braun). The concentration of loaded protein in the fractions 
obtained after purification was determined by a BCA assay following the manufacturer’s instructions 
(ThermoScientific).   
Before and after the coupling, the size of NPs was determined by dynamic light scattering with a Nano 
Zs Zetasizer (Malvern Instruments). The diameter of NPs varied between 25 nm - 40 nm. 
Generation of bone marrow derived DCs (BMDCs) 
Bone marrow derived CD11c+ dendritic cells (BMDCs) were generated by adapting the protocol 
described by Lutz et al 74. Briefly, BM cells were cultured for 8-9 days in the presence of 20 ng/mL of 
GM-CSF, changing the medium every 3 days.  After this time, CD11c+ cells constitute the 70-85% of 
the non-adherent population.   
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Immunizations 
All vaccines were administered intradermally (i.d.) into the four limbs. For peptide-loaded NP and free 
peptide immunization, a total of 2 ? g of Ag and 10 ? g of the TLR-9 agonist CpG-B (Microsynth) were 
injected per mouse. All NP and peptide batches were tested for endotoxin levels using a TLR activation 
assay based on HEK-Blue reporter cell lines (Invivogen) before immunization. For DC immunizations, 
BMDCs from day 8-9 were activated overnight with 20 ng/mL of LPS. Afterwards, cells were washed 
with full medium and pulsed with 10 ?M of peptide for 1 h at 37°C. To be sure no free peptide remained 
during the immunization, cells were washed extensively (3x) and finally resuspended in physiological 
saline solution at the desired concentration. Shortly before the immunization, the cell slurry was mixed 
with CpG-B. In total, with the exception of the dosing study, each mouse received a total of 2x106 cells, 
together with 10 ? g of CpG-B.  The dose of antigen used for BMDC pulsing and BMDC numbers were 
selected based on the ability to promote a similar expansion of P14 cells in spleen upon a single 
immunization compared to an immunization with NP-peptide (2 ? g) (Fig.S1). 
Adoptive transfers and cell sorting 
For adoptive transfers of naive antigen specific CD8 T cells, single cell suspensions were prepared from 
spleens of CD45.1 P14 mice. CD8 T cells were isolated using the EasySep™ Mouse T Cell Isolation 
Kit (Stemcell Technologies). Immediately after isolation, 5x104 cells were adoptively transferred i.v. 
into naïve host mice.  For viral challenge experiments, CD45.1 P14 CD8 memory T cells were isolated 
by flow cytometry-assisted cell sorting. 5x104 cells were adoptively transferred into naïve mice.  
In vivo cytotoxicity assay 
For in vivo cytotoxicity studies, CD45.1 P14 cells were adoptively transferred into wild type naïve mice, 
and one day after mice were immunized with soluble Ag, NP-GP33, or DC-GP33, as described above. 
Four days after the immunization, splenocytes from naïve mice (target cells) were divided in two groups: 
one group was left untreated, while the second group was pulsed with 10 ?M of GP33-41 for 40 min at 
37°C, and then washed two times in PBS to remove any free peptide. Following this step, the half that 
was left untreated was stained with 0.4 ?M of CFSE (low), while the half that was pulsed with peptide 
was stained with 4 ?M of CFSE (high).  Cells were mixed at 1:1 ratio, and a total of 2x107 cells were 
injected i.v. into previously immunized mice. The following day, spleens were harvested and the 
percentage of in vivo killing was calculated by the following formula: [1 – ([CFSEhigh/CFSElow for 
experimental]/[CFSEhigh/CFSElow for untreated)] × 100. 
Antigen persistence studies 
Mice were vaccinated with soluble Ag, NP-GP33, or DC-GP33 as described above. After either 7 or 21 
days, 1x106  CD45.1 P14 cells labeled with 2 ?M of CFSE were adoptively transferred into immunized 
mice, and 3 days after, lymph nodes and spleen were harvested for assessing CD8 T cell proliferation.   
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For the evaluation of antigen persistence in various cell compartments, mice were vaccinated with a 
peptide labeled with AF-647 either soluble or loaded in nanoparticles. After 7 days, LNs cells were 
assessed for the presence of AF-647 signal by flow cytometry.  
Cell preparation 
Lymph nodes were harvested and opened with needles and first digested in DMEM (1.2 mM CaCl2, 2% 
FBS, Pen/Strep) containing collagenase IV (1 mg/mL) and DNAse I (40 ? g/ml) to isolate lymphocytes. 
A second digestion step with DMEM and collagenase D (1mg/mL) and DNAse I (40 ? g/ml) was 
performed. Splenocytes were smashed through a 70 ?m filter, and red blood cells were lysed with ACK 
buffer.  The resulting cells were resuspended in PBS and stained for flow cytometry.  
Ex vivo restimulation 
Up to 3x106 cells from tissue isolated lymphocytes were plated in 96-well plates and cultured in 10%FBS 
-DMEM medium for 2 h at 37°C in the presence 1 ?M of GP33-41. Following this step, a final 
concentration of 5 ? g/mL of Brefeldin A was added to the culture and left for 3 additional h. For CD107a 
staining, cells were cultured together with the monoclonal antibody against CD107a and with Monensin 
at 2 ? g/mL for 5 hrs. Finally, cells were washed in PBS prior to staining for flow cytometry.   
Flow cytometry.  
Isolated lymphocytes were stained with a live/dead fixable dye (Life technologies) to assess cell 
viability, and stained for surface markers with a cocktail of monoclonal antibodies from Biolegend and 
eBiosciences. For intracellular staining, cells were fixed and permeabilized with the 
Foxp3/Transcription Factor Fixation/Permeabilization kit (eBiosciences) according to the 
manufacturer’s instructions.  Cells were stained in permeabilization buffer with a cocktail of monoclonal 
antibodies. After staining, cells were resuspended in staining buffer and samples acquired using a 
CyAnTM ADP (Beckman Coulter) or LSRII (BD biosciences) flow cytometer  
Data analysis 
Samples were analyzed using FlowJo (Tree Star) software and GraphPad Prism 5 Software (GraphPad 
Software Inc.). Statistically significant differences between the experimental groups were determine by 
a one-way ANOVA followed by Bonferroni post-hoc test correction when more than 2 groups were 
compared, and by a non-parametric Mann-Whitney U test when two groups were compared.  
Significance was determine for P values <0.05 ( *P?<?0.05, **P?<?0.01, ***P?<?0.001 and n.s.= no symbol).  
All error bars represent the mean ± standard error.  
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ABSTRACT 
Fatal infection with the highly pathogenic Lassa virus (LASV) is characterized by extensive viral 
dissemination, indicating broad tissue tropism. Although the principal LASV receptor dystroglycan 
(DG) is ubiquitously expressed, virus binding critically depends on DG’s post-translational modification 
with the unusual O-linked sugar polymer matriglycan. This functional glycosylation of DG is under 
tight tissue-specific control in vivo and does not always correlate with susceptibility. The broadly 
expressed phosphatidylserine (PS) receptors Axl and Tyro3 were recently identified as alternative 
LASV receptor candidates. However, their role in LASV entry is not entirely understood and published 
data seem conflicting. Here we examined LASV receptor candidates in primary human cells and found 
co-expression of Axl with differentially glycosylated DG. To study LASV entry in the context of 
productive arenavirus infection, we used recombinant lymphocytic choriomeningitis virus expressing 
LASV glycoprotein (rLCMV-LASVGP) as a validated BSL2 model. First, we confirm and extend 
previous work, showing that Axl can serve as an authentic LASV entry receptor in absence of functional 
DG using “apoptotic mimicry”, similar to other enveloped virus. We show that Axl-dependent LASV 
entry requires receptor activation and involves a pathway resembling macropinocytosis. Axl-mediated 
LASV entry is facilitated by heparan sulfate and critically depends on the late endosomal protein LAMP-
1 as intracellular entry factor. In endothelial cells expressing low levels of functional DG, both receptors 
are engaged by the virus and can contribute to productive entry. In sum, we characterize the role of Axl 
in LASV entry and provides a rationale to target Axl in anti-viral therapy.  
 
IMPORTANCE 
The highly pathogenic arenavirus Lassa (LASV) represents a serious public health problem in Africa. 
Although the principal LASV receptor dystroglycan (DG) is ubiquitously expressed, virus binding 
critically depends on DG’s post-translational modification, which does not always correlate with tissue 
tropism. The broadly expressed phosphatidylserine receptor Axl was recently identified as alternative 
LASV receptor candidate, but its role in LASV entry is unclear. Here we investigated the exact role of 
Axl in LASV entry as a function of DG’s post-translational modification. We found that in absence of 
functional DG, Axl can mediate LASV entry via “apoptotic mimicry”. Productive entry requires virus-
induced receptor activation, involves macropinocytosis, and critically depends on LAMP-1. In 
endothelial cells that express low levels of glycosylated DG, both receptors can promote LASV entry. 
In sum, our study defines the roles of Axl in LASV entry and provides a rationale to target Axl in anti-
viral therapy.  
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INTRODUCTION 
The Old World arenavirus Lassa (LASV) is the causative agent of a severe viral hemorrhagic 
fever with high mortality in humans [1, 8] and is currently considered as one of the most important 
emerging pathogens by WHO [76]. Carried in nature by persistent infection of reservoir rodent 
host of Mastomys species, LASV is endemic in large areas of Western Africa where it causes 
several hundred thousand infections per year with thousands of deaths. Transmission of LASV 
from rodents to humans occurs mainly via contaminated aerosolized rodent excreta and ingestion 
of contaminated food [1]. Human-to-human transmission has been reported in nosocomial 
settings [77]. Due to its transmissibility via aerosol [10] and high lethality, LASV is considered a 
Category A agent by the Centers of Disease Control [11]. 
Following productive infection at the sites of entry, the virus enters the bloodstream                            
and disseminates to lymph nodes, spleen, and liver. Severe LASV infection is characterized by 
extensive viral replication in many tissues, resulting in high viremia and progressive signs and 
symptoms of shock. Early targets of LASV during systemic dissemination are dendritic cells and 
macrophages, followed by infection of hepatocytes, endothelial cells, and epithelial cells of lung 
and kidney in severe disease [71]. A highly predictive factor for disease outcome is the viral load, 
indicating a close competition between viral spread and replication and the patient’s immune 
system [7]. There is no licensed vaccine and treatment is limited to supportive care and ribavirin, 
which reduces mortality when delivered early in infection [9]. Drugs targeting early steps of the 
viral life cycle may delay viral spread providing the immune system a window of opportunity to 
develop an anti-viral immune response. An in-depth understanding of the molecular mechanisms 
underlying LASV cell entry into relevant target cells is therefore of great importance to develop 
novel and efficacious anti-viral strategies.  
Arenaviruses are enveloped negative-strand RNA viruses, whose non-lytic life cycle is 
confined to the cytoplasm [2]. The arenavirus genome is comprised of two RNA segments that 
code for two proteins each, using an ambisense coding strategy. The small (S) RNA segment 
encodes the envelope glycoprotein precursor (GPC) and the nucleoprotein (NP), while the L 
segment encodes the matrix protein (Z) as well as the viral polymerase (L). GPC is synthesized 
as a single polypeptide and undergoes processing by signal peptidases and protease SKI-1/S1P 
yielding an unusually stable signal peptide (SSP), the N-terminal GP1, and the transmembrane 
GP2. The GP1 binds to cellular receptors, whereas GP2 mediates viral fusion and structurally 
resembles class I viral fusion proteins. 
Expression of cellular receptors is a key determinant for transmission, tissue tropism, and 
disease potential of a virus. The first cellular receptor for LASV and other Old World arenaviruses 
was identified as dystroglycan (DG), a ubiquitously expressed and highly conserved receptor for 
extracellular matrix (ECM) proteins [12]. Dystroglycan is expressed in most developing and adult 
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tissues and provides a molecular link between the ECM and the actin-based cytoskeleton. Initially 
encoded as a single polypeptide, DG is cleaved into the extracellular α-DG and membrane 
anchored β-DG [14]. In mammals, α-DG is subject to complex post-translational modifications 
that are essential for its function as a receptor for ECM proteins and arenaviruses [15, 21, 22]. 
The unusual O-linked trisaccaride [O-Man-β1-4-GlcNAc-β1-3GalNAc] on α-DG undergoes 
phosphorylation at the O-mannosyl residue, followed by synthesis of [Xyl-α1-GlcA-3-β1-3] co-
polymers by the dual-specific glycosyltransferase like-acetylglucosaminyltransferase (LARGE) 
[17, 18]. The LARGE-derived [Xyl-α1-GlcA-3-β1-3] polysaccharide, known as “matriglycan”, 
is recognized by ECM proteins and arenavirus GP1 via a lectin-type binding [15, 19, 20]. A 
genetic screen revealed that LASV strikingly mimics the molecular mechanisms of receptor 
recognition of host-derived ECM proteins [23]. The recently solved high-resolution X-ray 
structure of the pre-fusion conformation of LASV GP indicates that multiple residues located at 
the trimeric interface engage the DG-derived matriglycan polymers with high avidity [78].  
While the DG core protein is ubiquitously expressed in most mammalian cells, functional 
glycosylation by LARGE is under tight tissue-specific control [19], making DG a “tunable” 
receptor [19], whose virus-binding affinity greatly varies between tissues. Notably, the observed 
functional glycosylation of DG in human and animal tissues does not always correlate with 
susceptibility to LASV in vivo [70, 71, 79], suggesting the existence of alternative receptors. 
Using an expression cloning approach, the Tyro3/Axl/Mer (TAM) receptor tyrosine kinases Axl 
and Tyro3, as well as the C-type lectins DC-specific ICAM-3-grabbing nonintegrin (DC-SIGN) 
and LSECtin have been identified as candidate LASV receptors [34]. Based on their restricted 
expression patterns, DC-SIGN and LSECtin may contribute to LASV entry into specific cell 
types, such as particular dendritic cells, but their exact role is currently unclear [46]. The TAM 
kinases Axl and Tyro3 are conserved receptors for the phoshatidylserine (PS)-binding serum 
proteins Gas6 and protein S that are involved in removal of apoptotic cells [35, 36]. Over the past 
years, TAM kinases and other cellular PS receptors have been implicated in viral entry via 
“apoptotic mimicry”, a mechanism initially described by Mercer and Helenius for poxviruses [42] 
that is characterized by recognition of PS displayed on the viral lipid envelope [37, 80]. Viral 
apoptotic mimicry is increasingly recognized as an entry strategy for a broad spectrum of 
enveloped viruses and some non-enveloped viruses, including important emerging pathogens 
such as Ebola virus, Dengue, West Nile, and Zika virus [37, 80]. Currently, the exact role of TAM 
receptors in LASV entry is not entirely clear and published data appear conflicting [34, 37, 43]. 
The initial report identifying TAM kinases as a candidate LASV receptors provided evidence for 
a role of Axl and Tyro3 in DG-independent entry of lentiviral LASV pseudotypes [34]. However, 
a subsequent systematic study covering a large panel of emerging viruses, using different 
pseudotype platforms, concluded that the PS receptors Axl and T cell immunoglobulin and mucin 
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(TIM)-1 were unable to mediate productive LASV entry [43]. Here we sought to resolve these 
apparent contradictions and investigated the exact role of Axl in LASV entry in the context of 
productive arenavirus infection using a validated BSL2 surrogate model. We further investigate 
the mechanism underlying Axl-mediated LASV entry and provide a rationale for targeting Axl in 
anti-viral therapy.  
MATERIALS AND METHODS 
Antibodies and reagents 
Monoclonal antibody (mAb) IIH6 anti-?-DG (mouse IgM) has been provided by Dr. Kevin 
Campbell (Howard Hughes Medical Institute, University of Iowa). Mouse mAb 8D5 anti-β-DG 
was purchased from Novocastra. Purified polyclonal goat IgG anti-human Axl, mAb 96201 anti-
Dtk/Tyro3, and mAb 120507 anti-DC-SIGN were from R&D Systems and mouse mAb ab54803 
anti-Axl from Abcam. Mouse mAb sc-20011 anti-LAMP1 was from Santa Cruz Biotechnology. 
MAb 83.6 to LASV GP2 has been described [81] as has been mAb113 anti-LCMV NP [82]. MAb 
cl14a to phospho-β-DG PY982 was from BD Bioscience and mAb 4G10 to phospho-tyrosine 
from St. Cruz Biotechnology. Antibody to clathrin heavy chain was purchased from BD 
Biosciences. Other mAbs included mouse mAb B-5-1-2 anti-α-tubulin and goat polyclonal 
antibody to human IgG Fc (Sigma Aldrich). Horseradish peroxidase (HRP) conjugated polyclonal 
goat anti-mouse IgG, goat anti-mouse IgM, and rabbit anti-goat IgG weres from Dako. FITC-
conjugated goat anti-mouse IgG was from Jackson Immuno Research. The nuclear dye 4',6-
diamidino-2-phenylindole (DAPI) and phalloidin-FITC was purchased from Molecular Probes 
(Eugene, OR). The full-length GPC of Tacaribe virus (TCRV) was kindly provided by Juan-
Carlos de la Torre (Scripps Research Institute, La Jolla, CA). The Cell Titer Glo® assay system 
was obtained from Promega (Madison WI). Annexin-V from human placenta conjugated to 
biotin, heparin, and streptavidine-HRP were from Sigma. The DG fragment DGEKFc4 is 
comprised of amino acids 1 –485 of α-DG, followed by an enterokinase (EK) cleavage site and 
the Fc portion (hinge, CH2, and CH3) of human IgG1 and was produced and purified as described 
[83]. For optimal sensitivity of our assay, DGEKFc4 was produced in cells over-expressing 
LARGE, resulting efficient matriglycan modification, as described [21]. Inhibitors used in this 
study included R428 to Axl tyrosine kinase (Sellekchem), dynasore, dyngo-4a, pitstop-2 (Ascent 
Scientific), pirl1 (Chembridge), CT04, blebbistatin, cytochalasin D, 5-(N-ethyl-N-
isopropyl)amiloride (EIPA), IPA-3, jasplakinolide, latrunculin A, ML7, ribavirin, and ammonium 
chloride (NH4Cl) (Sigma).   
Cell culture 
Human lung carcinoma alveolar epithelial cells A549, the human fibrosarcoma cell line HT-1080, 
HeLa cells, and human embryonic kidney (HEK)-293H cells, were cultured in DMEM, 10 % 
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(vol/vol) FBS, supplemented with glutamine and penicillin/streptomycin. Primary human 
hepatocytes were isolated from liver specimens obtained after partial hepatectomy at Hannover 
Medical School and plated at a density of 1.3 x 106 cells on collagen-coated P6 dishes as described 
[84]. Cells were kept in hepatocyte culture medium (Lonza) for 1-3 days before cell lysis. Cultures 
were 90% confluent and cells showed typical hepatocyte morphology with multiple nuclei. 
Human umbilical vein endothelial cells (HUVEC) (CC-2517), primary human lung microvascular 
endothelial cells (HMVEC-L) (CC-2527), and primary human small airway epithelial cells 
(SAEC) (CC-2547) were purchased from Clonetics®/Lonza as cryopreserved specimens and 
cultured following the manufacturers protocol using endothelial cell growth medium EGMTM 
BulletKitTM, EGMTM 2MV BulletKitTM, and small airway epithelial cell growth medium (CC-
3118), respectively. HMVEC-L are isolated from small vessels within normal lung tissue cultured 
to ≥90% purity and represent a mixed population of both blood and lymphatic endothelial 
cells. HUVEC and HMVEC-L were passed 5 times, corresponding to < 15 population doublings 
to assure preservation of the differentiated phenotype. Expression of the differentiation marker 
CD31/105 was verified by immunofluorescence staining using mAb 28364 to CD31 (Abcam). 
SAEC are isolated from normal human lung tissue the distal portion of the lung in the 1 mm 
bronchiole area. Cells were passed 5 times and differentiation verified by staining for cytokeratin 
19 using mAb ab52625 (Abcam), as recommended by the manufacturer. For infection studies, 
cells were seeded in collagen- or poly-L-lysine-coated M96 tissue culture plates at 20’000 
cells/cm2 and experiments performed at a confluency of >90% after 2-3 days.  
Viruses and virus purification 
The generation, growth, and titration of recombinant LCMV expressing the envelope GP of 
LASV strain Josiah (rLCMV-LASVGP) and the G protein of vesicular stomatitis virus (rLCMV-
VSVG) have been described elsewhere [48, 85]. According to the institutional biosafety 
guidelines of the Lausanne University Hospital, the chimera rLCMV-LASVGP has been 
classified as a BSL2 pathogen for use in cell culture. Inactivated LASV strain Josiah was provided 
by Dr. Christina Spiropoulou, Special Pathogens Branch of the Centers for Disease Control and 
Prevention (CDC, Atlanta, GA). Recombinant human adenovirus (AdV)-5 expressing GFP has 
been described [86] as has recombinant vesicular stomatitis virus (VSV) expressing GFP [87]. 
Recombinant VSV pseudotypes bearing the envelope GP of Tacaribe virus (TCRV) were 
generated as reported earlier [87]. To obtain serum-free rLCMV-LASVGP, virus was purified 
following a modified protocol from Dutko et al. [88]. Briefly, rLCMV-LASVGP was grown in 
BHK21 cells as described [48]. Conditioned cell culture supernatants were harvested after 72 h 
and virus precipitated from cleared supernatants by addition of 6.5 g per 100 ml polyethylene 
glycol (PEG)-8000 and stirring over night at 6 °C. After centrifugation at 8,000 rpm for 30 min 
at 4°C, the PEG pellet was dissolved in TNE/EGTA (10 mM Tris/HCl pH 7.5, 100 mM NaCl, 1 
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mM EDTA, 5 mM EGTA) using 1 ml of TNE/EGTA for 50 ml of original supernatant. After 
incubation for 2 h at 4 °C, virus was layered on a discontinuous renografin gradient and purified 
by ultracentrifugation as described [88]. After dialysis against PBS, infectious virus titers were 
determined by immunofocus assay on VeroE6 cells in complete medium containing 10% (wt/vol) 
FBS. Concentrated virus titers were 108 -109 PFU/ml. Inactivated LASV obtained as PEG 
precipitate from CDC was treated with TNE/EGTA for 2 h at 4 °C, followed by purification over 
a renografin gradient.  A “mock-preparation” was prepared from conditioned supernatant of 
uninfected BHK21 cells subjected to PEG precipitation and purification over a renografin 
gradient analogous to the virus preparation.  
 
Capture ELISA for rLCMV-LASVGP and inactivated authentic LASV 
MAb 83.6 to LASV GP2 (10 μg/ml, 50 μl/well) was added to a 96-well microtiter plate 
(EIA/RIA) high-bond plates (Corning) and immobilization carried out at RT for 4 h. Wells were 
washed 3 times with PBS and non-specific binding blocked by adding 200 μl/well 1% (wt/vol) 
BSA/PBS for 1 h at RT. For capture of virus, serum-free preparations of rLCMV-LASVGP and 
inactivated authentic LASV were diluted to 107 PFU/ml and added (50 μl/well) in triplicates to 
immobilized mAb 86.3 for 16 h at 6° C. As a negative control, AdV5-GFP was included. Wells 
were washed 3 times with PBS. For detection of phosphatidylserine (PS) on bound virus, annexin-
V (ANX-V) biotin conjugate from human placenta (1: 50 in 1% (wt/vol) BSA/PBS) was added 
overnight at 6 °C in presence and absence of 5 mM EGTA. LASV GP1 was probed with 
DGEKFc4 (10 μg/ml in 1% (wt/vol) BSA/PBS) overnight at 6 °C.  Wells were washed 3 times 
with PBS. Bound ANX-V was detected with streptavidine HRP), 1:1000 in 1% (wt/vol) BSA/PBS 
for 2 h at 6 °C and DGEKFc4 with anti-human IgG Fc antibody conjugated to HRP, 1:1000 in 
1% (wt/vol) BSA/PBS for 2 h in the cold. After incubation, plates were washed four times and 
developed using 50 μl of 3,3,5,5’-tetramethylbenzidine (eBiosciences, MA). The color reaction 
was stopped by adding 20 μl of 2 M H2SO4. Plates were analyzed using a plate reader 
spectrophotometer (Tecan, Mannedorf, Switzerland) by measuring the absorbance at 450 nm with 
correction at 570 nm. Background binding to wells without immobilized antibody was subtracted 
and the ratios of GP1/PS binding calculated. 
Micro-scale isolation of DG using wheat germ agglutinin  
Enrichment of DG by wheat germ agglutinin (WGA) affinity purification was carried out 
following a modified protocol reported earlier [89]. Briefly, two T150 flasks of A549, 
HT-1080 cells and HUVEC (>90% confluency) were washed twice with 20 mM Hepes, 
pH 7.5, 150 mM NaCl. Cells were solubilized in 2 ml of cold solubilization buffer per 
flask: 50 mM Hepes pH 7.5, 200 mM NaCl/ 1% (wt/vol) NP-40, 1.2 mM EDTA, protease 
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inhibitor cocktail complete (Roche), 1 mM PMSF for 45 min. in cold-room. Lysates were 
cleared by centrifugation for 10 min at 14, 000 krpm in a microfuge and 5 mM MgCl2 
and 10 mM sodium pyrophosphate (final concentration) added.  The WGA matrix (20 
μl/ml) was added and incubated on a head-over shaker over night at 6 °C. The WGA 
matrix was washed 4 times with 10 volumes of 50 mM Hepes pH 7.5, 200 mM NaCl/ 
0.05% (wt/vol) NP-40, 1.2 mM EDTA, protease inhibitor cocktail, 1 mM PMSF, 5 mM 
CaCl2, 5 mM MgCl2. Elution of WGA-bound proteins was achieved by incubation of 
matrix with 5 x 5 volumes elution buffer: 10mM Tris (pH 8.0), 0.15 M NaCl, 0.2 M N-
acetyl glucosamine for 15 min at RT. Individual fractions  were probed for the presence 
of DG in Western blot using mAb 8D5 to β-DG and the most concentrated factions 
pooled, followed by dialysis against PBS.  
Solid-phase virus binding assay  
The WGA-purified DG fractions derived from A549, HT-1080 cells and HUVEC (above) were 
analyzed by Western blot and signals for β-DG quantified by densitometry to allow 
immobilization of normalized amounts of DG protein using the dilutions HT-1080 (1:1), HUVEC 
(1:1.32) and A459 (1:2.02) carried out overnight at 6°C. Wells are washed 3 times with PBS. 
Non-specific binding was blocked by adding 200 μl/well of 1% (wt/vol) BSA/PBS and incubation 
for 1 h at RT. Dilutions of rLCMV-LASVGP were prepared in 1% (wt/vol) BSA in PBS and virus 
(50 μl/well) added in triplicates for 16 h at 6 °C. Wells are washed 3 times with PBS and bound 
virus was detected with mAb 83.6 to LASV GP2 (20 μg/ml) in 1% (wt/vol) BSA in PBS for 6 h 
at 6° C. After three washes, bound primary antibody was detected using biotinylated goat anti-
mouse IgG combined with streptavidine as described [21]. Plates were developed as described in 
section “capture ELISA”. Background binding to wells without immobilized DG was subtracted 
and binding curves plotted.  
Virus infections 
Cells were seeded in 96-well plates at 2 x 104 cells per well and grown into confluent monolayers 
for 16-20 h, unless stated otherwise. Cells were treated with drugs as detailed in the specific 
experiments, followed by infection with the indicated viruses at the defined multiplicity of 
infection (MOI) for 1 hour at 37 °C. Unbound virus was removed, cells washed twice with 
DMEM, and fresh medium added. Infection of rLCMV-LASVGP and rLCMV-VSVG were 
quantified by detection of LCMV NP in immunofluorescence assay (IFA) with mAb 113 as 
described [90]. VSV pseudotypes, AdV5-GFP, and rVSV-GFP were detected via the GFP 
reporter using direct fluorescence.   
For the determination of serum-dependence of rLCMV-LASVGP infection in HT-1080 
cells, serum-free virus was pre-treated with complete medium containing increasing 
? ? ?
?
????
?
concentrations of FBS for 2 h at 4 °C. Virus was added to cells for another 2 h at 4 °C, followed 
by washing to remove unbound virus. Cells were shifted to 37 °C by adding 200 μl per well of 
warm complete medium containing 10% (vol/vol) FBS. After 1 h, 20 mM ammonium chloride 
was added and infection detected after 16 h as described above.  
Blocking with ANX-V was achieved by pre-treating virus with the indicated 
concentrations of ANX-V in DMEM, 20 mM Hepes for 2 h at 4°C as described [39]. Kinetics of 
virus-cell attachment and endosomal escape were determined as described [55].  
For perturbation with antibodies to Axl and DG, M96 plates were chilled on ice, medium 
removed, and cells washed three times with cold serum-free medium containing 2% (wt/vol) 
BSA, supplemented with 20 mM Hepes to remove serum proteins. Polyclonal Ab to Axl, mAb 
IIH6 to DG, and control Ab were diluted as indicated in serum-free medium containing 2% 
(wt/vol) BSA, supplemented with 20 mM Hepes and incubated with cells for 2 h at 4°C (50 
μl/well). Viruses were prepared at 10-fold final concentration in serum-free medium containing 
2% (wt/vol) BSA, supplemented with 20 mM Hepes. Five microlitees of virus inoculums were 
added to the Ab mixtures on cells, mixed carefully and incubated for another 2 h at 4°C. 
Inoculums were removed, cells washed three times with serum-free medium containing 2% 
(wt/vol) BSA, supplemented with 20 mM Hepes, and 200 μl/well complete medium added. Cells 
were cultured at 37°C, 5% CO2 for the indicated time periods, fixed, and infection assessed as 
described above.   
Immunoblotting  
For immunoblotting, proteins were separated by SDS-PAGE and transferred to nitrocellulose. 
After blocking in 3% (wt/vol) skim milk in PBS, membranes were incubated with 1-10 μg/ml 
primary antibody in 3% (wt/vol) skim milk, PBS overnight at 4 ºC. After several washes in PBS, 
0.1 % (wt/vol) Tween-20 (PBST), secondary antibodies coupled to HRP were applied 1: 5,000 in 
PBST for 1 h at room temperature. In Western blots detection tyrosine phosphorylated Axl and 
β-DG, membranes were rinsed three times in PBST containing 250 mM NaCl. Membranes were 
developed by chemiluminescence using LiteABlot kit (EuroClone). Signals were acquired by 
ImageQuant LAS 4000Mini (GE Healthcare Lifesciences) or by exposure to X-ray films. 
Quantification of Western Blots was performed with ImageQuant TL (GE Healthcare 
Lifesciences). 
Generation of DG-deficient HT-1080 cells using lentivirus-delivered small hairpin (sh)RNA  
To deplete DG core protein in HT-1080 cells, lentiviral vector expressing validated shRNA 
targeting human DG (sh-DG) (ID clone: TRCN0000056191, Thermo Scientific RHS3979-
9623375) or a scrambled control shRNA (sh-sc) were generated as described by the ViraPower™ 
Lentiviral Expression System protocol from Invitrogen (UK). Briefly, a puromycin kill curve 
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determination was performed in HT-1080 cells where 2 μg/ml was the minimum puromycin 
concentration required to kill untransduced cells. For the production of lentiviruses, 3 x 106 
HEK293T cells were cultured in 10 cm tissue culture dishes in serum-free 293 SFM II medium 
(Gibco™, Cat. No. 11686-029). At 24 h post-seeding, fresh medium was added to cells 4 h before 
the transfection. CaCl2 (250 mM CaCl2, ultrapure H2O) and HBS (50 mM Hepes, 1.5 mM 
Na2HPO4, 140 mM NaCl, ultrapure H2O) solutions were used to co-transfect the four required 
DNA plasmids: pLP1 helper (gag/ pol), pLP2 helper (rev), pCAGGS/ VSVGP, with sh-DG 56191 
(human pLKO.1) or with sh-sc (human pLKO.1) shRNA control. The transfected cells were 
incubated for16 h at 37°C. After 16 h, the transfection medium was replaced by fresh serum-free 
293 SFM II medium and cells incubated for 24 h at 37°C, 5% CO2. At 40 h post-transfection, cell 
supernatants were collected and centrifuged for 5 min at 500 x g to remove cellular debris. Each 
lentivirus was concentrated using the Amicon® Ultra-15 Centrifugal Filter Devices by ultra-
centrifugation according to the manufacturer’s instructions (Millipore, Ultracel® 100KREF. 
UFC910024). For infection, 5 x 105 HT-1080 cells/well were seeded in 6-well plates and cultured 
for 24 h at 37°C. The day after, cell medium was replaced by complete medium supplemented 
with 6 μg/ml polybrene® and 100 μl of each crude lentivirus stock. The cells were spinoculated 
at 2,600 rpm for 3 h at 23°C. Cells were then washed twice with medium. Transduced cells were 
incubated for 72 h at 37°C. After 72 h, cells were washed once with 1 x PBS and complete medium 
supplemented with 2 μg/ml puromycin added. After 48 h, cell death was checked and the selective 
medium replaced every two days during 2 weeks. Depletion of DG core protein from HT-1080 
cells was verified by Western blot using mAb 8D5 as described above. DG-deficient cells were 
passed for a maximum of 10 times and the DG null phenotype verified for cells used for our 
experiments.  
RNA interference 
RNA interference (RNAi) was performed using validated small interfering RNAs (siRNAs) 
ONTARGETplus SMARTpool for Axl (L-003104-00-0005) and scrambled siRNA (D-001820-
10-05) as control from Thermo Scientific Dharmacon (Lafayette, CO). For the depletion of 
clathrin heavy chain, siGENOME ON-TARGETplus SMARTpool duplex (J-004001-09) to 
human clathrin heavy chain and a control siRNA pool was obtained from Dharmacon Research 
(Lafayette, CO). A pool of the following siRNAs was used: siRNA #1: 5’-GAG AAU GGC UGU 
ACG UAA U-3’, #2: 5’-UGA GAA AUG UAA UGC GAA U-3’, #3: GCA GAA GAA UCA 
ACG UUA U-3’, #4: 5’-CGU AAG AAG GCU CGA GAG U-3’. Briefly, 3 x 106 HT-1080 cells 
were reverse transfected with 0.72 μM siRNA using a10-cm-diameter dish and Lipofectamine 
RNAiMAX (Invitrogen, Paisley, United Kingdom) according to the manufacturer’s 
recommendation. For LAMP-1 knock down, 3 x 105 cells were seeded over night and transfected 
using the Lipofectamine RNAiMAX Reagent (Invitrogen) with All Star scramble RNA or 
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LAMP-1 specific siRNA (Qiagen) at a final concentration of 50 nM  (siRNA 5’ 
CACGTAATGCATTGCCTGTAA 3’) for 48 h.  
Twenty-four hours after transfection, cells were replated in 96-well plate format, and 48 h post-
transfection, cells were infected with rLCMV-LASVGP (MOI = 0.1) and rLCMV-VSVG (MOI 
= 0.02) or mock infected. Parallel specimens were lysed to confirm Axl knock-down by Western-
blotting using goat pAb at Axl. To prevent secondary infection, 20 mM ammonium chloride was 
added to the cells 4 hours postinfection. Cells were fixed 16 hours post-infection and infected 
cells quantified by immunofluorescence assay (IFA) detection of LCMV NP using mAb 113 
(anti- LCMVNP) and combined with fluorescence-labeled secondary antibody as described [91].  
Virus-induced receptor signaling 
Purified rLCMV-LASVGP (8.4 x 108 PFU/ml) and equivalent volumes of mock preparation were 
incubated in 10 ml HBSS with 10% (vol/vol) FBS for 2 h at 4°C, followed by layering a cushion 
of 20% (wt/vol) sucrose in PBS containing 1 mM MgCl2 and 0.1 mM CaCl2. After spinning at 
35,000 rpm for 90 min in a SW41 swing-out rotor, supernatant was decanted completely. Pellets 
were resuspended in 250 μl of HBSS for 16 h at 4ºC in a closed vial on a shaker. Concentrated 
virus was titrated by IFA on VeroE6 cells. HT-1080 cells, HMVEC-L, and SAEC were seeded at 
4 x 105 cells per well in complete medium and cultured to obtain closed monolayers of >90% 
confluency. Cells were serum-starved for 16 h replacing FBS by 0.2% (vol/vol) horse serum. 
Cells were chilled on ice for 5 minutes. Medium was removed and 4 x107 PFU virus was diluted 
in 1 ml of serum-free medium added, corresponding to an MOI of circa 50. Virus was added to 
the cells in the cold and incubated for 2 h on ice. To control wells, mock-prep was added. Cells 
were washed twice in cold serum-free DMEM, followed by addition of pre-warmed serum 
DMEM (4 ml/well). Cells are shifted to 37°C. At the indicated time points, medium was removed 
and cells lyzed in cold lysis buffer: 1% (wt/vol) NP-40, 50 mM Tris, pH 7.5, 150 mM NaCl, 2 
mM EGTA, 0.2 mM EDTA, 50 mM NaF, protease inhibitor cocktail “Complete®” from Roche, 
and 1 mM PMSF. Cells were scraped off with a plastic cell scraper and passed 5 times through a 
blue tip, transferred to microtube and incubated on a head-over shaker in the cold-room for 30 
minutes. Lysates were cleared by centrifugation at 14,000 rpm in a microcentrifuge for 10 minutes 
in the cold. For the detection of tyrosine phosphorylated β-DG PY982 and β-DG protein with 
mAbs cl14a and 8D5, respectively, total protein was extracted [92], separated by SDS-PAGE and 
Western blot performed as described above. For the detection of tyrosine phosphorylation of Axl, 
total Axl was isolated by immunoprecipitation using a modified protocol reported by Meertens et 
al. [93]. For this purpose, purified polyclonal goat anti-IgG was immobilized on cyanogens 
bromide activated Sepharose 4B (Sigma) following the manufacturers recommendations. Anti-
Axl matrix was mixed with cleared lysate (10 μl of matrix per ml of lysate), and incubated on a 
head-over shaker for 4 h or overnight in the cold room. After antibody binding over night, matrix 
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was washed four times with lysis buffer and once with lysis buffer without detergent. 
Immunocomplexes were eluted by boiling in non-reducing SDS-PAGE sample buffer for 5 
minutes, followed by separation by SDS-PAGE using Tris/glycine running gels with 5.5% 
(wt/vol) polyacrylamide to achieve optimal separation of Axl from the IgG heavy chain. Axl 
protein was revealed in Western blot using a mouse mAb anti-Axl and tyrosine phosphorylation 
detected in anti-Axl IP using a mAb to tyrosine phosphate.   
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RESULTS 
Human cells targeted by LASV co-express Axl and differentially glycosylated DG 
Histological examination of mammalian tissues revealed that DG’s functional glycosylation by 
LARGE is under tight tissue-specific control, resulting in considerable variation in the length of 
DG-associated matriglycan chains [94], affecting DG’s function as LASV receptor. LARGE was 
originally discovered as a tumor-suppressor gene [95] and its expression is frequently altered in 
immortalized tumor cell lines [96]. In a first step, we therefore examined expression of functional 
DG and alternative LASV receptor candidates in a panel of primary human cells targeted by 
LASV ex vivo, including hepatocytes, endothelial cells, and epithelial cells [70]. Primary human 
hepatocytes were isolated from liver specimens obtained after partial hepatectomy and cultured 
as described in Materials and Methods [84]. As primary cell culture models for microvascular 
endothelial cells, human umbilical cord vascular endothelial cells (HUVEC) and human 
microvascular endothelial cells of the lung (HMVEC-L) were used. Primary human small airway 
epithelial cells (SAEC) served as model for primary respiratory epithelial cells. The extent of 
functional glycosylation of DG in these primary cells was assessed by Western blot combining 
mAb IIH6 specific for the α-DG-linked matriglycan epitope with mAb 8D5 directed to the β-DG 
core protein [97]. As controls, we included the human fibrosarcoma line HT-1080 that is deficient 
in LARGE expression [34] and the human alveolar epithelial cell line A549 expressing functional 
DG [22]. In line with in vivo data, primary hepatocytes expressed DG core protein without 
detectable matriglycan [94] (Fig. 1A). Both endothelial cell types expressed an under-
glycosylated α-DG form migrating at an apparent molecular mass of 100-110 kDa, whereas α-
DG from SAEC ran around 125-145 kDa, similar to the form detected in A549 cells and in adult 
lung epithelia in vivo [98] (Fig. 1A). Examination of the expression of the candidate receptors 
Axl, Tyro3, and DC-SIGN revealed the presence of Axl in all cell types, whereas Tyro3 and DC-
SIGN seemed absent. Together, the data indicated co-expression of Axl with differentially 
glycosylated DG on primary human cells targeted by LASV.  
 Previous studies demonstrated that distinct apparent molecular masses of α-DG in SDS-
PAGE are due to different lengths of the matriglycan chains [19, 97, 99]. Recent structural data 
on the pre-fusion conformation of mature LASV GP suggest an avidity-based binding mode of 
the GP1 trimers to DG-linked matriglycan chains [78]. To address this issue, we assessed virus 
binding affinity to differentially glycosylated DG employing a quantitative solid-phase binding 
assay [21]. Since LASV is a BSL4 pathogen, work with live virus is restricted. We therefore used 
a recombinant LCMV expressing the envelope GP of LASV strain Josiah (rLCMV-LASVGP). 
As viral entry is exclusively mediated by the viral envelope, this chimera represents a suitable 
BSL2 surrogate to study LASV entry and has been widely used for the characterization of LASV 
cell tropism in vitro [30, 32, 48, 49] and in vivo [100, 101]. Dystroglycan was enriched from 
A549, HUVEC, and HT-1080 cells by affinity purification using the lectin WGA that recognizes 
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generic N-glycans [99] (Fig. 1B). Equal amounts of DG protein were immobilized in microtiter 
plates and incubated with increasing concentrations of purified virus. Bound virus was detected 
with mAb 83.6 to LASV GP2 as described [21]. As shown in Fig. 1C, virus binding affinity 
indeed correlated with the apparent molecular mass of α-DG, consistent with the avidity-based 
binding mode proposed by the current structural model [78].       
 
Axl can mediate productive LASV entry in absence of functional DG  
In line with histological evidence, our examination of LASV candidate receptor expression on 
primary human cells revealed that Axl can be co-expressed with DG that either lacks functional 
glycosylation or bears matriglycan chains of different length. Considering the conflicting reports in 
the literature [34, 43], we sought to clarify the exact contribution of Axl in LASV cell entry as a 
function of DG’s post-translational modification in the context of productive arenavirus infection, 
using our rLCMV-LASVG chimera. A large body of evidence supports the current model of TAM 
receptor-mediated viral entry by apoptotic mimicry, involving recognition of PS in the virion 
envelope by the high affinity ligands Gas6 and protein S [37] that are naturally present in serum [39, 
102]. The exact ratio of LASV GP1 to PS in the viral envelope appears therefore critical to study 
receptor use. As a first step, we tried to validate our rLCMV-LASVGP chimera, comparing its 
GP1/PS ratio with authentic LASV using a capture ELISA (Fig. 2A). To remove serum-derived PS 
binding proteins that may interfere with our assay, viruses were treated with the Ca2+ chelator EGTA 
that efficiently dissociates Gas6 and pS [39], followed by purification over a renografin gradient, as 
detailed in Materials and Methods. Purified virus was added to microtiter plates coated with mAb 
83.6 that recognizes a highly conserved epitope in GP2 [81] and does not interfere with virus-receptor 
binding [12] (Fig. 2A). After specific capture of virus for 16 h in the cold, plates were washed and 
PS displayed on the viral envelope detected with the PS-binding protein annexin(ANX)-V. LASV 
GP1 was detected using the recombinant virus-binding DG fragment DGEKFc4, which contains a 
C-terminal human IgG1 Fc moiety [83]. Across different preparations, the GP1/PS ratios of rLCMV-
LASVGP were similar to the authentic virus (Fig. 2B), validating our chimera as a suitable BSL2 
model to investigate receptor use.      
 As our primary hepatocytes turned out to be challenging to manipulate in vitro, we needed a 
suitable cell model to study Axl-mediated cell entry of rLCMV-LASVGP in absence of functional 
DG. After examination of a panel of cell lines, we opted for the fibrosarcoma cell line HT-1080 that 
lacks functional DG and expresses Axl, similar to primary hepatocytes (Fig. 1A). To exclude any 
contribution of the remaining DG core protein, we depleted DG from HT-1080 cells using specific 
shRNAs delivered by lentiviral vectors (Fig. 3A). Cells depleted for DG and controls were infected 
with rLCMV-LASVGP at low multiplicity (MOI = 0.01). After 16 h, cells were fixed and productive 
infection assessed by detection of LCMV NP using mAb 113 in immunofluorescence assay (IFA). 
Depletion of DG core protein by >98% did not affect infection with rLCMV-LASVGP, excluding a 
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significant contribution (Fig. 3B). In contrast, knock-down of Axl using validated siRNAs markedly 
reduced productive infection by rLCMV-LASVGP, but not recombinant LCMV expressing the G 
protein of VSV (rLCMV-VSVG), which enters independently of TAM receptors [39] (Fig. 3C, D). 
The RNAi data were confirmed by antibody perturbation using a polyclonal antibody to Axl (Fig. 
3E). In sum, our results confirm that endogenous levels of Axl in HT-1080 cells can contribute to 
LASV entry in the context of productive arenavirus infection in absence of functional DG, in line 
with the original report [34].  
 
Axl-mediated LASV entry is serum-dependent and requires PS of the viral envelope  
A hallmark of Axl-mediated entry of most enveloped viruses via apoptotic mimicry is dependence 
on Gas6 that provides a molecular bridge between PS of the viral envelope and the TAM receptor 
[37, 39]. In a first step we assessed serum-dependence of Axl-mediated rLCMV-LASVGP 
attachment to HT-1080 cells. As a positive control, we used recombinant VSV pseudotypes bearing 
the envelope GP of the New World arenavirus Tacaribe (rVSVΔG-TCRVGP) that critically depend 
on PS receptors for cell entry [43]. As a negative control rLCMV-VSVG was included. Serum-
starved HT-1080 cells were incubated with purified rLCMV-LASVGP, rVSVΔG-TCRVGP, and 
rLCMV-VSVG at low multiplicity (MOI = 0.01) in presence of increasing concentrations of serum 
in the cold to allow virus-cell attachment without internalization (Fig. 4A). After 2 h, unbound virus 
was removed, fresh complete medium containing serum added, and cells shifted to 37°C. After 1 h, 
the medium was supplemented with 20 mM of the lysosomotropic agent ammonium chloride. When 
added to cells, ammonium chloride raises the endosomal pH instantly and blocks low pH-dependent 
endosomal escape of viruses, without causing overall cytotoxicity [103, 104]. After 16 h cells were 
fixed and productive infection quantified by detection of LCMV NP in IFA, whereas rVSVΔG-
TCRVGP was detected via its GFP reporter.  The presence of serum during viral attachment 
increased infection with rLCMV-LASVGP and rVSVΔG-TCRVGP in a dose-dependent manner, 
but did not affect rLCMV-VSVG (Fig. 4B). In a complementary approach, we tried to mask PS 
displayed in the lipid bilayer of rLCMV-LASVGP with ANX-V. For this purpose, purified rLCMV-
LASVGP and the rLCMV-VSVG control were pre-treated with increasing concentrations of ANX-
V, followed by infection of HT-1080 cells in presence of serum. ANX-V blocked entry of rLCMV-
LASVGP, but not rLCMV-VSVG in a dose-dependent manner, implicating PS in viral entry.  
 
Kinetics of Axl-mediated viral attachment and viral endosomal escape  
In a next step to characterize Axl-mediated infection of rLCMV-LASVGP, we assessed the kinetics 
of virus attachment. Specifically, we compared Axl-mediated binding of rLCMV-LASVGP to HT-
1080 cells with viral attachment to HEK293H cells, which express highly glycosylated DG but lack 
Axl (Fig. 5A). Differential receptor use in HT-1080 cells (Axl) and HEK 293H cells (DG) was 
verified by antibody perturbation (Fig. 5B). To estimate the kinetics of virus-receptor attachment, 
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purified rLCMV-LASVGP was pre-treated with 10% serum and added to cells at low multiplicity 
(MOI = 0.01) in the cold, allowing receptor binding without internalization. At different time points, 
unbound virus was removed by washing, and cells rapidly shifted to 37 °C to allow entry. After one 
hour, ammonium chloride was added to prevent further entry, followed by detection of infection by 
IFA after 16 h. In line with previous studies, DG-mediated virus attachment to HEK293H cells was 
rapid with 50% binding reached after a few minutes (Fig. 5C) [22]. In contrast, Axl-mediated virus 
binding to HT-1080 cells occurred slower with half-maximal binding after 15-20 min, consistent 
with a different binding mode (Fig. 5C).  
In productive infection, receptor-bound LASV is internalized by endocytosis, followed by 
delivery to late endosomes, where fusion occurs under low pH. We next compared the kinetics of 
late endosomal escape in HT-1080 and HEK293H cells, determining the time the virus required from 
receptor attachment to become resistant to ammonium chloride. Virus was added to cells in the cold 
to allow receptor binding without internalization. Temperature was rapidly shifted to 37°C and 
ammonium chloride added at the indicated time points and left throughout the experiment. Readout 
of productive infection revealed similar half-times for endosomal escape of 30-45 min in both cell 
types (Fig. 5D). The data suggest that once bound, both Axl and DG can mediate endocytosis 
followed by rapid delivery to late endosomes, where fusion occurs.  
 
Heparan sulfate proteoglycans contribute to LASV entry via Axl, but not DG 
A recent haploid screen for LASV entry factors in DG null cells uncovered several genes involved 
in the biosynthesis of heparan sulfate as candidates, suggesting a role of glycosaminoglycans in DG-
independent LASV entry [64]. To address this issue experimentally in the context of Axl-mediated 
cell entry, we pre-incubated rLCMV-LASVGP and rLCMV-VSVG with increasing concentrations 
of heparin in the cold. Subsequent infection of HT-1080 cells revealed an incremental, but consistent, 
dose-dependent reduction of Axl-mediated rLCMV-LASVGP (Fig. 5E). In contrast, infection of 
HEK293H cells via DG seemed not affected by heparin (Fig. 5E). The data support the genetic 
studies [64] and suggest a contribution of heparan sulfate in DG-independent LASV cell entry in our 
system. 
 
Virus-induced Axl tyrosine kinase activation is required for rLCMV-LASVGP entry  
Engagement of cellular receptors by viruses frequently induces cellular signaling that can serve as a 
“knock on the door” to prime the host cell for further steps of infection [26, 53, 105]. In previous 
studies, recombinant full-length Axl over-expressed in otherwise refractory cell lines enhanced entry 
of LASV pseudotypes [34]. Deletion of the cytosolic tyrosine kinase domain or insertion of “kinase 
dead” mutations reduced LASV pseudotype infection, providing first evidence for a role of Axl 
signaling in LASV entry [34]. To confirm these findings with endogenous Axl in the context of 
productive arenavirus infection, we used the novel small molecule Axl tyrosine kinase inhibitor R428 
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that shows high selectivity and fast drug action [106, 107]. To minimize the duration of drug exposure 
and unwanted off-target effects, we performed a drug washout assay outlined in Fig. 6A. Briefly, 
HT-1080 cells were pre-treated for 30 min with the inhibitor, followed by infection with rLCMV-
LASVGP at low multiplicity (MOI = 0.01) in presence of drug. As positive and negative controls, 
we included rVSVΔG-TCRVGP and the non-enveloped AdV5-GFP, respectively. After one hour, 
drug was washed out using medium containing ammonium chloride to block further entry. 
Productive infection was detected after 16 h by IFA. The Axl inhibitor R428 reduced rLCMV-
LASVGP and rVSV-TCRVGP infection in a dose-dependent manner, whereas AdV5-GFP was not 
affected (Fig. 6B). While the inhibitor reduced the number of infected cells per well, residual infected 
cells still expressed high levels of LCMV NP (Fig. 6C), suggesting an effect of the drug on viral 
entry, rather than transcription or replication. To further validate cell entry as the main target of R428, 
we performed “time-of-addition experiments”. As shown in Fig. 6D, the Axl inhibitor was highly 
active against rLCMV-LASVGP when added before or during infection, but had only a mild effect 
at later time points post-entry. The nucleoside analogue ribavirin that inhibits replication of the viral 
core was active at all time points during infection, as expected (Fig. 6D).  
 The observed inhibition of Axl-mediated entry by R428 confirmed that Axl tyrosine kinase 
activity was indeed required for rLCMV-LASVGP entry, in line with the original report [34]. Next, 
we addressed if engagement of cellular Axl by the virus could activate receptor signaling or whether 
Axl tyrosine kinase activity served merely as a “permissive signal”. To this end, we pre-incubated 
purified rLCMV-LASVGP with 10% FBS, followed by ultracentrifugation through a sucrose 
cushion. Pelleted virus was washed, re-suspended in HBSS, and infectious titers verified by IFA. As 
control, we included a “mock preparation” produced from the supernatants of uninfected cells by the 
same procedure, as described in Materials and Methods. Serum-starved HT-1080 cells were 
incubated with rLCMV-LASVGP at high multiplicity (50 PFU/cell) and equivalent amounts of mock 
preparation in the cold to prevent membrane fluidity and signaling. After removal of unbound virus, 
cells were rapidly shifted to 37°C and lysed at the indicated time points. Total Axl was 
immunoprecipitated (IP) with polyclonal anti-Axl antibody. Receptor autophosphorylation was 
detected by Western blot using a mAb to tyrosine phosphate, as described [93]. As shown in Fig. 6E, 
engagement of rLCMV-LASVGP induced detectable Axl tyrosine phosphorylation above 
background within circa 10 min. In sum, the data suggest that virus-induced Axl tyrosine kinase 
activity is required for DG-independent rLCMV-LASVGP entry.   
 
Axl-dependent LASV cell entry involves macropinocytosis and requires LAMP-1  
Although TAM receptors have been implicated in viral entry via apoptotic mimicry for many 
viruses [37], the endocytotic pathway(s) underling TAM-mediated virus uptake remain largely 
unknown. Early studies on Ebola virus demonstrated that engagement of Axl by the virus can 
enhance macropinocytosis [108]. However, more recent work on Zika virus provided evidence 
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for clathrin-mediated endocytosis (CME) [93], suggesting important virus-specific differences. 
To characterize the Axl-dependent entry pathway used by rLCMV-LASVGP in HT-1080 cells, 
we employed a panel of well-described “diagnostic” inhibitors to known cellular factors 
implicated in clathrin-mediated entry and macropinocytosis proposed by Mercer and Helenius 
[57, 59] (Table 1).  
To assess clathrin- and dynamin dependence of rLCMV-LASV entry via Axl, we used 
the inhibitor pitstop-2 that prevents ligand binding to the N-terminal domain of clathrin, and the 
dynamin inhibitors dynasore and dyngo4a, respectively. To target preferentially viral entry and 
minimize off-target effects, inhibitors were tested in the entry assay outlined in Fig. 6A.  As a 
positive control, a recombinant VSV expressing GFP (rVSV-GFP) was used. Pitstop-2, dynasore, 
and dyngo4a only mildly affected rLCMV-LASVGP, but reduced infection with rVSV-GFP 
[109] (Fig. 7A). In a complementary approach, clathrin heavy chain was depleted by RNAi [48]. 
Knock-down of >95% of clathrin heavy chain (Fig. 7B) did not affect rLCMV-LASVGP entry 
(Fig. 7C), supporting a clathrin- and dynamin-independent pathway. 
A conserved hallmark of viral entry via macropinocytosis is dependence on sodium 
proton exchangers (NHE) that are sensitive to amiloride drugs [57]. Inhibition with EIPA reduced 
rLCMV-LASVGP entry in a dose-dependent manner, but only mildly affected rLCMV-VSVG 
(Fig. 7D). A second conserved feature of macropinocytosis is actin-dependence [53, 54]. To 
address this issue, cells were treated with the inhibitors cytochalasin D and latrunculin A, that 
disrupt actin filaments, as well as jasplakinolide, a drug that stabilizes actin fibers and blocks 
actin dynamics. Pretreatment with all actin inhibitors markedly reduced infection with rLCMV-
LASVGP, without affecting overall cell viability (Fig. 7E). The small GTPases Cdc42, Rac1, and 
RhoA represent important downstream effectors of NHE involved in actin regulation [110]. Using 
the well-characterized inhibitors Pirl1, NSC23766, and CT04, we addressed the role of Cdc42, 
Rac1, and RhoA in Axl-mediated LASV entry. Pirl1 and NSC23766, but not CT04 specifically 
reduced productive infection with rLCMV-LASVGP, pinpointing Cdc42 and Rac1, but not RhoA 
as entry factors (Fig. 7F). Infection of rLCMV-LASVGP was likewise reduced after inhibition of 
the Cdc42 downstream effector p21-activating kinase (PAK)-1 with IPA-3 (Fig. 7G).  Productive 
entry of viruses via macropinocytosis frequently depends on non-muscle myosin II required for 
membrane fission during formation of early macropinosomes [54]. To address this issue, HT-
1080 cells were treated with blebbistatin, an inhibitor of myosin II as well as the myosin light 
chain kinase inhibitor ML-7. As shown in Fig. 7G, both inhibitors specifically reduced entry of 
rLCMV-LASVGP, suggesting that Axl-mediated entry of rLCMV-LASVGP involves a pathway 
related to macropinocytosis.  
Upon entry via DG, LASV is rapidly delivered to the late endosome, where the virus 
undergoes a “receptor switch” and engages the late endosomal/lysosomal resident protein LAMP-
1 that is essential for efficient fusion [64, 65, 67]. Although most Old World arenaviruses can use 
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DG as a receptor, the ability to hijack LAMP-1 as a late endosomal entry factor is unique for 
LASV [111]. We therefore investigated if LAMP-1 was also needed for Axl-mediated LASV 
entry into HT-1080 cells. Depletion of LAMP-1 by specific siRNAs impaired rLCMV-LASVGP 
entry in HT-1080, suggesting an essential role for LAMP-1 as a late endosomal entry factor also 
for Axl-mediated entry (Fig. 7H, I).   
 
Axl can contribute to LASV entry into endothelial cells 
Endothelial cells represent important targets for LASV late in infection and functional 
perturbation of the vascular endothelium precedes shock and death in fatal Lassa fever [112]. 
Early studies revealed that microvascular endothelial cells are highly susceptible to LASV 
infection in vitro and can become prodigious sources of infectious virus [113]. Examination of 
LASV candidate receptor expression in HUVEC and HMVEC-L in our present study revealed 
co-expression of Axl with an underglycosylated form of DG with relatively low virus binding 
affinity (Fig. 1). To address the relative contribution of DG and Axl to LASV entry, HUVEC and 
HMVEC-L were blocked with specific antibodies to Axl and functional DG, either alone or in 
combination, followed by infection. Perturbation of individual receptors hardly affected rLCMV-
LASVGP entry, whereas the antibody combination lowered infection significantly (Fig. 8A), 
suggesting that both Axl and DG may contribute to infection.  
Previous studies revealed that engagement of cellular DG by LASV GP induces tyrosine 
phosphorylation of β-DG’s cytosolic domain, resulting in dissociation from the cytoskeletal 
adaptor protein utrophin, which may facilitate internalization of the virus-receptor complex [30]. 
In a next step, we therefore assessed virus-induced tyrosine phosphorylation of Axl and DG in 
endothelial cells. Monolayers of HMVEC-L were exposed to rLCMV-LASVGP and mock 
preparation. After removal of unbound virus, cells were rapidly shifted to 37°C and lysed at the 
indicated time points. Activation of Axl was detected as described above (Fig. 6E). Virus-induced 
tyrosine phosphorylation of DG was examined in Western blot using a mAb that specifically 
recognizes β-DG phosphorylated at residue YP892 located in a C-terminal PPPY motif 
implicated in utropin binding [30, 114]. In HMVEC-L, rLCMV-LASVGP induced tyrosine 
phosphorylation of Axl and DG with similar kinetics, suggesting that both receptors are engaged 
(Fig. 8B).  
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DISCUSSION 
Many important human pathogenic viruses evolved to use different receptors. However, the exact 
operational definition of a receptor, co-receptor, attachment- and entry factors is frequently not 
straightforward and critically depends on species and cell type [26, 115]. For LASV, the situation 
seems particularly complicated considering remarkably complex tissue-specific post-translational 
modification of its major receptor DG that results in a large spectrum of receptor variants with 
strikingly different virus binding affinities [116]. The specific function of DG as a LASV receptor 
in a particular cell type appears therefore as a complex function of the expression of >20 genes 
currently implicated in the biosynthesis of functional DG [15]. As for many other emerging 
enveloped viruses, the broadly specific cellular PS receptors Axl and Tyro3 have been proposed 
as candidate LASV receptors [37, 80]. However, the published data on their specific role in LASV 
appear conflicting [34, 43]. In the present study, we thought to clarify and characterize the roles 
of Axl in LASV entry.   
Functional glycosylation of DG and expression of TAM receptors are frequently altered 
in tumor cells [96, 117]. In a first step of our study, we therefore examined the expression of 
LASV candidate receptors in relevant primary human cell types cultured ex vivo. In primary 
human hepatocytes derived from liver biopsies, we could not detect functional DG, in line with 
histological findings in adult liver tissue [79]. The detection of Axl in our primary liver cells was 
further consistent with the recently reported Axl expression in healthy human hepatic tissue [118]. 
Endothelial and epithelial cells are highly sensitive to LASV infection in vitro and in vivo [113, 
119] and represent important targets for the virus late in disease [1, 71]. Our examination of LASV 
candidate receptors in primary microvascular endothelial cells and respiratory epithelial cells 
revealed differential glycosylation of DG that correlated with distinct virus binding affinity, 
emphasizing the current concept of DG as a “tunable receptor” [15, 19]. Both, endothelial and 
epithelial cells expressed Axl, in line with recent reports [40, 120]. In sum, our results obtained 
from primary human cells are consistent with existing histological and biochemical in vivo data 
and confirm that susceptible human cell types co-express Axl with differentially glycosylated 
DG. 
The susceptibility of a given cell type to LASV at the level of entry is likely  a complex 
function of DG glycoslation and the expression levels of alternative receptors like Axl. The 
specific contributions of DG and Axl to LASV attachment and entry further critically depend on 
the exact GP1/PS ratio in the virion particles. Using a capture-ELISA, we consistently found 
GP1/PS ratios in the envelopes of rLCMV-LASVGP that were comparable to authentic LASV, 
validating our chimera as a suitable BSL2 model for entry studies in the context of productive 
arenavirus infection.  
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In a first step, we confirmed the findings of the original report by Shimojima and 
colleagues [34], showing that Axl can indeed function as an authentic LASV entry receptor in the 
context of productive arenavirus infection in absence of functional DG. We then characterized 
Axl-mediated virus-cell attachment and found similarities to the model of “apoptotic mimicry” 
proposed for many viruses [37, 80]. However, compared to glycosylated DG that rapidly captures 
free virus via avidity-based lectin-type binding [55], virus attachment to Axl followed a slower 
kinetics, consistent with the proposed distinct binding mode involving lipid-protein (PS-Gas6) 
and protein-protein (Gas6-Axl) interactions [37]. Using our rLCMV-LASVGP chimera, we 
further provide first experimental evidence that heparan sulfate can facilitate DG-independent 
LASV entry via Axl, in line with a recent genetic screen [64].  
Axl-mediated entry of several viruses requires receptor signaling through the receptor’s 
cytosolic tyrosine kinase domain [40, 93, 121, 122]. Interestingly, in most cases studies so far, 
including the flaviviruses Dengue, West Nile, and Zika virus, Axl signaling seems not required 
for virus internalization, but promotes later steps of viral multiplication, increasing infectious 
virus production [40, 93, 121]. In addition to their role in removal of apoptotic cells, TAM 
receptors play a crucial role in the negative regulation of innate immune signaling, regulating the 
host cell’s type interferon (IFN)-I response [36, 123, 124]. In a current model, engagement of Axl 
by enveloped viruses down-regulates innate immune signaling, blunting the IFN-I response thus 
promoting viral replication [37, 80, 121]. Similar to the situation with Zika virus [93] we found 
that engagement of cellular Axl by rLCMV-LASVGP induces rapid receptor signaling. However, 
a combination of drug wash-out and time-of-addition experiments, using the fast-acting Axl 
inhibitor R428, suggests a role for virus-induced Axl activation during rLCMV-LASVGP entry, 
but not at later steps of viral replication. Previous studies demonstrated that HT-1080 cells used 
in our study induce a robust IFN-I response when challenged with other RNA viruses [125], 
excluding an overall defect in innate anti-viral immunity. The observed difference to flaviviruses 
may rather be explained by the fact that infection of LCMV and LASV in many cell types, 
including HT-1080, fails to induce a robust IFN-I response [113, 125-128]. The ability of LASV 
and LCMV to evade innate immunity seems independent of receptor use and is based on the 
potent IFN antagonist function of the viral NP and Z proteins that efficiently block IFN-I 
induction, likely making attenuation via Axl obsolete [126, 129-132].  
Previous studies on Axl-mediated viral entry pinpointed different endocytotic pathways, 
including macropinocytosis [108] and CME for Zika virus [93], suggesting virus-specific 
differences. Application of a panel of well characterized “diagnostic” inhibitors revealed that Axl-
mediated entry of rLCMV-LASVGP occurs via an endocytotic pathway related to 
macropinocytosis, similar to filoviruses [133] and distinct from Zika virus [93]. The Axl-
mediated LASV entry pathway uncovered in our present study shares similarities with the 
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recently characterized unusual macropinocytosis-related pathway linked to DG-mediated entry of 
LASV and LCMV into epithelial cells and fibroblasts [52, 55]. However, we also noted important 
differences. In contrast to DG-mediated viral entry, the pathway linked to Axl depends e.g. on 
non-muscle myosin II, required for early macropinosome formation [54], similar to the pathways 
used by poxviruses [42] and Ebola virus [108]. Despite differences in attachment kinetics, both 
DG and Axl mediated rapid internalization and delivery of the virus to endosomes. The similar 
kinetics of viral endosomal escape suggests convergence of the endocytotic pathways, likely at 
the level of late endosomes. This is supported by our observation that LASV entry via both 
receptors critically depends on LAMP-1, making this late endosomal entry factor an attractive 
target for anti-viral therapeutic intervention. 
Examination of candidate receptors on endothelial cells revealed co-expression of Axl 
with an underglycosylated form of DG with relatively low virus binding affinity. Simultaneous 
blocking of both DG and Axl was required to affect rLCMV-LASVGP entry, whereas 
perturbation of the individual candidate receptors had only mild effects, suggesting some degree 
of redundancy. In line with this observation, viral attachment to endothelial cells was followed 
by rapid virus-induced tyrosine phosphorylation of both receptors, suggesting that DG and Axl 
may be engaged during productive viral entry. This seems distinct from Zika virus that uses Axl 
as a primary receptor in endothelial cells in a non-redundant manner [120].  
In sum, our study confirms and extends previous work, supporting the notion that Axl 
can fulfill different functions in LASV entry in different cell types, depending on the extent of 
post-translational modification of DG. Based on the combined information available, we propose 
the following model for the specific functions of DG and Axl during LASV infection: During 
zoonotic transmission, highly glycosylated DG present in epithelial cells can rapidly catch and 
internalize the virus, acting as a primary entry receptor [55]. A role of DG glycosylation as a host 
determinant during virus-human co-evolution is indeed suggested by genome-wide association 
studies that uncovered positive selection for specific LARGE alleles in populations from regions 
of Western African where LASV is endemic [6, 24, 25]. In severe LASV infection, the virus 
rapidly spreads via the bloodstream, reaching, among other organs, the liver and the vascular 
endothelium. In human hepatocytes and other cells lacking functional DG, the Axl-dependent, 
DG-independent LASV entry pathway characterized here may be operational. Interestingly, 
chronic infection with hepatitis C virus (HCV) in humans markedly increases Axl expression in 
the liver [118]. Considering the high prevalence of HCV in many regions of Western Africa [134], 
chronic viral hepatitis may contribute to susceptibility of local populations to LASV infection. In 
endothelial cells, DG and Axl may both contribute to LASV entry, making this cell type highly 
susceptible and contributing to the endothelial dysfunction that precedes shock and death. 
Therapeutic strategies against LASV may therefore consider Axl as an additional drug target. 
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FIGURES 
 
 
 
FIG1. Primary human cells LASV co-express Axl and differentially glycosylated DG.  (A) 
Detection of candidate LASV receptors in primary human cells. Total cell protein was extracted 
from primary human hepatocytes (PHHC), HUVEC, HMVEC-L, and SAEC, separated by SDS-
PAGE and blotted onto nitrocellulose. Functional DG was detected with mAb IIH6 recognizing 
the matriglycan sugar polymers on α-DG. Presence of the core protein was probed with mAb 8D5 
to β-DG. A549 and HT-1080 cells were included as positive and negative controls, respectively. 
Axl, Tyro3, and DC-SIGN were detected with goat pAb anti-human Axl, mAb 96201 anti-human 
Tyro3, and mAb 120507 anti-DC-SIGN. Human THP-1 monocytes and THP-1-derived immature 
dendritic cells were used as positive controls for Tyro3 and DC-SIGN, respectively [46]. As a 
negative control for Axl, HEK293H cells were included. The negative control lane of the Axl blot 
was taken from the same membrane and moved, as indicated by the thin white line. Primary 
antibodies were detected with HRP-conjugated secondary antibodies using enhanced 
chemiluminescence (ECL) for development. The observed differences in the apparent molecular 
masses of Axl in different cells may be due to different glycosylation patterns. The expression 
levels of Axl in PHHC varied between donors and a representative example was selected. (B) 
Western blot of WGA-purified DG. Dystroglycan was purified from the indicated cells by WGA 
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affinity chromatography. Concentrated fractions were probed in Western blot for functional 
glycosylation of α-DG with mAb IIH6 and for β-DG with mAb 8D5 as in (A). (C) Solid-phase 
virus binding assay. Equal amounts of DG purified from the indicated cells were immobilized in 
microtiter plates and incubated with the indicated concentrations of purified rLCMV-LASVGP. 
Bound virus was detected with mAb 83.6 to LASV GP2 using a biotinylated secondary antibody 
and HRP-conjugated streptavidine for signal amplification in a color reaction. Data are means + 
SD, n = 3.   
 
FIG2. Determination of GP1/Ps ratios in rLCMV-LASVGP and authentic LASV. (A) 
Schematic of the capture-ELISA. Virus is captured by immobilized mAb 86.3 that recognizes a 
conserved non-neutralizing epitope in GP2. After removal of unbound material, bound virus is 
probed with ANX-V to detect PS displayed in the lipid bilayer of the viral envelope and 
DGEKFc4 that binds to GP1. For details, please see text. (B) Detection of GP1 and PS. Purified 
rLCMV-LASVGP, authentic inactivated LASV, were incubated with immobilized mAb 83.6, 
using the non-enveloped AdV5-GFP as a negative control. After washing, bound virus was 
incubated with biotin-conjugated ANX-V in presence and absence of EGTA, as well as 
DGEKFc4. Bound biotinylated ANX-V and DGEKFc4 were detected by streptavidine HRP and 
HRP-conjugated anti-human Fc antibody in a color reaction. Please note the reduced ANX-V 
binding in presence of the Ca2+-chelator EGTA. Data are means + SD, n = 3. (C) The ratios of 
GP1/PS for the virus preparations tested in (B).  
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FIG. 3. Axl can mediate productive LASV entry in absence of functional DG. (A) Knock-
down of DG in HT-1080 cells. HT-1080 cells were transduced with a lentiviral vector expressing 
a DG-specific shRNA (shRNA-DG) or scrambled shRNA (shRNA-sc), or mock transduced 
(mock), followed by selection with puromycin as detailed in Materials and Methods. Depletion 
of DG core protein was verified in Western-blot using mAb 8D5 to β-DG and α-tubulin (Tub) as 
a loading control. The asterisk (*) indicated an unspecific band. Efficiency of depletion was 
assessed by densitometric analysis, followed by calculation of the signal ratios of β-DG/α-tubulin 
(β-DG/Tub). (B) HT-1080 cells transduced with shRNA-DG or shRNA-sc (A) were seeded in 96 
well plates and infected with rLCMV-LASVGP (300 PFU/well) for one hour. Cells were washed 
with medium supplemented with 20 mM ammonium chloride to prevent secondary infection. 
After 16 h incubation in presence of ammonium chloride, cells were fixed and infection detected 
by IFA using mAb 113 to LCMV NP, combined with a Alexa488-conjugated secondary antibody. 
Infection was quantified by counting infected cells per well considering cell doublets as single 
infection events. Data are means + SD, n = 3. (C) Depletion of Axl from HT-1080 cells. HT-1080 
cells were transfected with siRNAs to Axl (siRNA-Axl) and scrambled control siRNAs (siRNA-
sc) as detailed in Materials and Methods. After 72 h, expression of Axl was detected in Western 
blot using α-tubulin (Tub) as a loading control. In some blots, a lower molecular mass band (*) 
was detected. However, this was not consistently observed. Efficiency of Axl depletion was 
assessed by densitometry, followed by calculation of the signal ratios of Axl/α-tubulin (Axl/Tub). 
(D) Infection on Axl-depleted HT-1080 cells. HT-1080 cells transfected with siRNA-Axl and 
siRNA-sc were infected with 300 PFU/well rLCMV-LASVGP (LASV) and rLCMV-VSVG 
(VSV) and infection detected as in (B). Data are means + SD, n = 3. (E) Blocking of Axl-mediated 
infection by antibody perturbation. HT-1080 cells were chilled on ice, washed with cold serum-
free medium, and blocked with goat pAb anti-Axl (20 μg/ml), and control goat IgG for 2 h in the 
cold in absence of serum. Cells were then incubated with 300 PFU/well of rLCMV-LASVGP 
(LASV) and 200 PFU/well of rLCMV-VSVG (VSV) in presence of antibody for 2 h in the cold. 
Unbound virus was removed by washing and cells cultures in complete medium at 37°C. After 
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45 min, 20 mM ammonium chloride was added and infection detected as in (B). Data are means 
+ SD, n = 3.   
 
 
 
FIG.4. Axl-mediated LASV entry is serum-dependent and requires PS of the viral envelope. 
(A) Schema of the entry assay. For details, please see text, LE, late endosome. (B) Entry of rLCMV-
LASVGP into HT-1080 cells serum-dependent. Purified rLCMV-LASVGP (300 PFU/ml), rLCMV-
VSVG (200 PFU/well), and rVSVΔG-TCRVGP (100 PFU/well) were pre-treated with the increasing 
concentrations of serum and added toHT-1080 cells cultured in 96 well pates for 2 h in the cold. Cells 
were washed 3 times and incubated with complete medium containing 10% (wt/vol) FBS. After 1 h, 
complete medium containing 20 mM ammonium chloride was added, followed by 16 h incubation 
in presence of the lysosomotropic agent. Infection was detected by IFA as in (3B). Data are means + 
SD, n = 3. (C) Blocking of infection of HT-1080 cells with ANX-V. Purified rLCMV-LASVGP and 
rLCMV-VSVG were diluted in DMEM and pre-treated with the indicated concentrations of ANX-
V for 2 h in the cold. The virus/ANX-V mix was then diluted 1:10 in complete medium containing 
10% (wt/vol) FBS, resulting in a virus concentration of 300 PFU/ml, and added to HT-1080 cells for 
1 h at 37 °C. After 1 h, complete medium containing 20 mM ammonium chloride was added, 
followed by 16 h incubation and detection of infection by IFA as in (3B). Data are means + SD, n = 
3.  
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FIG.5. Kinetics of Axl-mediated viral attachment and viral endosomal escape. (A) Detection 
of functional DG and Axl in HEK293H and HT-1080 cells by Western blot as in (1A), including 
the LARGE-deficient cell line HeLa. Please note the residual signal for functionally glycosylated 
α-DG in HeLa cells that was absent in HT-1080. The double band for Axl in HT-1080 cells was 
not consistently observed. (B) Verification of DG and Axl-mediated entry of rLCMV-LASVGP 
into HT-1080 and HEK293H cells, respectively. The indicated cells were blocked with mAb IIH6 
to glycosylated α-DG (100 μg/ml), goat pAb anti-Axl (20 μg/ml), and control antibodies (Ctrl) 
for 2 h in the cold as in (3E). Cells were then incubated with rLCMV-LASVGP at 100 PFU/well 
(HEK293H) and 300 PFU/well (HT-1080) for 2 h in the cold in presence of antibodies. Cells 
were washed, kept in complete medium for 45 min at 37°C, followed by addition of 20 mM 
ammonium chloride, cultured for 16 h, fixed, and infection detected as in (3B). Data are means + 
SD, n = 3. (C) Virus attachment to HEK293H and HT-1080 cells. The indicated cell lines were 
chilled on ice, followed by incubation with rLCMV-LASVGP at 100 PFU/well (HEK293H) and 
300 PFU/well (HT-1080). At the indicated time points, unbound virus was removed by washing 
with cold medium and cells rapidly shifted to 37°C. After 1 h at 37°C, 20 mM ammonium chloride 
was added to the medium and cells incubated for a total of 16 h. Virus infection was detected by 
IFA with mAb 113 to LCMV NP, combined with Rhodamine Red-X anti-mouse IgG and 
quantification performed as in (3B). Data are means + SD, n = 3. (D) Endosomal escape of virus. 
rLCMV-LASVGP at 100 PFU/well (HEK293H) and 300 PFU/well (HT-1080) was attached to 
monolayers of the indicated cells in the cold for 2 h. Unbound virus was removed and cells rapidly 
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shifted to 37°C. At the indicated time points, 20 mM ammonium chloride was added and left 
throughout the experiment. After 16 h, infection was assessed by IFA as in (C). Given are means 
+ SD, n = 3. (E) Blocking of infection of HT-1080 and HEK293H cells with heparin. rLCMV-
LASVGP (LASV) and rLCMV-VSVG (VSV) (300 PFU/ml) were diluted in complete medium 
and pre-treated with the indicated concentrations of heparin for 1 h in the cold, followed by 
infection of monolayers of HT-1080 cells for 1 h at 37 °C in presence of the inhibitor. After 1 h, 
complete medium containing 20 mM ammonium chloride was added, followed by 16 h incubation 
and detection of infection by IFA as in (3B). Data are means + SD, n = 3.     
 
 
 
FIG.6. Virus-induced Axl tyrosine kinase activity is required for rLCMV-LASVGP entry. 
(A) Schema of the inhibitor experiment. For details, please see text, LE, late endosome. (B) 
Infection of rLCMV-LASVGP depends on the activity of Axl tyrosine kinase. HT-1080 cells 
were pre-treated with the Axl tyrosine kinase inhibitor R428 at increasing concentrations for 30 
min, followed by infection with the indicated viruses at (200 PFU/well) in presence of drug. After 
1 h, cells were washed 3 times with medium containing 20 mM ammonium chloride, followed by 
16 h incubation in presence of the lysosomotropic agent. Infection was detected by IFA as in (3B). 
Data are means + SD, n = 3. (C) Example of the inhibition of rLCMV-LASVGP infection by 
R428 revealed by IFA using mAb 113 to LCMV NP (green) and counter-staining of nuclei (DAPI, 
blue). Note the similar intensity of the NP staining with increasing inhibitor concentration. (bar = 
50 μm). The lower panel shows AdV5-GFP used as a negative control. NP or GFP positive cells 
were scored, considering cell doublets as single infectious events. (D) Time-of-addition 
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experiment. HT-1080 cells were infected with rLCMV-LASVGP (300 PFU/well) with R428 
added at the different time points pre- or post-infection at 1 μM. Virus was added at time point 0, 
followed by washing and addition of ammonium chloride after 1 h (+1). Ammonium chloride was 
kept throughout the experiment and cells subjected to IFA after 16 h. Data are means + SD, n = 
3. Examination of cell viability by Cell TiterGlo® assay recelaed no significant toxicity of R428 
under our experimental conditions (data not shown). (E) Engagement rLCMV-LASVGP induces 
activation of Axl’s tyrosine kinase. Serum-starved HT-1080 cells were incubated with rLCMV-
LASVGP at 50 infectious particles/cell and equivalent amounts of mock preparation for 2 h in 
the cold. Unbound virus was removed and cells shifted to 37°C. At the indicated time points, cells 
were lysed and Axl isolated by IP with goat polyclonal Ab anti-Axl immobilized on Sepharose 
matrix. Immunocomplexes were eluted by non-reducing sample buffer, followed by SDS-PAGE 
using 5.5% (wt/vol) running gels. Total Axl protein in IP was revealed in Western blot using a 
mouse mAb anti-Axl (10% of sample) and tyrosine phosphorylation detected in by a mAb to 
tyrosine phosphate (90% of sample). For detection TrueBlot® HRP-conjugated anti-mouse IgG 
was used in ECL. Blots for tyrosine phosphate (PY) were exposed for 2 minutes and blots 
detecting total Axl for 10 seconds.  
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FIG.7. Axl-dependent LASV cell entry involves macropinocytosis and requires LAMP-1. 
(A) Axl-mediated entry of rLCMV-LASVGP is independent of dynamin and clathrin. HT-1080 
cells were pre-treated with inhibitors for dynamin-2 (dynasore, dyngo-4a) and clathrin (pitstop-
2) at the indicated concentrations for 30 min, followed by infection with rLCMV-LASVGP (300 
PFU/well) and rVSV-GFP (100 PFU/well) in presence of drugs. After 1 h, cells were washed 3 
times with medium containing 20 mM ammonium chloride, followed by incubation in presence 
of the agent. After 16 h, cells were fixed and infection detected by IFA using mAb 113 to LCMV 
NP as in (3B). Infection with rVSV-GFP was assessed after 8 h by detection of the EGFP reporter 
in direct fluorescence microscopy. (B) Depletion of clathrin heavy chain (CHC) by RNAi. HT-
1080 cells were transfected with a pool of siRNAs specific for CHC, control scrambled siRNAs, 
or mock transfected as in (3C). After 72 h, expression of CHC was detected in Western blot using 
α-tubulin (Tub) as a loading control. Efficiency of CHC depletion was assessed by densitometry, 
followed by calculation of the signal ratios of CHC/α-tubulin (CHC/Tub). (B) HT-1080 cells 
subjected to RNAi for CHC (B) were infected with rLCMV-LASVGP (LASV) at 300 PFU/well 
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and rLCMV-VSVG (VSV) at 100 PFU/well for one hour. Infection was detected by IFA as in 
(A). Data represent means + SD, n = 3. (D) The amiloride drug EIPA blocks Axl-mediated entry 
of rLCMV-LASVGP. HT-1080 cells were pre-treated with the indicated concentrations of EIPA 
for 30 min, followed by infection with rLCMV-LASVGP (300 PFU/well) and rLCMV-VSVG 
(100 PFU/well) in presence of drugs for 1 h and detection of infection by IFA as in (A). (E) Actin 
inhibitors block Axl-dependent rLCMV-LASVGP infection without causing cell toxicity. HT-
1080 cells were pre-treated with the indicated concentrations of cytochalasin D (CytoD), 
latrunculin A (LatA), and jasplakinolide (Jas) for 30 min, followed by infection with rLCMV-
LASVGP (300 PFU/well) as in (A). Data are means + SD, n = 3. Cell viability was monitored by 
CellTiter Glo® assay as described in Materials and Methods measuring cellular ATP levels in a 
luminescence assay. Data are displayed in relative light units (RLU), means + SD, n = 3. (F) Axl-
mediated entry of rLCMV-LASVGP depends on Cdc42 and Rac1, but not RhoA. HT-1080 cells 
were pre-treated with DMSO vehicle control, or the inhibitors pirl1 (Cdc42), NSC23766 (Rac1), 
and CT04 (RhoA) at the indicated concentrations followed by infection with rLCMV-LASVGP 
(300PFU/well) and rLCMV-VSVG (100 PFU/well) for 1 h in presence of drugs, followed by 
detection of infection as in (A), means + SD, n = 3. (G) Axl-dependent entry of rLCMV-LASVGP 
requires PAK1, non-muscle myosin II, and myosin light chain kinase. HT-1080 cells were treated 
with the indicated concentrations of IPA-3, blebbistatin, and ML7, followed by infection with 
rLCMV-LASVGP (300 PFU/well), and rLCMV-VSVG (100 PFU/well) as in (D). Data are means 
+ SD, n = 3. (H) Knock-down of LAMP-1 by RNAi. HT-1080 cells were transfected with a 
siRNAs specific for LAMP-1 and control scrambled siRNAs. After 48 h, depletion of LAMP-1 
was verified in Western blot using α-tubulin (Tub) as a loading control. (I) Axl-dependent 
infection of rLCMV-LASVGP depends on LAMP-1. LAMP-1 depleted and control HT-1080 
cells (H) were infected with rLCMV-LASVGP at 300 PFU/well and rLCMV-VSVG (100 
PFU/well) for one hour. Infection was detected by IFA as in (A). Data are means + SEM, n = 3 
for rLCMV-LASVGP and n = 2 for rVSVΔG-VSVG.           
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FIG.8. Axl contributes to LASV entry into endothelial but not epithelial cells. (A) Antibody 
perturbation of rLCMV-LASVGP entry in microvascular endothelial cells. Confluent monolayers 
of HUVEC and HMVEC-L were blocked with mAb IIH6 to glycosylated α-DG (Anti-DG, 100 
μg/ml), goat pAb anti-Axl (Anti-Axl, 20 μg/ml), the combination of both antibodies (Anti-DG + 
Anti-Axl), a combination of control antibodies (IgG + IgM), and medium only (no Ab) in absence 
of serum for 2 h in the cold as in (5B). HT-1080 cells and HEK293H cells were included as 
positive controls for Axl- and DG-mediated viral entry, respectively.  Cells were then incubated 
with rLCMV-LASVGP at 300 PFU/well (HUVEC and HMVEC-L), 100 PFU/well (HEK293H) 
and 300 PFU/well (HT-1080) for 2 h in the cold in presence of antibodies under serum-free 
conditions. Cells were washed, and incubated with complete medium. After 16 h incubation in 
presence of ammonium chloride, cells were fixed and infection detected as in (3B). Data are 
means + SD, n = 3. (B) Entry of rLCMV-LASVGP to HMVEC-L cells induces tyrosine 
phosphorylation of Axl and DG. Monolayers of HMVEC-L cells were incubated with rLCMV-
LASVGP (50 infectious particles/cell) and equivalent amounts of mock preparation for 2 h in the 
cold. Unbound virus was removed and cells shifted to 37°C. At the indicated time points, cells 
were lysed. Total protein was extracted from 10% of cleared lysate and probed in Western-blot 
with mAb cl14a (anti-β-DG PY892) and antibody 8D5 to β-DG. The positions of β-DG and β-
DG PY892 are indicated. Blots for β-DG PY892 were exposed for 4 minutes and blots detecting 
total DG for 10 seconds. Axl was isolated by IP from 90% of the lysate and tyrosine 
phosphorylation of Axl detected as in (6E). Blots for tyrosine phosphate (PY, 90% of sample) 
were exposed for 2 minutes and blots detecting total Axl (10% of sample) for 10 seconds.  
 
Table 1: Panel of “diagnostic” inhibitors used in the study  
Inhibitor   target    concentrations (μM)  
Dynasore   dynamin   40, 80  
Dygo4a              dynamin   10, 20 
Pitstop-2   clathrin                2, 8 
EIPA    NHE    10, 20, 40 
Cytochalasin D               actin    5, 10 
Latrunculin A   actin    0.5, 1 
Jasplakinoline   actin      0.5, 1 
Pirl1    Cdc42    5, 10 
NSC237766   Rac1    10, 25 
CT04    RhoA    2, 5 
IPA-3    PAK1    20, 40 
ML7    Myosin light chain kinase 20, 80 
Blebbistatin   Myosin kinase II  10, 20 
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